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Summary 
Dendritic cells (DCs) are commonly known as the most potent antigen presenting cells in 
several inflammatory diseases. In the lung the main function of DCs is to sample incoming 
antigens, transport them to the draining lymph nodes, where they will activate naive T cells to 
become effector T cells or regulatory T cells. The outcome of the response depends on the 
type of antigen, the type of instructing signals encountered in the periphery but also on the 
nature of the dendritic cell subsets presenting the antigen to T cells.  
 
In chapter 3 we have tried to understand the immune response developed towards antigens 
trapped in the lung vascular filter. We have shown that these antigens were presented to T 
cells by interstitial lung DCs in the mediastinal lymph nodes. In addition, we found that these 
interstitial lung DCs secrete monocyte-chemotactic protein-1 (MCP-1) after embolic antigen 
exposure, leading to the recruitment of monocytes. Deletion of interstitial DCs resulted in 
reduced inflammatory aggregates in the lung and antigen presentation in the MLN. Adoptive 
transfer of purified bone marrow monocytes into DC- depleted mice resulted in conversion of 
injected monocytes into monocyte-derived DCs and presentation of the antigen in the MLN.  
In chapter 4 we describe that bile acid ursodeoxycholic acid (UDCA) has immune regulatory 
properties by directly acting on the nuclear farnesoid X receptor on DCs. Treatment with UDCA 
during the secondary immune responses resulted in reduced features of allergic airway 
inflammation.  
Recent studies revealed an important role for structural cells, especially epithelial cells, in 
allergic asthma. Lung epithelial cells express pattern recognition receptors (such as TLR4) and 
respond to allergens by producing DC-instructing factors. Chapter 5 demonstrates that 
exposure of lung epithelial cells to HDM leads to release of uric acid (UA). Secreted UA acts as 
a danger signal to promote Th2 immune responses to harmless inhaled antigens. UA-driven 
responses were mediated by DCs through Syk and PI3Kδ signalling pathway. Treatment of mice 
with uricase at the time of HDM sensitization reduced the features of allergic airway 
inflammation. Chapter 6 shows that after HDM exposure, IL-1α is one of the key cytokines 
released by epithelial cells and acts in an autocrine loop to enhance Th2 inflammatory 
responses. Signalling through the IL-1α/IL-1RI pathway induces the secretion of various 
chemokines and Th2 instructing cytokines by lung epithelial cells. We found that IL-1α induced 
production of IL-33 and GM-CSF by lung epithelial cells. These two cytokines were found to be 
crucial in driving Th2 immunity to HDM. Unexpectedly, we also found that epithelial-derived 
thymic-stromal lymphopoietin (TSLP) did not play a role in a mild model of HDM-induced 
asthma. However, the use of higher doses of HDM  (inducing more severe asthma features) 
revealed a more important role for TSLP.  
 
In conclusion, this thesis shows that lung DCs are important for the sampling of antigens in 
different lung compartments. In some cases, like upon exposure to inhaled allergen such as 
HDM, epithelial cell-derived factors control DC-induced responses. This crosstalk between 
epithelial cells and DCs involves cytokines such as IL-1α, IL-33 and GM-CSF but also 
endogenous danger signals like uric acid. Our findings place airway epithelial cells at the origin 
of Th2 sensitization and therefore, airway epithelial cells can be considered as a therapeutic 
target for allergic asthma. 
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Samenvatting 
Dendritische cellen (DCs) staan algemeen bekend als de beste antigeen-presenterende cellen 
in chronische ziektes zoals astma. De belangrijkste functie van DCs in de long is het 
fagocyteren van ingeademde antigen en deze te transporteren naar de drainerende 
lymfeklieren. Daar worden naieve Tcellen geactiveerd om vervolgens effector-T cel of 
regulatoire T cel te worden. De afweerreactie hangt af van het type antigeen, de instructies 
van het perifere weefsel en ook het type DC-subset dat het antigeen aan de Tcellen 
presenteerd. 
In hoofdstuk 3 onderzochten we de afweerreactie die gericht is op antigenen die zijn 
vastgelopen in de filterende haarvaten van de long. We laten zien dat deze antigenen aan T 
cellen werden gepresenteerd in de mediastinale lymfeklieren (MLN) door interstitiële long-DCs. 
Ook vonden we dat deze interstitiële long DCs monocyte-chemotactisch protein 1 (MCP-1) 
uitscheiden na de blootstelling aan embolische antigen, hetgeen leidde tot de aantrekking van 
monocyten uit het bloed. Het verwijderen van de interstitiële DCs liet een reductie in de 
ontstekingshaarden zien alsmede minder antigen presentatie in de MLN. 
In hoofdstuk 4 laten we zien dat het galzuur ursodeoxycholic acid (UDCA) de eigenschap heeft 
om immunologische reacties te beïnvloeden door te binden aan de farnesoid X receptor op 
DCs. Behandeling met UDCA tijdens de secundaire afweerreactie leidde tot een vermindering 
van de allergische luchtwegontsteking. 
Recentelijk is aangetoond dat er een belangrijke rol bestaat voor structurele cellen, met name 
epitheelcellen, in allergisch astma. Epitheelcellen van de longen brengen patroon herkenings 
receptoren (zoals TLR4) tot expressie en reageren op allergenen door DC-instruerende 
factoren vrij te maken. Hoofdstuk 5 laat zien dat blootstelling van long epitheelcellen aan 
huisstofmijt (HDM) tot de secretie van urinezuur (UA) leidt. Het vrijgekomen UA reageert als 
alarmsignaal om Th2 reacties op ingeademde antigenen te versterken. Voor UA-geïnduceerde 
reacties zijn DCs van belang via Syk en PI3Kδ. Behandeling van muizen met uricase bij het 
ontstaan van astma, verminderde de eigenschappen van allergische luchtwegontsteking. 
Hoofdstuk 6 laat zien dat na de blootselling aan HDM, IL-1α een van de belangrijkste cytokines 
is, dat wordt vrijgesteld door epitheelcellen en op een autocriene manier Th2 
ontstekingsreacties versterkt. Binding van IL-1α aan IL-1RI leidt tot de secretie van 
verschillende chemokines en Th2-instruerende cytokines door long epitheelcellen. In deze 
experimenten vonden we dat IL-1α de productie van IL-33 en GM-CSF door epitheelcellen 
stimuleerde. Deze cytokines zijn cruciaal gebleken in het ontstaan van Th2 reacties op HDM. 
We vonden onverwacht ook dat epitheelcel-afkomstig thymic-stromal lymphopoietin (TSLP) 
geen rol speelde in een mild astma-model. Maar als hogere dosissen van HDM werden 
gebruikt (Hetgeen leidt tot een ernstigere vorm van astma) was er een belangrijke rol voor 
TSLP weggelegd. 
Tot besluit, dit proefschrift laat zien dat long-DCs belangrijk zijn voor het opnemen van 
allergen in verschillende compartimenten. Voor de interactie tussen epitheelcellen en DCs zijn 
cytokines zoals IL-1α, IL-33 en GM-CSF van belang, net als endogene alarmsignalen zoals UA. 
Onze bevindingen plaatsen het luchtwegepitheel aan het begin van de Th2 sensitizatie en 
daardoor zijn long epitheelcellen een potentieel doel voor toekomstige therapieën in allergisch 
astma. 
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Introduction 
 
Allergic asthma 
It has been estimated that 300 million people are affected by asthma worldwide.  The 
incidence of allergic sensitization and asthma has increased dramatically in developed 
countries over the last 50 years. Even more alarming is the ever increasing severity of the 
disease causing about 250.000 deaths per year [1]. Asthma is a chronic immune-mediated 
inflammatory disorder of the airways, characterised by attacks of coughing, wheezing and 
breathlessness due to eosinophilic airway inflammation, airway wall thickening, mucus 
secretion by goblet cell metaplasia, bronchoconstriction and airway hyperresponsiveness to 
non-specific stimuli. In allergic asthmatics, airway inflammation is initiated by specific triggers 
(inhalation of allergen) and exacerbated by non-specific triggers (like air pollutants and viral 
infection). These patients have elevated levels of allergen-specific IgE in serum and a positive 
skin prick test to common allergens.  The presence of allergen-specific IgE is a strong risk factor 
for developing allergic asthma, on the background of genetic predisposition.  GWAS studies in 
asthma have found multiple SNPs in genes that deal with host-immune system interaction (like 
NOD1, TLR-2,-6 and-10, sCD14), antigen presentation (HLA-DR, DENND1B), immune regulation 
(IL4R, IL13, IL12B, GATA3, STAT6, FCERIB), epithelial cytokine (receptors) (GM-CSF, IL-33R, IL1R, 
TSLP), epithelial barrier function (Fillagrin, GPRA, DPP10, Protocadherin 1, Defensin beta 1), 
tissue repair response (ADAM33, COL29A1, ALOX5, NOS1), bronchoconstriction (ADRB2, 
PDE4A, GPRA), and unfolded protein response (ORMDL3). 
In the mid-1980s, Mosmann et al. published a landmark paper that characterized T-
helper (Th)1 and Th2 subsets [2]. Over the past 30-years this Th1-Th2 paradigm has dominated 
the asthma research. As such, it has become clear that the immune response to inhaled 
allergens is characterized by an aberrant Th2 lymphocyte response that has the potential to 
cause the features of asthma, through the production of Th2-type cytokines like IL-4, IL-5, and 
IL-13 [3].  Subsequently, a large body of data from animal models in which CD4 T cells and 
these Th2-type cytokines have been individually neutralized suggested that Th2 cells can 
promote allergic airway inflammation. This view has been extended by the discovery of other T 
cell subsets, such as Th17, Th9, and regulatory T cells (Treg). However, the fact that Th2-like 
eosinophil-rich responses could also be induced in mice lacking T and B cells, suggests a 
potential role for other cells (so called innate lymphoid cells or ILCs) during allergic immune 
responses [4]. Innate lymphocytes type 2 (ILC-2) are also known as nuocytes or natural helper 
cells and produce copious amounts of IL-5, IL-9 and IL-13. In mice, ILC2s derive from 
committed T1/ST2
+
 pre-ILC2s that develop from common lymphoid progenitors in the bone 
marrow under the influence of IL-33 and/or IL-25 but not TSLP.  As most experiments looking 
at the role of ILC2s have been performed in mice lacking T and B cells, it is still unclear what 
the precise role of these cells in asthma is.  Therefore, most investigators still agree that 
allergic type inflammation is mostly controlled by adaptive CD4 T lymphocytes that secrete IL-
4, IL-5 and IL-13, and require antigen presenting cells for their activation. 
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Antigen presentation by dendritic cells 
The lung is continuously exposed to foreign matter (allergens, microbes, diesel particles etc.) 
by inhalation or sometimes via the bloodstream. Allergens and pathogens need to bridge 
physical barriers formed by lung stromal cells to be recognized by the host immune system. 
Most inhaled particles are immunologically inert, and therefore the usual outcome of their 
inhalation is tolerance. In the absence of inflammatory triggers, dendritic cells (DCs) that take 
up these harmless antigens do not properly express costimulatory molecules and consequently 
fail to reach the threshold necessary to induce T cell activation and instead induce an abortive 
T cell response.  
DCs are the main antigen presenting cells (APC) of the immune system [5] situated near 
endothelial cells and lung epithelial cells under homeostatic conditions [6]. They are essential 
for priming and  Th2 differentiation of naïve T cells towards aeroallergens [7]. DCs play a 
central role in the initiation of primary immune responses and enhancement of secondary 
immune responses [8, 9]. Inhaled allergens are captured by DCs through endocytosis. The 
captured allergens are processed and generally presented by major histocompatibility complex 
(MHC) class II molecules to CD4
+
 Th cells [5]. DCs that have captured antigen subsequently 
migrate to the T cell area of mediastinal lymph nodes (MLN) where they report the inhaled 
antigen to recirculating T cells (Figure 1). Under certain conditions, lung DCs can also capture 
antigens from infected cells and crosspresent this to CD8 T cells, thus mounting antiviral 
immune responses [10]. 
Antigen sampling
CCR7 dependent 
migration to LN
Antigen presentation
to naïve Tcells
Th2 attraction and restimulation
Recruiting eosinophils
Mucus secreting epithelial cells
First allergen exposure second allergen exposure
 
 
Figure 1: Dendritic cells situated just underneath the airway epithelial cell layer sample for the presence of inhaled 
allergens. Upon recognition and activation they migrate to the draining lymph node, while they process the antigen. 
In the mediastinal lymph node (MLN) DCs activate the naïve T cells. Subsequently, primed effector T cells leave the 
MLN, but can be recruited to the site of a second allergen exposure, where DCs release chemokines and cytokines 
to recruit and activate the extravasating effector T lymphocytes to mount the immune response to allergens and 
cause allergic type inflammation. 
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While processing recognizing allergens, DCs acquire a mature phenotype, meaning that they 
upregulate CD80, CD86 and CD40 costimulatory molecules and acquire the capacity to 
stimulate an effector response in dividing T cells [11-14]. DCs become a reporter of their 
earlier microenvironment and have the potential to induce a polarized Th1, Th2 or Th17 type of 
response [15, 16]. Many factors are decisive in the process of T-helper polarization. The type of 
antigen, presence of a microbial matter, route of exposure and genetic background of the 
host, all play an important role [17, 18]. These signals are translated, at the level of the APC, 
into signals that can be read by T cells. The most critical defining factors in this translational 
step are the type of DCs (conventional CD11b
+
 cDCs or CD103
+
 cDCs, plasmacytoid DCs and 
monocyte-derived DCs [19], see below) involved in the interaction with T cells, the type of co-
stimulatory molecules expressed on the surface of the DCs, and the secretion of polarizing 
cytokines by DCs or presence of polarizing cytokines in the microenvironment during antigen 
presentation [20, 21]. DCs not only activate the immune cells, but also tolerize lymphocytes to 
prevent autoimmune responses. Tolerance is a feature of lung DCs in steady state, and is the 
best shown in mouse models of allergic asthma where ovalbumin (OVA) is used as an allergen. 
If OVA is applied without an adjuvant, such as aluminium hydroxide at the first exposure, no 
sensitization will occur [22], and an active counterregulatory response made up of Treg cells 
can be induced [21, 23] 
 
Dendritic cell subsets 
The main function of DCs is to initiate antigen-specific adaptive immune responses to foreign 
antigens that reach the tissues and to maintain tolerance to self-antigens. This is in contrast to 
macrophages whose main role is to detect and engulf damaged and dying cells, phagocytose 
opsonized microbes and promote tissue repair [24]. The role of DCs in adaptive immunity 
relies on their ability to process and present foreign antigens in complexes of peptide and MHC 
molecules on the cell surface, and their ability to migrate to the tissue-draining lymph nodes to 
activate T and B cells [25-27]. The emerging field of studying DC subsets in the immune 
response is very active.  As a result, nowadays several DC subsets have been described, which 
vary per tissue and expression of several surface markers [28, 29]. Mouse lung DCs express the 
integrin CD11c as well as intermediate or high levels of MHC molecules on their surface. These 
markers are also expressed by alveolar macrophages but they can be distinguished based on 
autofluorescence [30]. Differentiation of DCs and macrophages in mice starts in the bone 
marrow. Hematopoietic stem cells (HSCs) give rise to granulocyte-myeloid (GMP) and 
lymphoid (LP) committed precursors (Figure 2). GMPs are precursors of monocytes, some 
populations of macrophages, and common DC precursors (CDPs). Subsequently, CDPs give rise 
to preclassical dendritic cells (pre-cDCs) and pDCs which are uniquely able to produce large 
amounts of the antiviral cytokine interferon-α and initiate T cell immunity to viral antigens [6, 
31]. Pre-cDCs circulate in blood and enter lymphoid tissue, where they give rise to CD8α
+
 and 
CD8α
–
 cDCs [32]. These Lymphoid tissue–resident cDC subsets are functionally specialized, 
CD8
+
 cDCs are best in cross-presentation of cell-associated antigens to CD8
+
 T cells, whereas 
CD8
-
 cDCs are the most potent at stimulating CD4
+
 T cells [33]. In nonlymphoid tissues pre-cDC 
give rise to CD11b
+
 and CD103
+
 cDCs. Similar  
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Figure 2:  Hematopoietic stem cells (HSCs) give rise to common myeloid (CMP) and common lymphoid (CLP) 
committed precursors. CMP can differentiate into granulocyte-myeloid precursors (GMPs) which could be  
precursors of monocytes,and macrophage-DC precursors (MDP). MDP give rise to monocytes, some populations of 
macrophages, and common DC precursors (CDPs). CDPs give rise to preclassical dendritic cells (pre-cDCs) and 
plasmacytoid DCs (pDCs). Pre-cDCs circulate in blood and enter lymphoid tissue, where they give rise to CD8α
+
 and 
CD8α
–
 cDCs. In nonlymphoid tissues pre-cDC give rise to CD11b
+
 and CD103
+
 cDCs. Under inflammatory conditions 
monocytes can differentiate into monocyte-derived DCs (mo-DCs). DCs in the nonlymphoid tissue are able to 
migrate to the lymph nodes (Mig-DCs) where they join resident DCs (resDCs).  
to lymphoid-tissue CD8
+
 cDCs, nonlymphoid-tissue CD103
+
 cDCs are efficient cross-presenters 
of cell-associated antigens and are the most potent at stimulating CD8
+
 T cells. Our group 
showed that under lung-inflammatory conditions CD11b
+
 cDCs are prone to sensitize to clinical 
relevant allergens such as house dust mite (HDM). Using markers CD64 and MAR-1, monocyte-
derived DCs (mo-DCs) and CD11b
+
 cDCs could be separated. HDM-specific Th2 immunity is 
induced by CD11b
+
 cDCs, while mo-DCs mainly produce chemokines and allergen presentation 
during the challenge phase [19]. Studies from our group have demonstrated that tolerance is 
induced by particular DC subsets; pDCs suppress T cell effector generation. Strikingly, in the 
absence of pDCs, exposure to harmless antigen led to Th2 cell sensitization and features of 
asthma [21]. If pDCs promote tolerance and cDCs promote immunity, it is logical to assume 
that the balance between both subsets is tightly controlled. In support, administration of Flt-3 
ligand, a cytokine that induces the differentiation of pDCs, in sensitized mice reduced all 
features of asthma [34]. Interestingly, we have shown that pDCs are anti-inflammatory 
irrespectively of their maturation state, however their protective effects are mediated through 
programmed death (PD)-1/PD ligand 1 interactions [34].  Current research focusses on 
progenitors and specific expression of transcription factors in between DC subsets [35, 36]. 
This information could be useful to specifically target a subset of DCs in inflammatory diseases. 
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Allergen recognition in the airways involves pattern recognition receptors 
Over the last years, more focus has been put on dissecting the molecular mechanisms 
underlying allergenicity and Th2 sensitization. Allergens are a complex mixture of biologically 
active molecules such as proteases, chitins [37], glycans, endotoxin, and a variety of still 
unidentified components. It has become increasingly clear that most of the environmental 
allergens express pathogen associated molecular patterns (PAMPs) that might trigger innate 
receptors such as Toll Like receptors (TLRs), NOD like receptors and C-type lectin receptors 
[38]. Signalling through TLRs
 
strongly activates DCs to upregulate co-stimulatory molecules
 
(CD80 and CD86) and to produce pro-inflammatory cytokines (TNFα, IL-1, IL-6, and IL-12) [39, 
40]. PRRs ‘sense’ bacterial products and activate intracellular cascades that lead to 
inflammatory responses [41, 42]. PAMPs sensed by host inflammatory cells early during 
infection, are potent stimuli for innate immunity and are often referred to as ‘exogenous 
danger signals’ (table 1). Contamination of allergens with lipopolysaccharide (LPS) [39] or in 
combination of environmental exposures (respiratory viruses, air pollution or cigarette smoke) 
might pull the trigger in DC activation [43, 44].  
 
 
Table 1: examples of pathogen associated molecular pattern (PAMP) and damage associated molecular pattern 
(DAMP) receptors expressed on dendritic cells and lung epithelial cells. 
 
Interestingly, polymorphisms in several pattern recognition receptors (PRRs) have been found 
associated with allergen sensitization and asthma [45]. As an example, both chitin that is 
present in HDM and cockroach frass are able to induce T cell responses that are TLR2- myeloid 
differentiation primary-response protein 88 (MyD88)-dependent [46-48]. Although both 
compounds trigger the same TLR, the outcome of induced immune response differs 
dramatically. Indeed, chitin was found to induce Th2 responses and to promote allergen 
sensitization, whereas cockroach frass appeared to be protective against the development of 
allergic airway inflammation [46, 49]. We have shown that Der p 1, the major allergen from 
HDM, has proteolytic enzymes that can directly activate DCs and epithelial cells, promoting Th2 
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sensitization [20]. It has been demonstrated that water-soluble mediators
 
of birch-pollen 
promote their Th2 potential and change the chemokine receptor profile of human DCs, thus 
favouring the attraction of Th2 cells to the site of allergic inflammation. The water-soluble 
extract from birch pollen consists predominantly of E1- phytoprostanes (lipids), which resemble 
the structure and function of prostaglandin E2.  These findings support the hypothesis
 
that 
pollen grains themselves appear to contain important signals
 
to pave the way towards a Th2-
dominated immune response [50, 51]. 
A possible explanation in the recognition of complex allergens involves triggering of several 
PRRs and signalling pathways, since some allergens can also trigger TLR4. Kim Bottomly’s group 
has shown that the low amounts of LPS in the model allergen OVA lead to TLR4/MyD88-
dependent Th2 responses in the airways [52-54]. The fact that the TLR4/MyD88-axis was able 
to mediate a Th2 responses was somewhat surprising since LPS, the prototypical ligand for 
TLR4, had been shown to protect from Th2 sensitization [52]. However, the involvement of 
TLR4 signalling in mediating Th2 responses has been recently supported by others using 
relevant allergens, like HDM, to induce Th2 sensitization [55, 56]. TLR4 triggering by allergens 
has often been attributed to their endotoxin content [52], although there seems to be a more 
intimate link between allergic sensitization and TLR4 signalling. Surprisingly, the endotoxin 
contamination of HDM extracts used to induce allergic asthma are in the subnanogram range, 
much lower than the dose described promoting Th2 responses to OVA [55]. Suggesting another 
molecule contributing in TLR4 signalling by HDM on epithelial cells.  It has been reported that 
Derp 2, one of the major allergens of HDM, is a functional homolog of MD2, the LPS-binding 
member of the TLR4 signalling complex [57]. As such, Derp 2 might promote or facilitate TLR4 
signalling. Other studies have shown that HDM can trigger TLR4 and Dectin-2 directly on DCs. 
Indeed, allergens such as house dust extracts or cockroach frass induced DC maturation and 
promoted the production of LTC4 [58], pro-inflammatory cytokines IL-6 and IL-23, and lowered 
levels of IL-12p70. The activation of DCs by HDM relied on downstream MyD88 signalling, 
although others have shown the involvement of IRF3 and Syk signalling [58, 59]. It is important 
to note that TLRs are not the only PRRs triggered by environmental allergens. In fact, some 
airborne allergens contain proteases or glucans that can facilitate allergen sensitization by 
stimulating various PRRs (protease activated receptors, C-type lectins) on various immune cells 
[60-63]. 
 
DAMPs stimulate DC-induced sensitization 
Oxidative stress or tissue damage can trigger inflammation even in the absence of pathogens. 
Inflammation triggered by tissue damage in the absence of infection is often referred to as 
sterile inflammatory response. It is now appreciated that immune cells react to molecules 
released by injured or necrotic, but not apoptotic cells [64]. These molecules alert immune 
system of an impending danger, and are therefore also referred to as ´alarmins´, ‘endogenous 
danger signals’ or danger associated molecular patterns (DAMPs) [65]. These DAMPs interact 
with PRRs (shared with PAMPs) contribute to the induction of inflammation by recruitment of 
innate inflammatory cells. The actual repertoire of DAMPs in damaged tissues can vary greatly 
depending on the type of cell (epithelial or mesenchymal) and injured tissue.  A few danger 
signals are heat shock proteins (HSP), high mobility group box 1 (HMGB1) protein, uric acid (UA) 
and adenosine triphosphate (ATP). DAMPs can be intracellular proteins secreted actively 
10 
 
through nonclassical pathways and endowed with inflammatory activity so-called leaderless 
secretory proteins (LSPs). These LSPs can be released by dying cells and behave as DAMPs. 
HMGB1 is a prototypical LSP that is passively released by injured or necrotic cells, or by 
immune cells in response to endotoxin promoting tissue inflammation [66]. A study on PBMCs 
however showed that HMGB1 alone cannot induce detectable levels of IL-6, except after co-
administration of LPS, CPG-ODN, PAM3CSK4 or IL-1 [67]. Compelling evidence suggests that a 
tight collaboration between PAMPs and DAMPs is needed to start an immune response to 
allergens [68, 69]. In contrast to necrotic cells, apoptotic cells retain HMGB1 in their nuclei and 
therefore do not initiate inflammation [70]. These data suggest some similarities between 
infectious and sterile inflammation, since PAMPs and DAMPs seem to share PRRs [42]. 
 
Alum-induced Th2 responses 
One recent illustration of the potential implication of endogenous danger signals to the 
process of allergic sensitization comes from our studies on the mechanism of action of alum 
adjuvant. Alum is used in mouse models of asthma as a prototypical Th2 adjuvant, whose 
mechanism of action is poorly understood. Alum added to DCs in vitro, poorly activates APC 
function with the notable exception of IL-1β induction [71]. In vivo however, alum strongly 
recruits and stimulates inflammatory DCs and boosts their potential to induce Th2 responses, 
associated with production of bio-active IL-1β. We found that alum induces the release of UA, 
an endogenous danger signal released by dying cells or cells exposed to oxidative stress [72]. 
UA is known to induce the release of IL-1β, to promote Th2 polarizing responses by DCs and 
induces IgG1 [73]. The release of IL-1β requires the presence of a TLR agonist, IL-1 receptor I or 
TNF receptor I/II signalling acting on APCs to promote activation of NF-κB, subsequently 
leading to transcription and translation of pro-IL-1β [74]. Pro-IL-1β is cleaved by caspase-1 in 
the cytoplasm, whose activation in turn depends on triggering of a NLR, NALP3 (also known as 
cryopyrin), via endogenous danger signals [75, 76] leading to the release of bio-active IL-1β 
(figure 3). Recently, NALP3 activation was shown to in cells undergoing necrosis in vitro and in 
vivo, resulting in the production of mature IL-1β [77]. In addition, extracellular ATP has been 
known for years to activate caspase-1, and several studies have demonstrated the 
requirement of P2X7 receptors (in a complex with pannexin-1) for ATP-induced caspase-1 
activation and subsequent IL-1β maturation [78, 79]. Besides, in vivo, UA-mediated Th2 cell 
development can act as an additional trigger. Certainly UA promotes the development of Th2 
responses when added to DCs in vitro [73, 80]. Therefore it is no surprise that mice deficient in 
NALP3, ASC (apoptosis-associated speck-like protein containing a caspase recruitment 
domain), and caspase-1 have a defect in crystal-induced IL-1β secretion and fail to mount 
alum-induced Th2 mediated inflammation in vivo [80, 81]. However this finding has been 
debated and it seems that alum induces the formation of the NALP3 inflammasome and 
requires the ASC protein leading to activation of IL-1β [82, 83]. But NALP3 activation was not 
necessary for the alum-induced adjuvanticity [81,161,162]. Cleaving of pro-IL-1β into its bio-
active form does not occur only intracellularly by NLR activation. Double stranded DNA which 
is released by necrotic cells, is also potently able to induce caspase-1 activation as soon as it is 
cytosolic. Recently, PYHIN (pyrin and HIN domain-containing protein) family member absent in 
melanoma 2 (AIM2) is described as a receptor for cytosolic DNA to regulate caspase-1 induced 
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IL-1β maturation [84], via noncanonical activation of NALP3. AIM2 is the first non-NLR family 
member forming an inflammasome and is composed of AIM2, ASC and caspase-1 [164,165]. 
Neutrophils which are attracted to inflammatory sites, secrete proteinase-3, an enzyme which 
is able to cleave pro-IL-1β extracellularly. Other proteases such as elastase, matrix 
metalloproteases, granzyme A and the mast cell chymase also generate active IL-1β [85]. 
Therefore not all IL-1β-induced responses are necessarily NALP3 dependent. Another 
complicating factor is that many experiments addressing the role of caspase-1 in caspase-1 
deficient mice are flawed by the presence of an additional mutation in caspase-11 in these 
animals. Therefore, many experiments addressing the in vivo importance of caspase-1 will 
have to be performed again in mice with an exclusive caspase-1 deficiency [86]. Moreover, 
caspase-11 is able to activate caspase-1 in response to non-canonical stimuli such as E.coli and 
cholera toxin B [86]. It is also possible that the dependence on the Nlrp3/ASC/Casp1 axis 
depends on the site of primary allergen exposure. Indeed, skin sensitization to HDM seems to 
require this pathway, whereas sensitization via the lungs does not [87]. 
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Figure 3. Schematic representation of classical NALP3 inflammasome activation by lipopolysaccharide (LPS) and 
adenosine triphosphate (ATP) followed by release of inflammatory cytokines. Microbial molecules, such as LPS, bind 
to TLR4, which recruits MyD88. MyD88 will in most cases bind to IL-1 receptor associated kinase (IRAK), which will 
lead to nuclear factor-kB (NF-κB) activation. NF-κB is a transcription factor which is responsible for the transcription 
of inflammatory cytokines. Pro-IL-1β and pro-IL-18 are then released in the cytosol. The second signal activating the 
P2X7 receptor by ATP, leads to large pore formation by pannexin-1. DAMPs (for example uric acid) are than able to 
enter the cytosol and activate the NALP3 inflammasome [78–80]. Activated NALP3 consists of a pyrin domain, a 
NACHT domain and 11 leucine-rich repeat (LRR) domains. Activated NALP3 oligomerizes, recruits ASC and pro-
caspase-1, which results in caspase-1 processing and activation. Active caspase-1 subsequently cleaves the 
precursor forms of IL-1β and IL-18 leads to release of the bio-active cytokines 
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Crosstalk between epithelial cells and lung DCs  
Although DCs can directly respond to allergens in vitro, one major caveat is that most of the 
studies performed have used bone marrow-derived DCs (BMDCs) in mice or monocyte- 
derived DCs in humans to mimic lung DC responses. The direct effect of allergens in vivo on 
tissue- DCs remains unclear. There is evidence that allergens administered in the airways of 
mice or humans can recruit and activate lung DCs. However, this activation is not always 
necessarily direct. Stromal cells like epithelial cells are uniquely positioned at the interface 
between ‘inside versus out,’ making them perfect candidates for orchestrating immune 
responses. Epithelial cells possess microbial-detection mechanisms and express a tightly 
regulated and specifically localized set of PRRs (table 1), which enables them to respond to 
antigens and allergens like immune cells. An emerging concept is that the epithelial barrier 
influences the development of antigen-specific immunity, suggesting that the type of immune 
response is defined by the local tissue microenvironment [7]. It is therefore very likely that 
antigen recognition by epithelial cells determines the functional properties of tissue-residing 
DCs, thereby instructing the outcome of antigen-specific immunity. This concept has important 
implications for the regulation of mucosal homeostasis and the initiation of innate and 
adaptive immune responses [88]. In vitro studies have shown that airway epithelial cells (AECs) 
exposed to HDM produce CCL2 and CCL20, chemokines attracting immature DCs and their 
precursors [63, 89]. CCL20 secretion was not dependent on TLR2/4 expression or on the 
protease activity of allergens, but relied on beta-glucan moieties within HDM [63, 90]. 
Proteases in pollens, cockroach and HDM were found to disrupt epithelial tight junctions and, 
in this way, gain access to DCs. In addition, allergens induce the production of inflammatory 
and instructing pro-Th2 cytokines by AECs [91-94]. All these data point to the fact that allergen-
activated AECs might contribute to instruct DCs and promote Th2 sensitization. This has been 
confirmed in vivo in a series of experiments using bone marrow chimeric mice lacking TLR4 on 
either immune cells or radioresistant epithelial cells. The response to HDM was substantially 
altered when epithelial cells could not sense the endotoxin in the allergen [55, 95]. 
Interestingly, NF-κB activation was often observed in epithelial cells exposed to allergens and 
several studies have demonstrated that lung epithelial cell-specific deletion of NF-κB lead to 
decreased cytokines responses [96-98]. On the opposite, the selective activation of NF-κB in 
airway epithelial cells was enough to drive allergic airway inflammation [99, 100]. 
 
Epithelial cell-derived factors instruct lung DCs to induce Th2 responses to allergens 
NF-κB activation of AECs in response to inhaled allergens, leads to a release of  a variety of 
cytokines (GM-CSF, TSLP, IL-25, IL-33 and IL-1 family members), contributing to DC maturation 
and driving into a Th2-activating mode [55, 101] (Figure 4). These cytokines are described in 
more detail below. 
 
GM-CSF 
GM-CSF is produced by AECs exposed to allergens [90, 102]. The importance of GM-CSF in Th2 
responses came from data obtained in mice overexpressing GM-CSF in the lung. When 
exposed to the harmless antigen ovalbumin, mice overexpressing GM-CSF showed a break of 
inhaled tolerance and developed a strong allergic airway inflammation driven by mature DCs 
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[103]. Along this line, BMDCs grown in the presence of GM-CSF were found to be very effective 
at inducing Th2 priming [16, 104]. Moreover, the administration of HDM in the airways also 
leads to Th2 sensitization that was partially mediated by endogenous GM-CSF [105]. In mouse 
models of HDM-induced asthma, GM-CSF neutralization led to reduced Th2 responses [106, 
107].  GM-CSF is a protypical cytokine used to induce the formation of monocyte-derived DCs 
from bone marrow progenitors in vitro.  When GM-CSF cultured DCs are pulsed with protein 
antigens or real life allergens, and are subsequently transferred to the airways of naïve mice, 
they induce vigorous Th2 immunity and asthma develops upon subsequent intranasal challenge 
with the protein or allergen [16].  However, in vivo it is not known yet how crucial GM-CSF is 
for the formation of moDCS under conditions of inflammation.  One recent study observed no 
reduction of moDC formation in a mouse model of inflammation in GM-CSFR deficient mice 
[108]. 
 
TSLP 
 Another well-described cytokine affecting DCs, B cells and CD4+ T cells is TSLP. It is produced 
not only by epithelial cells [55] but also by mast cells and DCs under inflammatory conditions 
[109, 110]. Various groups have reported correlations between TSLP polymorphisms and/or 
protein expression levels and the development of asthma or allergic rhinitis [111-113]. Its role 
in Th2 responses was shown in a model of asthma in which mice lacking TSLP receptor (TSLPR) 
were found to have attenuated Th2 features [114], whereas mice overexpressing TSLP in the 
lung epithelium had increased asthma features [115]. Recently, TSLP has been shown to break 
inhaled tolerance by inhibiting the generation of induced allergen-specific regulatory T cells 
[116]. Moreover, blockade of TSLP using soluble TSLPR in vitro led to reduced expression of 
maturation markers on TSLP-activated DCs.  In addition, administration of this soluble TSLPR 
before sensitization reduced eosinophilia, IgE levels and Th2 cytokines in vivo [117]. TSLP 
induces Th2 responses most likely through its capacity to activate DCs to upregulate OX40L, 
allowing them to expand Th2 memory cells and enhance the expression of IL-25R (IL-17RB) on 
these memory cells [118-120].  Overexpression of TSLP in bronchial epithelial cells boosts Th2 
immunity in the lungs [114]. However, in mouse models of asthma, driven by natural allergens, 
the neutralization of TSLP does not necessarily lead to reduced features of allergy [121, 122]. 
Despite these doubts on the potential of neutralizing TSLP as a therapeutic strategy, the 
expression of TSLP is increased in bronchial biopsies and sputum of human asthmatics, 
particularly in severe disease [123, 124]. Genetic polymorphisms in the promoter region of 
TSLP are associated with increased risk of asthma [125].  Proteolytic allergens, diesel exhaust 
particles, and cigarette smoke induce epithelial production of TSLP that causes DC activation 
[126, 127].  TSLP promotes the growth and differentiation of basophils from the bone marrow 
[128]. The TSLPR is not only expressed by hematopoietic cells but also by human bronchial ECs. 
TSLP stimulates the proliferation of bronchial epithelial cells and EC IL-13 production [124]. 
One further caveat regarding therapeutic targeting of TSLP is that it can contribute to epithelial 
repair both by inducing secretory leukocyte protease inhibitor (SLPI) and via other mechanisms 
[124, 129]. Expression of SLPI has the potential to dampen allergic airway inflammation and 
interfering with TSLP therapeutically might abolish this protective pathway [130].  
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Figure 4: Both lung DCs and epithelial cells express pattern recognition receptors (PRRs) and can be activated 
directly by allergens. In response to allergens, lung epithelial cells produce chemokines (CCL2, CCL20) that attract 
immature cDCs and inflammatory monocytes. Activated epithelial cells produce instructing cytokines (like IL-1, GM-
CSF, and TSLP) and danger signals (ATP, uric acid),  favoring DC maturation and their migration to the MLN, where 
they will induce Th2 responses. These cytokines and danger signals also recruit and activate innate immune cells, 
such as basophils, mast cells and ILCs. Basophils secrete IL-4 and type 2 innate  lymphoid cells make IL-5 in response 
to IL-33 release by epithelial cells, providing a pro-Th2 environment.  Some epithelial-derived cytokines like IL-37 are 
able to suppress immune responses by inhibiting DC activation. 
 
IL-25 
IL-25 (also known as IL-17E) has initially been reported as a Th2 cell-derived cytokine [131]. 
However, it can also be produced by basophils [132] and epithelial cells in response to 
allergens and respiratory viruses [133, 134]. The proteolytic enzyme MMP7 from bronchial ECs 
is necessary for optimal production of IL-25 [135]. The production of IL-25 by epithelial cells is 
suppressed by IL-22 [136]. IL-25 acts on the IL-25R that consists of the IL17RB and IL25R 
subunits and signals via the adaptor Act1. Although IL-25 promotes Th2 immunity in the lung 
[132, 137], its potential to activate DCs remains unclear. Epithelial-derived IL-25 induces 
Jagged-1 expression on DCs and leads to Th2 responses in the lung of RSV-infected mice [138]. 
Furthermore, IL-25 induces IL-9 production by Th9 cells, via the IL-17RB subunit [139]. When 
administered via the airways, it acts directly on pre-ILC2 to induce their expansion and 
activation [140]. Recently, it was shown that IL-25 also expands a population of granulocytic 
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myeloid cells that produce IL-5 and IL-13 and contribute to lung pathology in mice and humans 
[141]. Epithelial IL-25 also acts directly on fibroblasts and endothelial cells to promote airway 
remodeling and angiogenesis and boosts production of TSLP and IL-33 [142].  Together, these 
studies imply that IL-25 and IL-17RB may be effective therapeutic targets, as they are upstream 
of Th2, Th9 and ILC2 immunity and epithelial activation. Besides, the number of IL-25-
expressing and IL-25R-expressing cells is increased in biopsies of asthmatic patients [143, 144]. 
In mice, overexpression of IL-25 in lung epithelial cells led to increased allergic inflammation 
[133], probably owing to the capacity of IL-25 to activate DCs in driving Th2 responses [134]. 
Injection of neutralizing anti-IL-25 antibodies strongly reduced allergic airway inflammation 
and airway remodelling [133, 145].  
IL-1RI binding family members  
The IL-1 family consists of several members and the family is still increasing. IL-1α, IL-1β and IL-
1Ra both bind to IL-1 receptor 1 (IL-1RI), which is present on almost all cell types, including 
structural cells. IL-1β is released from cultured AECs following protease allergen exposure and 
enhances the release of the DC-attracting chemokine CCL20, and of the DC maturation 
cytokines TSLP and GM-CSF [146, 147]. Remarkably mice deficient of IL-1 α/β showed identical 
AHR as control mice in an asthma model with OVA alum sensitization. However, in a milder 
model using repetitive OVA injections intraperitoneally, mice deficient of IL-1 α/β showed a 
reduced AHR. In addition, mice deficient for IL-1RA (natural antagonist) showed increased 
influx of DCs to the lung, AHR and levels of specific IgE and Th2 responses [148]. Mice lacking 
IL-1RI had reduced features of asthma in the mild model, but not when alum adjuvant was 
used to sensitize the mice [149]. Monocytes and dendritic cells were the main inflammatory 
cell types secreting IL-1β [150]. IL-1RI signalling involves the adaptor molecule MyD88, also 
found downstream of several TLRs. Interestingly, HDM induced Th2 responses in the lung were 
found strongly reduced in MyD88-/- mice [56]. In this study, DC migration to the LNs was 
altered in MyD88-/- but not in TLR4-/- mice, suggesting that some aspects of DC biology might 
be controlled by IL-1 family members signalling through MyD88. Recently, more attention has 
been put on trying to elucidate the role of other IL-1 family members. As such, IL-37 was 
reported to be different from other members of the family since it was able to suppress 
inflammatory responses. When expressed in lung epithelial cells or in macrophages, IL-37 
decreased the production of pro-inflammatory cytokines, such as IL-1α, TNFα and IL-6 by 
these cells [159]. Little information is available about another member called IL-1F9. Elevated 
levels of this cytokine have been detected in AECs of allergen-challenged mice and it was 
shown to promote inflammation [160]. Whether this epithelial-derived cytokine is able to 
instruct lung DCs to induce Th2 responses to inhaled allergens remains to be elucidated. 
 
IL-33 
DCs have been shown to express ST2, the receptor for the IL-1 family member IL-33. This 
cytokine is expressed in AECs where it is constitutively stored in the nuclei. Its location is 
unexpected and how it is released in the extracellular environment remains unclear. Although 
it has been postulated that IL-33 might act as an alarmin in case of allergen exposure [151]. 
Besides DCs other inflammatory cells express ST2, like eosinophils, basophils, mast cells and 
type 2 innate lymphoid cells (ILC2). DCs exposed to IL-33 increased their expression of 
16 
 
maturation markers, such as CD40, CD80 and OX40L and became very potent at inducing Th2 
responses [152, 153]. Intratracheal administration of IL-33 induces eosinophilia in the lung and 
increased immunoglobulin serum levels [152]. Moreover, human eosinophils were shown to 
become activated by signalling of the ST2 receptor in vitro [154]. In addition, in a mild asthma 
model treatment of mice with an antibody against IL-33, features of airway inflammation were 
inhibited [155]. IL-33 was found to be elevated in biopsies from asthmatics compared to 
control subjects [156]. This cytokine is also released by lung epithelial cells upon HDM 
challenge and levels were found to correlate with AHR  [55, 157]. Recently IL-33 was found to 
be cleaved by caspase-1 just like its family members IL-1β and IL-18. However, the cleaved 
protein was inactive and not able to bind to the ST2 receptor and induce signalling, unlike the 
intact IL-33 [158]. 
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Aims and outline of the thesis 
As described in the introduction, DCs are the main antigen presenting cells responsible for 
immune activation in the lung. DCs can react directly to variety of antigen and allergens.  At 
the outset of this thesis, we had three questions that also currently dominate the field of lung 
DC biology: 
1/ Which subsets are performing the task of antigen presentation in the lung?  
2/ Which signals are required to get proper activation of DCs in the lungs in response to 
foreign matter introduction?  
3/ Can we exploit DCs to design better therapies for inflammatory lung disease?  
 
Although the primary focus of this thesis is on asthma, we also addressed the function of the 
lung DCs that surround the lung capillaries, one of the last DC subsets on which very little is 
known. In chapter 3, we investigated if and how large particulate antigens that were injected 
in the bloodstream are presented by DCs in the lungs. We describe a model using sepharose 
beads to investigate antigen sampling and presentation by blood vessel lining DCs. We found 
that inflammatory mo-DCs are presenting the antigen to T cells in the MLN. In chapter 4 we 
describe the potential therapeutic application of the immunomodulary compound, 
ursodeoxycholic acid (UDCA) in a model of experimental asthma. We found that UDCA is 
reducing allergic lung inflammation by acting on the farnesoid X-receptor on DCs.  
While investigating the role of endogenous danger signals in allergic asthma to better 
understand the activating signals of lung DCs, we show in chapter 5 that uric acid acts on lung 
DCs during sensitization to allergens and depends on TLR4 signalling on structural cells. Trying 
to elucidate the downstream effects of IL-1 in allergic asthma, we found that IL-1RI signalling 
on radioresistant stromal cells plays a key role in the sensitization in allergic asthma. As 
presented in chapter 6 we found that IL-1α, not IL-1β, was important in allergic asthma leading 
to release of GM-CSF and IL-33 by AECs, instructing DCs to induce a Th2 immune response. In 
chapter 7 we discuss some recent findings relevant to the published data and touch upon the 
clinical applicability of our findings.   
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In this chapter we have set up a model to study large embolic antigens. Dendritic cells were 
found to surround the blood vessels in the lung. Conventional DCs recruit monocytes to the 
site of inflammation by releasing MCP-1. We found that recruited monocyte derived-DCs are 
capable to present these antigens to primary T cells in the draining lymph node. 
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The lung vascular filter as a site of immune induction for T cell 
responses to large embolic antigen 
 
Abstract 
The bloodstream is an important route of dissemination of invading pathogens. Most of the 
small bloodborne pathogens, like bacteria or viruses, are filtered by the spleen or liver 
sinusoids and presented to the immune system by dendritic cells (DCs) that probe these filters 
for the presence of foreign antigen (Ag). However, larger pathogens, like helminths or 
infectious emboli, that exceed 20 μm are mostly trapped in the vasculature of the lung. To 
determine if Ag trapped here can be presented to cells of the immune system, we used a 
model of venous embolism of large particulate Ag (in the form of ovalbumin [OVA]-coated 
Sepharose beads) in the lung vascular bed. We found that large Ags were presented and cross-
presented to CD4 and CD8 T cells in the mediastinal lymph nodes (LNs) but not in the spleen or 
liverdraining LNs. Dividing T cells returned to the lungs, and a short-lived infiltrate, consisting 
of T cells and DCs, formed around trapped Ag. This infiltrate was increased when the Toll-like 
receptor 4 was stimulated and full DC maturation was induced by CD40 triggering. Under these 
conditions, OVA-specific cytotoxic T lymphocyte responses, as well as humoral immunity, were 
induced. The T cell response to embolic Ag was severely reduced in mice depleted of CD11c
hi
 
cells or Ly6C/G
+
 cells but restored upon adoptive transfer of Ly6C
hi
 monocytes. We conclude 
that the lung vascular filter represents a largely unexplored site of immune induction that 
traps large bloodborne Ags for presentation by monocyte-derived DCs. 
 
Introduction 
DCs are the most important APCs for mounting a primary immune response to foreign antigens 
(Ags) that invade the various barriers of the body such as the skin, gastrointestinal, and 
respiratory mucosae (Banchereau and Steinman, 1998). DCs have been well studied and their 
function is to take up Ag across the lining barrier, integrate signals on the pathogenicity of the 
Ag, and migrate via the afferent lymph to the regional draining LNs. In the T cell area of these 
draining LNs, DCs induce a tailor-made immune response that is optimal to clear the pathogen 
in the best possible way while avoiding damage to self (Banchereau and Steinman, 1998). 
Another portal of entry, but also a portal of dissemination of invading pathogens, is the 
bloodstream. Pathogens that reach the bloodstream, either through direct puncture of the 
skin or invasiveness through mucosal surfaces such as the nasopharynx or lung, are easily 
carried throughout the body. It is most often assumed that these Ags will be filtered by the 
splenic microarchitecture, particularly the splenic marginal zone, and subsequently presented 
by splenic DCs and/or macrophages to naive T cells for induction of a primary protective 
immune response (De Smedt et al., 1996; Morón et al., 2002). Some bloodborne pathogens 
might also be filtered and presented in the bone marrow (Feuerer et al., 2003). For pathogens 
that replicate and invade the bloodstream via the gastrointestinal tract, the portal circulation 
can lead to filtering in the liver blood sinusoids and Ag presentation by DCs in liver draining LNs 
(Kudo et al., 1997). Another, often neglected mechanism might exist in the lungs to filter 
bloodborne pathogens. The pulmonary vascular system with its small diameter arterioles (20–
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500-μm diameter) and capillaries (<10-μm diameter) forms an extensive meshwork that 
receives the complete cardiac output of blood (for comparison, the spleen receives only 5% of 
cardiac output or 200–300 ml/min). Large particles that circulate in the bloodstream (called 
emboli in the medical literature) and exceed the diameter of the small pulmonary vessels are 
very efficiently trapped by this system. It is currently unknown whether Ags or pathogens that 
clog the lung vascular system would be presented to the immune system in a way that leads to 
protective immunity, which is analogous to the splenic or liver filter system. The lung vascular 
bed is situated in the lung interstitium, where a well-developed network of interstitial DCs and 
macrophages is present (GeurtsvanKessel and Lambrecht, 2008). However, APCs of the lung 
interstitium have generally been regarded as sessile cells that only stimulate already primed T 
cells, for example, during pulmonary delayed-type hypersensitivity reactions and granuloma 
formation (Holt et al., 1988; Gong et al., 1994; Iyonaga et al.,2002; Tsuchiya et al., 2002). DCs 
are also found to line the intima and adventitia of larger (pulmonary) vessel walls and, 
therefore, could probe the luminal contents for the presence of Ags, although it is unclear to 
what Ags this sampling system would react (Millonig et al., 2001; Perros et al., 2007; Choi et 
al., 2009). The purpose of this study was to determine whether the lung vascular system allows 
Ag sampling and, thus, acts as a site of immune induction for T cell responses after i.v. injection 
of particulate Ag. For this, we injected large Sepharose beads coupled or not to ovalbumin 
(OVA). Because of their size (± 40–150 μm), i.v.-injected beads are specifically retained in the 
vascular bed of the lung. Our studies revealed a hitherto unexplored potential of CD11c
+
 DCs 
and their immediate monocytic precursors to sample the lung vascular compartment for 
trapped Ag, leading to Ag presentation in lung draining LNs and generation of effector 
responses to OVA. 
 
Results 
Embolic large particulate Ag is presented and cross-presented exclusively in the mediastinal 
LNs (MLNs) draining the lung  
We i.v. injected large Sepharose beads coupled or not to OVA323-339 peptide (coded, 
respectively as OVA beads [OBs] and uncoated beads [UBs]), the immunodominant MHCII-
restricted peptide of OVA. To allow detection of the precise site of primary T cell activation and 
division, 2 d earlier, mice received a cohort of CFSE-labeled CD4+ OVA TCR transgenic (Tg) 
DO11.10 T cells (Fig. 1 A), recognizing the OVA323-339 peptide in the context of I-A
d
 (MHCII). The 
precise localization and degree of T cell proliferation, as measured by sequential halving of 
CFSE intensity with each round of T cell division, was measured over time in different 
anatomical compartments, including the lung, draining MLN, peripheral nondraining LN, and 
spleen, up until 16 d after bead injection. Proliferation of naive OVA-specific T cells first 
occurred exclusively in draining MLNs of the lung 2 d after injection of OBs but not after 
injection of UBs (Fig. 1 B). Despite the i.v. injection of Ag, no divisions were observed in spleen 
or nondraining peripheral LNs (PLNs), illustrating that free or particle-bound Ag did not leak 
from trapped Ag or pass beyond the lung capillary filter. More specifically, we also tested 
whether primary divisions were found in the liver draining LNs yet found no evidence for this 
(Fig. S1). When we focused on the lung interstitium itself, which was obtained by enzymatic 
digestion of a lung lobe, we could not detect divided T cells 2 d after injection of beads (Fig. 1 
C). When the T cell response was followed over time (Fig. 1 B), it became evident that by day 4 
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after injection of OBs, divided CD4+ T cells appeared in the nondraining nodes as well as the 
spleen. These T cells had divided at least three to four times and expressed high levels of CD44 
while having down-regulated the early activation marker CD69, which is consistent with an 
activated phenotype, as previously reported (Lambrecht et al., 2000; unpublished data). 
Strikingly, these divided cells could also be traced back to the lung interstitium (by flow 
cytometry; Fig. 1 C), where they were found surrounding the injected OBs (by confocal imaging 
and immunostaining for DO11.10 TCR; Fig. 1 D). Some OVA-specific DO11.10 T cells were seen 
in immediate proximity of lung vessels in the vicinity of OBs, suggesting a specific recruitment 
mechanism at this site. When the immune response was evaluated even later (days 8 and 16), 
it was clear that divided CD4
+
 T cells could no longer be traced back in the LNs, spleen, or lung, 
suggesting that they were deleted or their numbers had declined to a level below the 
threshold of detection by flow cytometry (Fig. 1 B). Although these findings certainly 
suggested that there is a mechanism of immune induction for Ag trapped in the lung 
vasculature, these experiments were not conclusive as to whether Ag would also be processed, 
as beads were coated with preprocessed OVA peptide. We therefore also studied whether 
whole OVA protein coupled to Sepharose beads would be processed and presented to CD4 and 
cross-presented to CD8 T cells. We therefore turned to the C57BL/6 background, in which both 
CD4 (OT-II) and CD8 (OT-I) TCR Tg mice are available (Barnden et al., 1998). For this, C57BL/6 
mice received MHCI-restricted OT-I or MHCII-restricted OT-II OVA TCR Tg T cells. In both 
circumstances, we observed T cell divisions in the MLNs 4 d after injection of OBs (Fig. 1, E and 
F). Again, injection of OBs did not lead to T cell divisions outside the draining area of the lung 
(unpublished data). In the lungs, we followed the size of the inflammatory lesions surrounding 
OBs or UBs. By day 4 of the response, the inflammatory lesions (as measured by the mean 
surface area of the inflammation minus the surface area of the bead divided by the bead 
surface area [see Materials and methods]) was greatly enhanced in mice receiving OBs 
compared with UBs. However by days 8–16, all inflammation surrounding the beads had 
disappeared, illustrating the transient nature of lung inflammatory lesions (Fig. 1 G). Together, 
these data suggested the presence of an active immune surveillance mechanism in the lung 
vascular bed that was induced in the mediastinal nodes.  
 
Monocyte-derived DCs accumulate around particulate Ag trapped in the lung vasculature 
We next addressed by which mechanism trapped Ag would be presented in the lung vascular 
bed. First, we studied the distribution of injected beads after i.v. injection. Injected beads were 
found exclusively in the lung vascular bed (Fig. 2 A) but not in the draining MLN, nondraining 
LN, or spleen (not depicted). As there was Ag presentation in the MLN, despite absence of 
macroscopic beads at this site, we reasoned that a migratory APC population might carry 
antigenic cargo to the node. As soon as 6 h after injection of UBs or OBs, we detected a 
population of CD11c
+
 cells around the injected beads, irrespective of whether beads were 
coated with OVA peptide (Fig. 2 A, days 1–16) or not (not depicted). In addition, MHC class II
+
 
cells started to appear around these beads around this time period. Double staining revealed 
these cells to be CD11c
+
 and MHC class II
+
 double positive, strongly suggesting they were DCs 
(Fig. 2 A). When followed over time, the number of MHCII
+
CD11c
+
 cells was increased at day 4 
after injection of OBs compared with injection of UBs, a time point when inflammatory lesions 
and accumulation of CD4
+
 T cells were also maximal (Fig. 2 B). Later in the response, CD11c
+
 
29 
 
 Figure 1. Embolic large particulate Ag in the lung is presented in draining MLNs. (A) BALB/c or C57BL/6 were 
injected with OVA-specific CFSE-labeled TCR Tg T cells 2 d before i.v. injection of particulate Ag (OVA 323-339 
peptide, LPS-free OVA, or control glycine). At 1, 2, 4, 8, and 16 d after injection of particulate Ag, mice were 
sacrificed and MLNs, PLNs, spleen, and lungs were analyzed for a T cells response. This experiment was performed 
three times with four mice at each time point. (B) Response of OVA-specific CFSE-labeled CD4
+
 DO11.10 T cells after 
injection of OBs or UBs at indicated days. MLNs, PLNs, and spleens were analyzed for the occurrence of OVA T cell 
division (CFSE profile, x axis) in OVA-specific KJ1.26
+
 T cells (y axis). Recirculating divided T cells are indicated in 
rectangles. FACS plots represent a single animal of a group of five at each day point. The experiment was performed 
three times. (C) Division profile (CFSE, x axis) of KJ1-26
+
 CD4
+
 DO11.10 T cells (y axis) in the lung at 2 and 4 d after 
injection of OB or UB. Recirculating divided T cells are indicated in rectangles. FACS plots represent a single animal 
of a group of five at each day point. The experiment was performed three times. (D) Confocal imaging of frozen 
section of lungs stained with the OVA-specific TCR-specific marker KJ1-26 (red). At day 4 after injection of OBs, OVA-
specific T cells could be found in close proximity to blood vessels (BV) and around the OB. Bars, 40 μm. (E) Whole 
particulate Ag is cross-presented in draining MLNs of the lung. At day - 2, OVA-specific Tg CD8
+
 CFSE-labeled OT-I 
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were injected i.v., and at day 0, OBs (LPS free) or UBs were injected i.v. At day 4, MLNs were gated on CD8 T cells 
and analyzed for division CFSE profile (x axis) of Vβ 5.1/5.2–PE-positive OVA-specific T cells (y axis). This experiment 
was performed three times with four mice per group. (F) Whole particulate Ag is presented in draining MLNs of the 
lung. Division CFSE profiles (x axis) of CD4 + Vβ 5.1/5.2–PE-positive (y axis) OT-II OVA-specific T cells in MLNs, 4 d 
after OB injection. Cells were gated for CD4 positivity. This experiment was performed three times with four mice 
per group. (G) Size of inflammation surrounding UBs or OBs in the lung as measured by image analysis measuring at 
days 4, 8, and 16 after injection of UBs (white bars) and OBs (black bars). Groups consisted of five mice at each day 
point. The experiment was performed three times. Mean ± SEM of the group is depicted. *, P < 0.05. 
 
DCs were still present around OBs but, gradually, their numbers decreased. To check for the 
presence of myeloid cells (like monocytes, neutrophils, and some DC subsets), we also  stained 
for the presence of CD11b
+
 cells. We found CD11b
+
 cells to be abundantly present around OBs 
(Fig. 2 A, bottom). The CD11c integrin is expressed on different cell types in the mouse lung 
but is mainly restricted to CD11b
-
 and CD11b
+
 conventional lung DCs, inflammatory type 
CD11b
+
 DCs, and CD11b
+
 alveolar macrophage in the lung (de Heer et al., 2004; van Rijt et al., 
2004; Vermaelen and Pauwels, 2004; Sung et al., 2006; GeurtsvanKessel et al., 2008). Lung 
plasmacytoid DCs (pDCs) are characterized by intermediate expression of CD11c and 
expression of Gr1 (Ly6G/C), B220, and the specific marker BST2 (recognized by the mAb 
120G8; Asselin-Paturel et al., 2003; de Heer et al., 2004, 2005). To analyze which subset of 
CD11c
+
 DC was recruited to particulate Ag, frozen sections were stained with CD11c and Gr1 
(recognizing Ly6C/G) or B220. Remarkably, CD11c
+
 cells surrounding beads were Gr1
+
 but 
lacked expression of the B220 marker, which is normally expressed on the surface of pDCs (Fig. 
S2). We also stained for pDCs by using the pDC-specific antibody 120G8, and this staining 
confirmed that Gr1
+
 CD11c
+
 DCs were not pDCs (unpublished data). We did not observe 
significant amounts of CD103, which is found on a subset of CD11b
-
 lung DCs (unpublished 
data). The expression of Gr1 (Ly6G/C) on lung CD11c
+
 cells surrounding beads was unexpected, 
as this marker is classically not found on lung DCs in steady state (GeurtsvanKessel and 
Lambrecht, 2008; GeurtsvanKessel et al., 2008). Gr1 also recognizes the Ly6C Ag, expressed on 
a subset of monocyte-derived inflammatory DCs (Randolph et al., 1999; Geissmann et al., 
2003; Sunderkötter et al., 2004; León et al., 2007; León and Ardavín, 2008). In the mouse, 
circulating monocytes can be discriminated into Ly6C
+
 CX3CR1
int
 CD11b
+
 monocytes and Ly6C
+
 
CX3CR1
hi
 CD11b
+
 monocytes (Geissmann et al., 2003). Several groups have now shown that 
both types of monocytes are immediate circulating precursors for lung DCs but not steady-
state lymphoid tissue conventional DCs (Geissmann et al., 2003; Landsman et al., 2007; Varol 
et al., 2007; Jakubzick et al., 2008). To test the presence and differentiation of monocytes 
around injected beads at earlier time points, we injected CX3CR
GFP
 mice with OBs (Jung et al., 
2000). In these CX3CR
GFP
 mice, all monocytes (and some T cells and NK cells) can be identified 
by GFP positivity and precisely localized in tissues using confocal imaging. As shown in Fig. 2 C, 
6 h after injection of OBs, CX3CR-GFP
+
 cells were seen around injected beads. At the same 
time, Ly6C
+
 and CD11c
+
 cells were seen. The majority of cells were triple positive. It is of note 
that few cells were CX3CR1
+
Ly6C
-
 , signifying resident blood monocytes, although some cells 
expressed CX3CR1 and Ly6C without CD11c, representing recruited inflammatory monocytes 
(Auffray et al., 2007). 
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Figure 2. DCs and their monocytic precursors surround trapped particulate Ag. (A) 6-μm lung sections at 1, 2, 4, 8, 
and 16 d after injection of OBs were double stained for CD11c and MHC class II expression to identify the 
appearance of DCs around the particulate Ag. Furthermore, myeloid cells surrounding OB were stained with an anti-
CD11b antibody on a consecutive slide. UBs are not shown in A but are summarized under B. This experiment was 
performed three times with four mice per group. Bars, 40 μm. (B) Absolute number of DCs surrounding OB and UB 
(double stained for CD11c
+
 and MHCII
+
 ) were counted for n = 4 mice per day per group. Results are shown as mean 
of CD11c
+
 MHCII
+
 DCs of 30 separate lesions surrounding beads ± SEM. *, P < 0.05. This experiment was performed 
twice. (C) Presence of monocytic markers on CD11c
+
 cells surrounding OBs. For this purpose, C57BL/6 CX3CR-GFP 
(green) Tg mice received OBs and OTII T cells. Lungs were sampled 6 h after OB i.v. injection. Slides were 
additionally stained for Ly-6C (red) and CD11c (blue). Beads are marked by dashed circles and a capital B. Overlays 
of a frame depicted in the top middle (rectangle) are shown in the bottom. This experiment was performed twice. 
 
Monocyte-derived DCs are necessary and sufficient for presentation of particulate Ag 
trapped in the lung vasculature 
These findings of Ag presentation in the MLN draining the lungs and accumulation of 
Ly6C
+
CD11c
+
 cells around injected beads suggested that DCs were the major APC population 
presenting bead-associated intravascular Ag to T cells. To address the precise contribution of 
CD11c
+
 DCs, we used mice expressing the human diphtheria toxin (DT) receptor (DTR) under 
the control of the murine CD11c promotor, allowing the DT-induced conditional depletion of 
all conventional CD11c
+
 DCs but leaving pDCs largely unaffected (Jung et al., 2002; Sapoznikov 
et al., 2007). We administered DT i.p. at the time of OB injection and followed the division of 
CFSE-labeled DO11.10 T cells. As seen in Fig. 3 A, T cell proliferation at day 4 of the response in 
the MLNs of CD11c- DTR Tg mice given DT was dramatically reduced to the level seen in mice 
given UBs. However, non-Tg littermate control mice given DT (or CD11c-DTR Tg mice given PBS 
[unpublished data]) still mounted a normal response to bead injection. The reduction of T cell 
proliferation in DC-depleted mice was accompanied by a severe reduction in the size of the 
inflammatory lesions surrounding the OBs at day 4 after injection (unpublished data). To study 
if DT treatment depleted local CD11c+ cells around injected beads, we performed 
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immunostaining for CX3CR1, Ly6C, and CD11c. Whereas in DTR-Tg mice given PBS treatment 
there was a clear recruitment of triple-positive cells 24 h after injection of OBs, these cells 
were severely reduced by DT treatment. Very strikingly, the depletion of CD11c
hi
 cells using DT 
also led to a reduction in CX3CR
+
Ly6C
+
CD11c
+
 inflammatory monocytes (Fig. 3 B). As the 
depletion of these monocytes in CD11cDTR Tg mice has never been demonstrated before and 
as these cells lack expression of CD11c, whose promotor is driving DTR expression, we 
hypothesized that DT treatment led to a reduction of inflammatory monocytes indirectly. It 
has been shown that CD11c
+
 cells of the lungs are a predominant source of chemokines for 
recruitment of other inflammatory cell types (Beaty et al., 2007). In support of this hypothesis, 
we performed stainings for monocyte chemotactic protein 1 (MCP-1, also known as CCL2), the 
major chemokine recruiting CCR2
hi
 inflammatory monocytes (Fig. 3 C). In PBS-treated DTR-Tg 
mice given OBs, there was a strong signal for MCP-1 colocalizing with DAPI
+
CD11c
+
 cells and a 
clear MCP-1 signal localized to the DAPI
neg
 extracellular space. However in DT-treated DTR-Tg 
mice, both CD11c associated and extracellular MCP-1 staining was abolished. This data 
suggested that the effect of DT treatment on Ag presentation of bead-associated Ag could be 
the result of direct effects on resident DCs or to indirect effects on recruited monocytes that 
subsequently differentiate to inflammatory type DCs. To further study the contribution of 
inflammatory DCs in presentation of large embolic Ag, we sorted Ly6C
+
CD11b
+
CD11c
+
 
inflammatory DCs from the MLN and lungs 24 h after injection of OB or UB (Fig. 3 D). Whereas 
lung-derived inflammatory DCs did not present the OVA to CD4 T cells, MLN derived 
inflammatory DCs readily did. Similar experiments using CD8 OVA-specific T cells as a read out 
demonstrated that both MLN and lung inflammatory DCs presented to CD8 T cells (Fig. S3). In 
contrast, autofluorescent F4/80
+
CD11c
+
 alveolar macrophages did not present the Ag to CD4 
or CD8 T cells (Fig. 3 D and Fig. S3). Cells with this phenotype were not seen to migrate to the 
MLN. To more directly address the functional role of Ly6C
+
 monocytes and their offspring in 
causing T cell proliferation after i.v. injection of embolic Ag, we performed depletion 
experiments in which monocytes were depleted using the Gr1 (Ly6C/G) antibody (Jakubzick et 
al., 2008). Single injection treatment with this antibody did not affect the number of lung-
resident DC subsets (unpublished data). At day 4, mediastinal T cell division was severely 
reduced in Gr1- treated mice, compared with isotype-treated mice (Fig. 3 E), almost down to 
the level of mice injected with UBs (not depicted). The formation of inflammatory lesions 
around injected OB was also significantly suppressed and delayed until day 8 after injection of 
beads in mice depleted of Gr1
+
 cells compared with the control isotype-treated mice, which 
had the maximum inflammatory lesions at day 4 (Fig. S4 A). However, by day 16, all 
inflammatory lesions had cleared, even in Gr1-treated mice. The Gr1 antibody has also been 
used to deplete pDCs from the lungs of mice (de Heer et al., 2004; Smit et al., 2006). To 
address the specific contribution of pDCs in this response, we also treated mice with the 
depleting antibody 120G8, recognizing the more pDC-restricted Ag bone marrow-stromal Ag-2 
(Asselin-Paturel et al., 2003). The treatment with 120G8 around injection of OBs did not affect 
the degree of T cell proliferation in draining MLNs at day 4 of the response, compared with 
isotype-treated mice (Fig. S4 B), nor did it affect the size of inflammatory lesions (not 
depicted). As these experiments in CD11c
+
-depleted and Gr1-treated mice clearly 
demonstrated that these cells were necessary for immune induction in the lung capillary filter, 
we next questioned if Ly6C
+
 monocytes would also be sufficient for inducing an immune  
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Figure 3. Monocyte-derived CD11c + DCs are essential and sufficient for priming of naive CD4
+
 in lung draining 
MLNs in response to Ag trapped in the lung vasculature. (A) Effect of DT treatment in CD11c-DTR Tg mice on Ag 
presentation of large embolic Ag. At day 4 after injection of OB, hardly any division in CFSE-labeled DO11.10 OVA-
specific CD4
+
 T cells could be found in draining lung MLNs in DT-treated DTR-Tg mice, whereas strong divisions were 
seen at that same time point in non-Tg littermates mice receiving OB and DT or DTR-Tg mice receiving OB and PBS 
as a control treatment. (B) Effect of DT treatment on presence of monocytes and DCs around beads. 24 h after DT 
treatment, fewer CX3CR1
+
 Ly6C
+
  monocytes and CX3CR1
+
 Ly6C
+
 CD11c
+
 inflammatory DCs were found around 
injected OB in CD11c-DTR-Tg mice compared with PBS treatment. Beads are marked by dashed circles. (C) Effect of 
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DT treatment on monocyte specific chemokines. CD11c
+
 cells were depleted with DT injection on day 0 in CD11c 
DTR-Tg mice. 24 h after DT treatment and OB injection, no MCP-1 was found around injected beads, whereas in 
PBS-treated Tg mice, MCP-1 was found co-localizing with CD11c and in the extracellular space not containing DAPI + 
nuclei. Beads are marked by dashed circles. (D) DCs and macrophages were sorted from MLN and lung from mice 
injected with UB or OB. These APCs were subsequently put in co-culture with CFSE-labeled OT-II cells for 4 d. 
Autofluorescent alveolar macrophages were not detected (n.d.) in the MLNs. (E) Effect of depletion of Ly6C/G cells 
using Gr1 antibody. CFSE-labeled OVA-specific CD4
+
 DO11.10 division profile in draining MLNs in mice treated with 
anti-Gr1 or isotype i.p. at day 0 and injected with OB, measured at day 4. (F) Ly6C
hi
 monocytes restore T cell division 
in CD11c-depleted mice. CD11c/DTR-Tg mice or non-Tg littermates (nTg) received CFSE-specific OVA-specific CD4
+ 
T 
cells at day -2, with DT at day 0, with either UB (nTg) at day 0 or OB (nTg) at day 0, or OB at day 0 (DTR-Tg mice) with 
or without 3.5 × 10
5
 bone marrow–purified (>99%) Ly6C
hi 
CD11b
hi
 monocytes. CD4
+
 OVA-specific T cell divisions in 
these groups are shown in draining MLNs at day 4 after UB or OB injection. DTR-Tg mice depleted of CD11c
+
 by DT 
show reconstitution of divisions by monocyte i.v. injection at day 0. (G) Depletion of langerin
+
 lung DCs, using DT 
injection, in langerin-DTR mice showed no effect on OVA-specific T cell proliferation, compared with nTg mice given 
DT. These experiments were performed two to five times with five mice per group per time point. 
 
response to Ag trapped in the lung vasculature. For this purpose, Ly6C
hi
 monocytes were 
sorted from the bone marrow (based on expression of CD11b and Ly6C and lack of expression 
of CD31) and adoptively transferred i.v. in CD11c DTR Tg mice given DT around the time of 
bead injection. As seen in Fig. 3 F, restoration of OVA-specific CD4+ T cell divisions could be 
accomplished by injection of bone marrow–purified Ly6C
hi
 monocytes. Monocytes have also 
been shown to be precursors of Langerin
+
 DCs in the lungs (Jakubzick et al., 2008) and 
Langerhans cells of the skin (Ginhoux et al., 2006), and DT treatment of CD11c-DTR might 
target these langerin
+
 DCs directly, as they express high levels of CD11c. Therefore, we also 
addressed whether lung langerin
+
 DCs were involved in this response by treating C57BL/6 
langerin-DTR mice systemically with DT. In these mice, depletion of langerin
+
 cells had no 
effect whatsoever on divisions of OVA-specific OTII T cells in the MLNs, which is in sharp 
contrast to the same treatment in CD11cDTR mice (Fig. 3 G). Together, these data therefore 
suggest that venous embolic Ags are filtered in the lung vascular bed and presented by 
monocyte-derived CD11c
+
 DCs in the MLNs. 
 
Induction of maturation of monocyte-derived DCs by microbial stimuli and trimeric CD40L 
increases effector  potential of T cells without affecting T cell division 
In all our experiments, we observed that inflammatory lesions around the OBs eventually 
resolved by day 8 of the response. This could be a result of the fact that OBs are seen as 
relatively harmless Ags, leading to a failure of functional maturation in monocyte-derived 
CD11c
+
 DCs. To address this point, mice were injected with OBs that were also coated or not 
with LPS and/or trimeric CD40L or as a control with UBs. Trimeric CD40L is an effective agonist 
of CD40 on DCs and is known to induce DC maturation, particularly when a concomitant TLR 
agonist such as endotoxin is administered (Schulz et al., 2000). In mice receiving OB coated in 
combination with trimeric CD40L and LPS, there was a strong increase in the size of 
inflammatory lesions around the OBs (Fig. 4 A, inflammatory lesions at day 4 after bead 
injection). LPS co-coating of OB by itself was insufficient to obtain this effect (Fig. 4, A and B). 
This enhancing effect was maintained until day 16 after injection of beads, although 
inflammatory lesions became much smaller compared with those seen on day 4 (Fig. 4 B). 
Despite the occurrence of larger inflammatory lesions around OBs with LPS and sCD40L, at day 
16 all inflammatory lesions were again resolved. Provision of these DC-maturing stimuli did not 
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affect the strength of T cell divisions in the MLN at day 4 after OB injection (Fig. 4 C). When the 
amount of cytokine production was measured in cultures of MLN, restimulated for 4 d in the 
presence of OVA Ag, the addition of LPS and/or sCD40L clearly enhanced the production of 
IFN-γ, whereas IL-4 remained at the detection limit of the ELISA (Fig. 4 D). To address whether 
CD40 and TLR4 triggering had to occur physically on the same particulate OB, mice received 
beads coated simultaneously with OVA, LPS, and anti-CD40 or mice received beads coated 
separately with OVA, LPS, or anti-CD40. OB and LPS-aCD40 OB-injected mice also received 2/3 
UB to equalize the amount of beads and the amount of OVA Ag given between groups. As 
shown in Fig. 4 E, restimulated MLN cells secreted more IFN-γ  when the beads were coated 
with OVA, LPS, and anti-CD40 simultaneously, compared with mice given a mixture of 
separately labeled OB, anti-CD40 beads, and LPS beads. We also addressed whether injection 
of OBs in conjunction with CD40 and TLR4 triggering led to induction of CTL responses to OVA-
pulsed target cells. For this, we injected an equal amount of OVA-pulsed or unpulsed BM-DC 
targets, stained, respectively, with CMTMR and CFSE (Ritchie et al., 2000). As shown in Fig. 4 F, 
simultaneous triggering of CD40 and TLR4 on beads led to induction of OVA-specific lytic 
effectors that killed 50% of injected OVA-pulsed DCs, whereas injection of UBs or OVA-LPS–
coated beads did not have this effect. Finally we also addressed the induction of humoral OVA-
specific immunity by injection of these beads. We observed induction of OVA-specific IgG1 
after injection of OBs already when only TLR4 was triggered, whereas injection of UBs did not 
induce OVA-specific antibodies. 
 
Discussion 
In this paper, using a system of traceable Ag-reactive T cells specific to OVA, we report that the 
meshwork of small lung vessels allows the effective filtering of large embolic Ags followed by 
uptake of the Ag by monocyte-derived CD11c
+
 DCs and Ag presentation to CD4
+
 and CD8
+
 T 
cells in the MLNs. Primed T cells subsequently return to the lung and form short-lived 
inflammatory lesions that are ultimately cleared. This response clearly depends on Ly6C
+
 
monocytes and CD11c
hi
 DCs, as it is eliminated in mice with a conditional deletion of CD11c
+
 
cells and depleted of Gr1 (Ly6C/G)
+
 cells, and restored by adoptive transfer of Ly6C
hi
 
monocytes (Jung et al., 2002). These data, therefore, identify a third filtering network for 
bloodborne Ags, in addition to the spleen and liver, that is specialized for immune induction 
against large embolic material. Strikingly, early after injection of embolic material, there was 
an accumulation CD11c
+
MHCII
+
 DCs surrounding the injected beads of which the origin can be 
debated. One possibility is that the resident interstitial DCs of the lung that can be found in 
alveolar septa would migrate to the occluded vessels and sample the vessel content. 
Numerous studies in mouse and rat have indeed demonstrated that alveolar septa contain DCs 
in close proximity to small diameter arterioles and alveolar capillaries (Sertl et al., 1986; Holt et 
al., 1988, 1992). However, these interstitial DCs have classically been described as sessile cells 
that fail to migrate to draining LNs and would merely restimulate already primed T cells during 
pulmonary delayed-type hypersensitivity–like reactions (Kradin et al., 1993; von Garnier et al., 
2005). Another possible explanation would be that DCs accumulated on the injected beads 
from within the vessel lumen. Pulmonary vessels already contain a large marginating pool of 
DC precursors, possibly hardwired for Ag recognition at this site. This has been suggested by 
Suda et al. (1998), who demonstrated that the blood cannulated from the lungs of rats  
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Figure 4. Effect of triggering TLR4 receptor and CD40 on Ag presentation to Ag trapped in the lung vasculature. (A) 
Mice received OVA-specific CD4
+ 
DO11.10 T cells at day -2, and UBs, OBs, OB co-coated with LPS (LPS-OB), or OB co-
coated with LPS and trimeric CD40L (LPS-CD40L-OB) at day 0. 4 d later, inflammation surrounding the beads is 
shown in these groups. Bars, 100 μm. (B) Size of inflammation surrounding the beads in the lungs in these groups is 
shown at days 4, 8, and 16. Data are shown as mean ( n = 4 mice/group) ± SEM. *, P < 0.05. (C) Representative flow 
cytometry analyses of ( n = 4 per group) OVA-specific CD4
+ 
T cell divisions in draining lung MLNs at day 4 are shown. 
(D) Cytokine production in cultures of MLN, restimulated for 4 d in the presence of OVA Ag. The level of IL-4 was at 
the detection limit of the IL-4 ELISA (15 pg/ml). *, P < 0.05. Error bars represent statistical significance between 
these groups. (E) IFN-γ production by T cells was also analyzed in supernatant of restimulated MLN cells, from mice 
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injected with 3 × 10
3
 UB, 10
3
 OB combined with 2 × 10
3
 UB, 10
3 
LPS-aCD40 OB combined with 2 × 10
3
 UB, or mixed 
beads. The mice receiving mixed beads were injected with 10
3
 OB, 10
3
 LPS-B, and 10
3
 anti-CD40-B. Therefore, all 
mice received the same number of beads and the same amount of Ag. *, P < 0.05. Error bars represent statistical 
significance between these groups. (F) To analyze the OVA-specific effector T cell function in this model, mice were 
injected with UB, OB, or LPS- anti-CD40-OB and, after 6 d, injected subcutaneously with OVA peptide–pulsed DCs 
mixed with unpulsed DCs, respectively CMTMR and CFSE labeled. This graph shows the ratio of alive OVA peptide 
DCs versus unpulsed DCs, 4 d after injection of target DCs. *, P < 0.05. Error bars represent statistical significance 
between these groups. (G) In serum of these mice, OVA-specific IgG1 levels were measured by ELISA. *, P < 0.05. 
Error bars represent statistical significance between these groups. These experiments were done three times with 
five mice per group. 
 
contained much more DC precursors than vena cava–cannulated blood, and these cells 
obtained DC potential after culture in appropriate cytokines. Whether this sequence of DC 
differentiation from vascular precursors would occur in our system remains to be shown. 
Although all of these scenarios are not mutually exclusive, we favor a third potential source for 
bead-associated CD11c
+
 DCs. Ag presentation in our system of i.v. embolization occurred as 
the result of Ag recognition by Gr1
+
 (Ly6C/G) CD11c
+
 cells that accumulated as early as 6 h 
after bead injection. These cells most likely represented monocyte-derived DCs and not pDCs, 
as they lacked expression of B220 and 120G8. The evidence for this comes from the co-
expression of the fractalkine (CX3CR) receptor, Ly6C, and CD11c on these cells and the fact 
that T cell proliferation and development of inflammatory lesions in the lung were significantly 
reduced when mice were depleted of Gr1 (Ly6G/C)
+
 cells but not by depletion of 120G8
+
 cells. 
In previous studies, Ly6C
+
 monocytes have been shown to be precursors for inflammatory-type 
DCs, thus acquiring APC function and expression of the CD11c marker, and most likely 
represent the immediate precursor to nature’s adjuvant, the immunogenic DC (Serbina et al., 
2003; Le Borgne et al., 2006; Naik et al., 2006; León et al., 2007; Shortman and Naik, 2007; 
Kool et al., 2008). In the mouse, circulating monocytes can be discriminated into Ly6C
+
 CX3CR
int
 
CD11b
+
 inflammatory monocytes and Ly6C
+
 CX3CR
hi
 CD11b
+
 monocytes (Geissmann et al., 
2003). Several groups have now shown that both types of monocytes are also immediate 
circulating precursors for lung DCs but not steady-state lymphoid tissue DCs (Geissmann et al., 
2003; Landsman et al., 2007; Varol et al., 2007; Jakubzick et al., 2008). Strikingly, Ly6C
hi
 
monocytes express the CCR2 receptor for MCP-1. Although we have not measured the level of 
this chemokine, others using an injection model of Schistosomal egg antigen or 
Mycobacterium purified protein derivate (PPD)–coated Sepharose beads could measure an 
early production of this chemokine by lung structural cells (Hogaboam et al., 1999). Supporting 
a crucial role for inflammatory monocytes in early granuloma formation, CCR2-deficient mice 
had a defect in early (day 1–2) granuloma formation. It will be interesting to study whether 
these CCR2-deficient mice also have a reduced DC accumulation around beads and delayed Ag 
presentation in our model. This could be a possibility, as CCR2 was shown to be crucial for DC 
recruitment to the other lung compartment, the airway mucosa, under inflammatory 
conditions (Robays et al., 2007). Alternatively, a population of CX3CR
med
 Ly6C
-
 monocytes has 
been shown to patrol the inside of the vessel wall (Auffray et al., 2007; Geissmann et al., 2008) 
We do not believe, however, that this subset was involved in presenting trapped embolic Ag in 
the lung, as the majority of CX3CR
gfp+ 
cells were Ly6C
+
 and depletion of Gr1
+
 cells abolished 
most Ag presentation, whereas adoptive transfer of Ly6C
hi
 monocytes restored it. Systemic DT 
treatment of CD11c-DTR at the time of bead injection led to a reduction of CX3CR1
+ 
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Ly6C
+
CD11c
+
 DCs and inflammatory CX3CR1
+
Ly6C
+
CD11c
-
 monocytes around injected OB. 
These findings were very striking, as injected DT only kills cells expressing high level CD11c and 
circulating monocytes with this phenotype have not been described to be depleted in these 
mice (Geissmann et al., 2003; Landsman et al., 2007; Sapoznikov and Jung, 2008). The fact that 
DT has a very short half-life also did not support a model in which CD11c (and consequent DTR 
expression) was up-regulated on monocytes after recruitment to the beads, rendering 
monocytes sensitive to DT. We favor a model in which resident CD11c
+
 DCs act as gatekeepers 
that chemo-attract the inflammatory DCs, which, in their turn, are the true vehicles of 
immunity. In support of this, we found that CD11c
+
 DCs were a predominant source of MCP-1, 
the major chemokine attracting CCR2
+
 inflammatory monocytes. In CD11c-DTR Tg mice, 
treatment with DT largely eliminated the presence of MCP-1 around the injected beads, 
explaining how DT treatment can also lead to a reduction in monocytes not expressing CD11c. 
Strikingly, a lot of the MCP-1 was found not associated with the DAPI nuclear signal. 
Previously, MCP-1 was found indeed to be able to mediate its chemotactic effects at a distance 
from its site of production, displayed on extracellular matrix proteoglycans (Palframan et al., 
2001). However, the extracellular MCP-1 signal was completely eliminated in DC-depleted 
mice, suggesting that a CD11c
hi
 cell was the predominant source for extracellular MCP-1. The 
exact subtype of lung DCs expressing MCP-1 in our model remains to be established. Resident 
CD11c
+
CD11b
+
CD103
neg
 DCs are found in the lung interstitium and have been shown to be a 
prominent source of chemokines (Beaty et al., 2007). Recently also, Choi et al. (2009) identified 
a population of vascular CD11c
+
CD11b
+
 cells that probes the large systemic vessels. One 
surprising observation of this and other models of embolization, such as injection of 
Schistosoma mansoni soluble Ag-coated or Mycobacterium PPD Ag-coated Sepharose beads, 
was that inflammatory lesions around injected embolic material were very short lived 
(Chensue et al., 1994; Iyonaga et al., 2002). It is also known that parasites or parasite eggs that 
gain access to the venous system as part of their replicative cycle end up in the lung arterioles 
and capillaries, leading to formation of lung granulomas or transient pulmonary inflammatory 
infiltrates (called Löffler’s syndrome). One explanation of these findings would be that, like in 
our model, monocyte-derived CD11c
+
 DCs would not get the proper activation status to induce 
full blown effector cells, thus leading to a program of deletional proliferation of T cells. In 
support of this, IFN-γ cytokine production of dividing T cells of mice receiving OBs was not 
above the level seen in mice receiving UBs. Arguing against this possibility is the fact that 
injection of CD40 and LPS, two known activators of the DC system and its potential to produce 
IL-12p70 (Schulz et al., 2000), enhanced the size of the inflammatory lesions, production of 
IFN-γ by dividing T cells, production of IFN-γ by tissue-infiltrating T cells, and lytic activity of 
CD8 CTLs, but eventually these were still cleared from the lung. Also, models in which PPD-
coated beads or S. mansoni eggs are injected would lead to full DC activation, but still these 
granulomata are cleared eventually (Iyonaga et al., 2002). Such a system to clear the lung 
interstitial tissue of overt inflammatory lesions makes evolutionary sense as this is the site of 
vital gas exchange (Lambrecht, 2006). Several mechanisms in the lung, such as the suppressive 
function of the nearby alveolar macrophage with its secretion of anti-inflammatory factors, 
such as TGF-β, IL-1RA, IL-10, and prostaglandins, might keep inflammation in check by down-
regulating the Ag-presenting capacity of DCs (Holt et al., 1988; Iyonaga et al., 2002). 
Alternatively, early fibrosis occurring around injected beads could effectively shield off the Ag 
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so that it is further ignored by the immune system, eventually leading to apoptosis of T cells 
(Hogaboam et al., 1999). In conclusion, we have provided evidence for a highly active Ag 
sampling mechanism for embolic material trapped in the small vessels of the lung that can 
potentially lead to the generation of effector T cell responses when properly triggered. It is 
likely that this system developed during evolution to allow the immune system to effectively 
recognize large particulate Ags acquiring access to the venous blood by invasion, such as 
parasite eggs or worms, or after direct (traumatic) access to the bloodstream. When such Ags 
would be retained in the lungs without a possibility for Ag recognition, this could lead to a very 
effective way of pathogen immune subversion, as the spleen or liver, two other major sites of 
immune induction against blood particulate Ags, cannot access these large Ags and the 
pathogen could mutate during residence in the lung. It will be interesting to study whether 
certain pathogens take advantage of this system by blocking DC migration to the mediastinal 
nodes. It could also be that allogenic cells disrupted as a group of cells from freshly 
transplanted vascularized organs are presented via this route, as these vascularized grafts lack 
a direct connection with afferent lymph and the lung vascular bed is the first small vessel filter 
encountered. Clearly, this pathway of immune induction in the lung vasculature deserves 
further study.  
 
Materials and methods 
Mice. 6–8-wk-old female BALB/c (H-2d) and C57BL/6 mice were purchased from Harlan. OVA-TCR Tg mice 
(DO11.10) on a BALB/c background, OT-II and OT-I OVA-TCR Tg mice on a C57BL/6 background, CD11c-DTR Tg mice 
on a BALB/c background, and Langerin DTR Tg mice on a C57bl/6 background (Bennett et al., 2005) were bred at 
Erasmus University (Rotterdam, Netherlands) and University of Ghent (Ghent, Belgium). CX3CR-GFP on a C57BL/6 
background was a gift from S. Jung (Weizmann Institute of Science, Rehovot, Israel; Jung et al., 2000). Mice were 
housed under specific pathogen-free conditions at the animal care facility at Erasmus University. All of the 
experimental procedures used in this study were approved by the Erasmus University Committee of Animal 
Experiments and the Animal Ethics Committee of the University of Ghent. 
 
Reagents and antibodies. OVA323-339 peptide was obtained from Ansynth Service B.V. OVA protein was obtained 
from Worthington Biochemical Corporation. CNBr-activated Sepharose 4B beads were obtained from Sigma-Aldrich. 
CFSE and CellTracker Orange (CMTMR) were obtained from Invitrogen. FITC-labeled anti-Gr1 (RB6-8C5) and PE-
labeled KJ1-26 (clonotypic OVA-TCR) were obtained from Invitrogen, PE-Labeled anti-B220 (RA3-6B2), CD8α (Ly-2), 
Vb 5.1/5.2, and APC-labeled anti-CD4 (RM4-5) were purchased from BD. Unconjugated anti-CX3CR1 and goat anti–
rabbit FITC were obtained from Acris Antibodies.  
 
Intravascular injection of emboli. BALB/c or C57BL/6 mice received i.v. in the lateral tail vein 10
4
 OVA-coated (OB) 
or noncoated (glycine; UB) CNBr-activated Sepharose 4B beads on day 0. Beads between 40 and 150 μm in diameter 
were prepared and coated with OVA, as described by others (Chensue et al., 1994), and were concentrated on a 40-
μm cell strainer to remove smaller beads. Because of low OVA-TCR–specific naive T cell frequency in these wild type 
BALB/c mice, 10 × 10
6
 live CFSE-labeled OVA-TCR Tg naive DO11.10 T cells were given i.v. 2 d before injection of the 
beads (day –2). OVA-specific TCR Tg T cells were collected from the lymphoid organs of naive 4–6-wk-old DO11.10, 
OT-I, or OT-II mice and stained with CFSE (Invitrogen), as previously described (de Heer et al., 2004). In some 
experiments, to address the role of DC maturation, mice also received OB co-coated with LPS (LPS-OB; LPS obtained 
from Sigma-Aldrich) or OB co-coated with LPS and trimeric CD40L (2 μg/ml sCD40L, 100 ng/ml LPS; LPS-CD40L-OB). 
Agonistic anti-CD40 was used at 200 ng/ml. Trimeric CD40L was a gift from Amgen.  
 
Detection of the primary T cell response to OB injection i.v. On days 1, 2, 4, 8, and 16, MLNs, PLNs (axillary), 
spleens, and lungs were removed, and individual cell suspensions were prepared as previously described 
(Lambrecht et al., 2000). Cell suspensions were stained either with antibodies to CD4, CD8, KJ1-26 (specific anti-TCR 
antibody for the TCR recognizing OVA peptide in I-A
d
), or Vβ5.1/5.2. Propidium iodide (Sigma-Aldrich) was added for 
exclusion of dead cells before analysis of CFSE profiles on a FACSCalibur flow cytometer using CellQuest (BD) and 
FlowJo software (Tree Star, Inc.). For measurement of cytokine responses, cell suspensions obtained from MLNs 
were cultured at 200,000 cells per well in the presence of 10 μg/ml OVA protein. IL-4 and IFN-γ were measured at 
day 4 by ELISA (BD). 
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Depletion of DCs and monocytes. In experiments to address the functional role of DCs in inflammation formation 
around beads, CD11c
+
 cells were depleted by injecting 100 ng DT i.p. in CD11c-DTR Tg mice (van Rijt et al., 2005). 
The same dose is used in Langerin DTR mice to deplete the Langerin
+
 cells. In experiments to address the functional 
role of pDCs, pDCs were depleted by 120G8 antibody injection (200 μg at the day of bead injection; provided by C. 
Asselin-Paturel, Shering-Plough, Dardilly, France; Asselin-Paturel et al., 2003). For monocyte depletion, anti-Gr1 i.p. 
injection was used, which was given at 200 μg on the same day of bead injection. In experiments to address if 
monocytes could restore immune responses in the DT-treated CD11c-DTR Tg mice, 3.5 × 10
5
 CD11b
+
Ly-6C
+
CD31
-
 
monocytes sorted from bone marrow of RAG2 γc -/- BALB/c mice (Geissmann et al., 2003) were injected i.v. on day 0 
after OB or UB injection. To investigate whether DCs migrated to the draining LNs and present OVA, DCs were 
sorted from the MLN and lung from mice that were injected 4 d earlier with OB and control mice that were injected 
with UB. Macrophages were sorted from the lungs of these mice as a control of APCs. DCs and macrophages were 
subsequently brought in and co-cultured for 4 d with CFSE-labeled OT-I and OT-II cells to analyze their presenting 
capacity. Monocytes, DCs, and macrophages were sorted on a cell sorter (FACS-ARIAII; BD). 
 
CTL response. C57BL/6 mice were injected with 10 × 10
6
 unlabeled OTI T cells and, 2 d later, with UB, LPS-OB, or 
LPS-aCD40-OB. DCs were cultured for 6 d from bone marrow of C57BL/6 mice with GM-CSF. At day 6, half of the DCs 
were pulsed with OVA peptide (10 μM SIINFEKL) for 2 h. These cells were harvested and labeled with 10 μM 
CMTMR (10 × 10
6
 cells/ml) according to the manufacturer’s protocol (Invitrogen). The unpulsed DCs were harvested 
and fluorescently labeled with 10 μM CFSE. Both types of DCs were mixed in a 1:1 ratio and injected 6 d after the 
subcutaneous bead injection. After another 4 d, the inguinal LNs were dissected and the migrated CMTMR
+
 DCs and 
CFSE
+
 DCs were analyzed by FACS. Serum was collected from these mice and OVA-specific IgG1 levels were 
detected with ELISA (BD). 
 
Confocal microscopy. Confocal analysis was performed on 6-μm cryostat sections of lungs stained with anti-
CX3CR1/goat anti–rabbit FITC (Acris Antibodies), anti-Gr1 FITC, anti-B220 PE, Ly-6C biotin-streptavidin Alexa Fluor 
555, CD11c Alexa Fluor 647, rabbit anti-MCP-1 (Abcam)/donkey anti–rabbit Cy3 (Jackson ImmunoResearch 
Laboratories, Inc.), and 120G8 coated with Quantum dots (Micro Probe, Inc.). Sections were collected on a confocal 
laser microscope (LSM-710; Carl Zeiss, Inc.) and analyzed using Imaris 5.0 software (Bitplane). 
 
Immunohistochemistry and analysis of inflammation surrounding beads. For immunehisto-chemistry analysis of 
the inflammation, 6-μm cryostat sections of lungs were stained with CD11c, CD11b, and MHCII. For inflammation 
size, hematoxylin-counterstained lungs were analyzed with an image analysis system (Quantimed; Leica), whereby 
30 beads per mice were measured, dividing the surface size of the bead (in micrometers squared) by the surface 
size of inflammation and bead together (in micrometers squared). 30 beads were chosen to attain a mean bead 
diameter, as slides were 6 μm.  Online supplemental material. Fig. S1 shows T cell divisions in spleen and draining 
LNs of the lung, liver, and periphery at days 2 and 4 after bead injection. Fig. S2 depicts a confocal image of a 
section of a lung 24 h after bead injection, stained with CD11c, GR1, and B220. Fig. S3 shows in vitro T cell 
proliferations of OT-I cells co-cultured with sorted DCs and macrophages from MLN and spleen 24 h after beads 
injection. In Fig. S4, the analysis of the size of the infiltrates after GR1 depletion, as well as the T cell proliferations 
after pDC depletion at day 4 after bead injection, is depicted.  
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Recent findings 
Current reports on antigen presentation of blood-derived antigens confirm our results on the 
importance of inflammatory DCs. We used markers such as Ly6C and CX3CR1 to show that the 
antigen presenting cells were derived from monocytes and could be therefore considered as 
inflammatory DCs. Nowadays, markers such as MAR-1 and CD64 are used to discriminate 
between conventional DCs or recruited mo-DCs. A recent paper using Ly6C demonstrated that, 
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in the spleen, monocytes can present antigen with or without upregulation of CD11c (Drutman 
et al., 2012). We also observe CD11clow/neg monocytes surrounding the embolic antigen in the 
lung (figure 3B), but we did not investigate if CD11c was expressed/ upregulated on monocytes 
presenting the antigen in the MLN. The inflammatory areas shown in this chapter consist 
mainly of T cells and DCs. Regulatory T cells were also found in the infiltrates (CD25+, FoxP3+). 
Interestingly, depleting Tregs by administration of diphtheria toxin into DEREG-DTR mice, at 
the time of bead injection, lead to a reduction in the size of inflammatory areas around the 
beads (unpublished data). Various groups have reported the importance of Tregs in controlling 
the immune response in sarcoidosis. Although Taflin showed that Tregs proliferated and 
accumulated within the granulomas (Taflin et al., 2009), Tregs in sarcoidosis patients have an 
impaired ex vivo immunosuppressive function and survival than Tregs of healthy donors (Broos 
et al., 2012). 
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Supplemental material 
 
 
 
Figure S1. Mice were injected with CFSE-labeled OVA-specific T cells and, 2 d later, injected with either UB or OB 
i.v. At 2 and 4 d after bead injection, lung draining LNs (MLNs), PLNs, liver LNs (LLNs), and spleen were analyzed by 
FACS for T cell proliferation. This experiment was performed twice. 
 
 
Figure S2. Confocal microscopy of frozen lung sections taken 24 h after injection of OBs in mice that received a 
cohort of DO11.10 T cells. (Top) Slides were double stained with anti-CD11c PE (red) and anti-Gr1 FITC (green). 
(Bottom) To discriminate pDCs, slides were also stained for CD11c
+
 cells (FITC, green) in combination with anti-B220 
PE (red). This experiment was performed twice. Bars, 10 μm. 
 
 
 
Figure S3. DCs and macrophages were sorted from MLN and lung from mice injected with UB or OB. These APCs 
were subsequently put in coculture with CFSE-labeled OT-I cells for 4 d. Autofluorescent alveolar macrophages were 
not detected (n.d.) in the MLNs. This experiment is performed twice. 
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Figure S4. Depletion of monocytes and pDCs by using GR1 depleting antibody around the time of bead injection 
showed a reduction of inflammatory infiltrate around beads at day 4, whereas treatment with pDC-depleting 
antibody (120G8) did not reveal differences in antigen presentation. (A) Measurement of the size the 
inflammatory infiltrate at day 4, 8 and 16 around beads in the lungs of mice receiving either UBs (white bars), OBs 
plus isotype (OB, gray bars), or OBs plus anti-Gr-1 (OB Gr1, black bars). Data are shown as mean (n = 4 mice/group) 
± SEM *, P < 0.05. (B) Effect of depletion of 120G8 positive pDCs. Comparison of CFSE labeled OVA specific CD4
+
 
DO11.10 division profile in draining MLNs, in mice treated with 120G8 (for pDC depletion) or isotype i.p. at day 0 
and injected with OB, measured at day 4. Both experiments were performed twice. 
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We investigated the immunomodulatory properties of ursodeoxycholic acid (UDCA) in allergic 
asthma, since UDCA is effective in reducing liver eosinophilia primary biliary cirrhosis. So far, 
no other groups have investigated the immunosuppressive properties of UDCA outside the 
gastro-intestinal tract. We show that UDCA alters DC/ T cell interaction, thereby reducing 
inflammation in the lungs. 
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Ursodeoxycholic acid suppresses eosinophilic airway inflammation 
by inhibiting the function of dendritic cells through the nuclear 
farnesoid X receptor 
 
Abstract 
Background: Ursodeoxycholic acid (UDCA) is the only known beneficial bile acid with immune-
modulatory properties. Ursodeoxycholic acid prevents eosinophilic degranulation and reduces 
eosinophil counts in primary biliary cirrhosis. It is unknown whether UDCA would also 
modulate eosinophilic inflammation outside the gastrointestinal (GI) tract, such as eosinophilic 
airway inflammation seen in asthma. The working mechanism for its immunomodulatory 
effect is unknown. 
Methods: The immunosuppressive features of UDCA were studied in vivo, in mice, in an 
ovalbumin (OVA)-driven eosinophilic airway inflammation model. To study the mechanism of 
action of UDCA, we analyzed the effect of UDCA on eosinophils, T cells, and dendritic cell 
(DCs). DC function was studied in greater detail, focussing on migration and T cell stimulatory 
strength in vivo and interaction with T cells in vitro as measured by time-lapse image analysis. 
Finally, we studied the capacity of UDCA to influence DC/T cell interaction.  
Results: Ursodeoxycholic acid treatment of OVA-sensitized mice prior to OVA aerosol challenge 
significantly reduced eosinophilic airway inflammation compared with control animals. DCs 
expressed the farnesoid X receptor for UDCA. Ursodeoxycholic acid strongly promoted 
interleukin (IL)-12 production and enhanced the migration in DCs. The time of interaction 
between DCs and T cells was sharply reduced in vitro by UDCA treatment of the DCs resulting 
in a remarkable T cell cytokine production. Ursodeoxycholic acid-treated DCs have less 
capacity than saline-treated DCs to induce eosinophilic inflammation in vivo in Balb/c mice. 
Conclusion: Ursodeoxycholic acid has the potency to suppress eosinophilic inflammation 
outside the GI tract. This potential comprises to alter critical function of DCs, in essence, the 
effect of UDCA on DCs through the modulation of the DC/T cell interaction.  
 
Introduction 
Bile acids are end products of cholesterol metabolism and have essential functions in 
controlling the secretion of bile fluid, regulating cholesterol elimination by the liver, and 
promoting absorption of lipids and fat-soluble vitamins, through detergent properties in the 
gut. Ursodeoxycholic acid (UDCA) is a naturally occurring dihydroxy bile acid that is only found 
in trace amounts (1–3% of bile acids) in human bile, but has strong choleretic activity and thus 
prevents cholestasis. Although UDCA is commonly used in the treatment for primary biliary 
cirrhosis (PBC) an autoimmune disease, the mechanisms behind this beneficial effect are not 
fully understood. In addition to promoting bile secretion, it has been suggested that UDCA has 
immunomodulatory properties (1–5), such as the suppression of immunoglobulin production; 
suppression of cytokine synthesis by lymphocytes; downregulation of MHC I expression on 
hepatocytes; inhibition of mast cell activation (6); inhibition of gall bladder inflammation (7, 8); 
and suppression of eosinophil activation and degranulation, typical of PBC (9, 10). The 
immunosuppressive effects of UDCA are, at least in part, mediated through the activation of 
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the glucocorticoid receptor (GR) and inhibition of NF-κB-dependent transcription through GR–
p65 interaction (11–13). The purpose of this study was to observe whether UDCA also has 
immunomodulatory effects outside the gastrointestinal (GI) tract. To study this, we turned to 
the lung because this organ is also exposed to the outside world, lined with mucosal epithelial 
cells, and has been shown to develop eosinophilic inflammation when triggered with allergens. 
In this model, we report that intratracheal administration of UDCA strongly suppresses the 
development of airway inflammation induced by allergen challenge. 
 
Results 
Ursodeoxycholic acid treatment reduces eosinophilic airway inflammation and IL-13 
production 
Ursodeoxycholic acid was used as a topical therapeutic drug in a mouse model of acute allergic 
inflammation in which we administered 30 µg UDCA in diluent (=PBS) (1 mM 80 µl) or diluent 
approximately 30 min before each OVA aerosol challenge during 30 min in OVA-immunized 
mice. Twenty-four hours later, animals were killed, and UDCA-treated animals (OVA–
alum/UDCA/OVA group) demonstrated a significant reduction in the percentage and the 
number of BAL eosinophils compared with the controls (OVA–alum/PBS/ OVA group) (Fig. 
1A,E). Matching the reduction in eosinophils, we found that the number and percentage of 
DCs and T cells (Fig. 1B,C,F,G) were also lower in the UDCA-treated group compared with the 
control (OVA–alum/PBS/OVA) group. Next, we measured BHR. A significant less response to 
MCH was observed in the UDCA-treated animals (OVA–alum/UDCA/OVA group) as compared 
to PBS-treated animals (OVA–alum/PBS/OVA group). Phosphate-buffered saline–alum controls 
showed no signs of BHR (Fig. 1I). To address the effect of UDCA treatment on cytokine 
production, the mediastinal LNs draining the lungs were stimulated with OVA in vitro. After 4 
days of OVA restimulation, levels of IL-13 (Fig. 2B) were markedly reduced, while other 
measured cytokines like IL-4 (Fig. 2A), IL-5 (Fig. 2C), and IL-10 (Fig. 2D) remained unchanged in 
OVA–alum/UDCA/OVA group compared with OVA–alum/PBS/OVA group. In line with the 
reduced eosinophilic BAL inflammation, significantly lower levels of IL-13 in the BAL were 
observed in OVA–alum/UDCA/OVA group (104 ± 3.7 pg/ml vs 140 ± 7.1 pg/ml, compared with 
OVA–alum/PBS/OVA group, P = 0.006). The controls, PBS–alum/UDCA/OVA group, and PBS–
alum/PBS/OVA group had much lower IL-13 concentrations that fell in the same range as the 
OVA–alum/UDCA/OVA group (Fig. 2E). Next, we measured intracellular IFN-γ in BAL and MLN 
and observed a trend (P = 0.06) of increased numbers of IFN-γ-positive CD4 T cells in BAL and 
significantly (P = 0.03) more IFN-γ-positive CD4 T cells in MLN in the UDCA-treated animals 
(OVA–alum/UDCA/OVA group) when compared with PBS-treated animals (OVA–alum/PBS/ 
OVA group) (Fig. 2F–G). 
 
Ursodeoxycholic acid induce IL-12 production in DCs and has no toxic effect on eosinophil, 
DC survival, and T cell cytokine production 
A detailed in vitro characterization of UDCA-treated eosinophils, DCs, and T cells is shown in 
Fig. S1 with the conclusion that UDCA is not harmful for eosinophils and DCs (Fig. S1A,B) and 
does not influence T cell cytokine production (Fig. S1C–E). As we found that UDCA enhances 
migration of bone marrow- derived DCs after i.t. injection (Fig. S1F), yet at the same time 
suppresses the potential of these cells to prime for Th2-dependent eosinophilic airway  
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Figure 1 Impaired eosinophilic airway inflammation after ursodeoxycholic acid treatment. Model of allergic airway 
inflammation in ovalbumin-sensitized mice. Bronchoalveolar lavage cells were stained for eosinophils (CCR3-
positive cells) and T cells (CD3-positive cells), as well as for B cells (data not shown) and macrophages and DCs. (A 
and E) eosinophils (cell numbers and percentage); (B and F) DCs (cell numbers and percentage); (C and G) T cells 
(cell numbers and percentage); (D and H) macrophages (cell numbers and percentage); (**P < 0.01 and *P < 0.05 n 
= 6 animals per group); (I) bronchial hyperreactivity measurements (*P < 0.05 n = 4–6 animals per group). 
 
inflammation, we sought to further identify the mechanism by which Th2 development was 
abolished. Previous studies in our group have identified that high-level production of IL-12 by 
GM-CSF-cultured DCs abolished their potential to induce Th2 immunity, via promotion of a 
counterregulatory Th1 response (18, 19). IL-12 is known to be a key inducer of cell-mediated 
immunity. In addition, IL-12 stimulates the differentiation of CD4-positive Th cells in IFN-γ-
producing Th1 cells (18). Incubation of DCs with increasing UDCA concentrations revealed a 
concentration-dependent increase in IL-12 production (Fig. 3A), promoting the induction of 
IFN-γ in responding T cells (Fig. 3C), while suppressing induction of Th2 cytokine IL-13 (Fig. 3B), 
and supports the migration of DCs (Fig. S1F). 
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Figure 2 Reduced interleukin (IL)-13 production after ursodeoxycholic acid (UDCA) treatment. Mediastinal lymph 
nodes (LN) cell suspensions were restimulated in vitro for 4 days with ovalbumin and assayed for IL-4 (A), IL-13 (B), 
IL-5 (C), IL-10 (D) production using enzyme-linked immunosorbent assay. The level of the IL-13 promoting Th2 
cytokines was significantly reduced in mice treated with UDCA. Levels of other cytokines seem to be unchanged in 
the UDCA-treated group. IL-13 levels (E) in bronchoalveolar lavage (BAL) fluid were lower in UDCA-treated animals 
compared with the diluent-treated animals (F) and (G) intracellular interferon-γ in CD4 T cells in, respectively, BAL 
cells and MLN cells (**P < 0.01 and *P < 0.05). 
 
Ursodeoxycholic acid-treated DCs were less effective in inducing asthma  
We employed experiments demonstrating that intratracheal administration of UDCA reduces 
the number of DCs in allergen-challenged lungs. In previous studies, we identified lung DCs as 
key pro-inflammatory cells that are necessary and sufficient for Th2 cell stimulation during 
ongoing airway inflammation (20). To test whether UDCA interferes with the potential of DCs 
to induce eosinophilic airway inflammation, we used an adoptive transfer model of DCs to 
immunize the animals, bypassing OVA–alum immunization (21). Myeloid DCs were grown for 8 
days from the bone marrow in GM-CSF, were subsequently pulsed with OVA or OVA in the 
presence of UDCA or PBS, and then 1x10
6
 DCs were injected into the trachea of mice. After this 
treatment, mice were given three additional OVA aerosol challenges. As previously reported 
(22), the adoptive i.t. transfer of OVA-pulsed mDCs leads to Th2 priming, and eosinophilic 
airway inflammation subsequently develops upon OVA aerosol challenge 10 days later. As 
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expected, in mice receiving unpulsed PBS DCs or UDCA DCs, only a few inflammatory cells 
were observed in the BALF (Fig. 4A). Mice immunized with OVA-pulsed DCs demonstrated a 
strong cellular recruitment of eosinophils and macrophages in the BALF (Fig. 4A, B). 
Ursodeoxycholic acid treatment of OVA-pulsed DCs abolished their potential to induce airway 
eosinophilia and macrophage influx into the lung. There was also a trend toward reduced T cell 
(Fig. 4C) and DC (Fig. 4D) influx, but this failed to reach statistical significance. 
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Figure 3 Ursodeoxycholic acid (UDCA) promotes the interleukin (IL)-12 production of DCs in a concentration-
dependent manner (A). The effect of UDCA treatment on DCs was studied in the context of the interaction between 
T cells and DCs. Levels of T cell cytokines were reduced when UDCA-treated DCs were used. Reduced levels in the 
production of IL-13 (B) were shown for concentrations up to 300 µM UDCA. This concentration is not toxic for DCs. 
Low doses of up to 10 µM of UDCA-treated DCs reduced the production of T cell cytokine interferon (IFN)- γ (C). 
Ursodeoxycholic acid concentrations of 30 µM and more induce a stronger IFN-γ response (*P < 0.05). 
 
Shorter interaction time between DCs and T cells when DCs were treated with UDCA 
Ursodeoxycholic acid has been shown to induce higher levels of IL-12 production in an UDCA 
concentration–dependent way. The migration of bone marrow-derived DCs after i.t. injection 
was increased. These phenomena, and the immunosuppressive action of UDCA in an allergic 
airway model, suggest that more factors are involved in affecting the DC/T cell interaction. It 
has become possible to study the duration of interaction as a marker for synapse formation 
between DCs (C57bl/6) and antigen-specific T cells in vitro (17). Untouched naive CD4-positive 
T cells were isolated from LNs obtained from OTII (OVA-specific TCR transgenic) mice carrying 
the Vα2 TCR chain, were cultured with MHCII-positive DCs for 40 min and formed cellular 
interaction. Unpulsed DCs showed short interactions between DCs and T cells, while OVA 
protein (100 µg/ml)–pulsed DCs showed long interactions between DCs and T cells. This was 
used as a method control. A long interaction time was also seen when DCs were pulsed with 
preprocessed OVA peptide. However, significantly shorter interactions were observed when 
OVA peptide (1 µg/ml)–pulsed DCs were treated with UDCA (10 µM) compared with saline 
(Fig. 5A). 
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Figure 4 Ursodeoxycholic acid (UDCA)-treated dendritic cells (DCs) are less effective in inducing a Th2 response. 
Effects of in vitro UDCA treatment on the potential of mDCs to induce eosinophilic airway inflammation. On day 0, 
mice received an i.t. injection of diluents ovalbumin (OVA)-DCs, UDCA OVA-DCs, diluent DCs, or UDCA DCs. From 
days 10–13 onwards, mice were OVA aerosol– challenged. Total number of eosinophils in bronchoalveolar lavage 
(BAL) (A); total number of macrophages in BAL (B); total number of T cells (C); and total number of DCs (D). Data 
indicate mean ± SEM. *P < 0.05 n = 6 animals per group. 
 
Dendritic cells express transcription factor farnesoid X receptor 
Bile acids are ligands of the FXR, a nuclear receptor that mediates, among others, hepatic bile 
acid synthesis (23, 24). Fluorescence activated cell sorting (FACS) analysis indicated that the 
FXR is expressed on DCs grown in GM-CSF (Fig. 5B), suggesting the possibility that the 
suppressive effects of UDCA on DCs are partly mediated via FXR.  
 
 
Ursodeoxycholic acid promotes DC-driven Th1 development by acting on the farnesoid X 
receptor  
We finally wanted to find the molecular mechanism by which UDCA promotes Th1 induction 
and suppresses airway eosinophilia. To study whether FXR is involved in mediating the effects 
of UDCA on DC function, we grew myeloid DCs from FXR knockout mice and their wild-type 
littermates (C57bl/6). The DCs were stimulated with OVA (100 µg/ml) only, OVA and UDCA (10 
µM), or PBS, and UDCA. Subsequently, 1x10
6
 DCs were injected intratracheally to sensitize 
C57bl/6 mice. Ten days later, the mice were challenged with OVA aerosols on three 
consecutive days. Twenty-four hours later, animals were killed, and UDCA-OVA-WT-DC-treated 
animals demonstrated no significant reduction in the number of BAL eosinophils, 
macrophages, and DCs compared with the  DC-treated control animals. Moreover, UDCA-OVA-
FXR KO-DC-treated animals demonstrated no significant differences in the number of BAL  
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Figure 5 The duration of interaction between T cells and dendritic cells (DCs) is strongly reduced if DCs are treated 
with ursodeoxycholic acid (UDCA), and DCs express farnesoid X receptor (FXR). The duration of interaction between 
T cells and DCs is strongly reduced if DCs are treated with UDCA. (A). Bile acid acts as a ligand on the transcription 
factor FXR, a nuclear receptor for bile acid. GM-CSF-cultured bone marrow- derived DCs stained positive for FXR 
receptor, as indicated by FACS analyses with rabbit anti FXR antibodies. As a negative control, we used rabbit 
antihuman IgE, and as a positive control, we used NOS antibodies (B). 
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Figure 6 Higher interferon (IFN)-γ-positive T cell numbers in eosinophilic airway inflammation after ursodeoxycholic 
acid (UDCA) treatment. A model of asthma in ovalbumin (OVA)-sensitized mice. Bronchoalveolar lavage (BAL) cells 
were stained for eosinophils (CCR3-positive cells) and macrophages and DCs (A; eosinophils) (B; DCs) (C: 
macrophages). Bronchoalveolar lavage cells were stimulated with phorbol 12-myristate 13-acetate and ionomycin 
in the presence of Golgistop for 4 h. T cell cytokine production as measured by intracellular cytokine staining 
showed significantly (P = 0.006) higher IFN-γ -positive T-cell numbers in the UDCA-OVAWT- DC group compared with 
saline-OVA-WT-DC group and compared with saline-OVA-farnesoid X receptor-KO-DC group (D). No other 
differences were observed in the number of IFN-γ-positive T cells. Interleukin-4-positive T cells showed no 
differences between the groups (E) (**P < 0.01 n = 6 animals per group). 
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eosinophils, macrophages, and DCs compared with the saline-OVA-FXR-KO-DC-treated control 
animals (Fig. 6B–D). To check for Th polarization, BAL T cell cytokine production was 
estimated. Intracellular cytokine staining showed significantly (P = 0.006) higher IFN-γ-positive 
T cell numbers in the UDCA-OVA-WT-DC group compared with saline-OVA-WT-DC group and 
compared with saline-OVA-FXR KO-DC group (Fig. 6E). No differences were observed in the 
number of IFN-γ-positive T cells between saline-OVA-WT-DC group and saline-OVA-FXR-KO-DC 
group and between saline-OVA-FXR-KO-DC group and UDCA-OVA-FXR-KO-DC group. In vivo, 
there was no difference in the number of IL-4-positive T cells between the groups (Fig. 6F). 
 
Discussion 
Ursodeoxycholic acid modulates cellular and immunological processes in vivo and in vitro. 
Here, we have shown that UDCA treatment lowers the production of T cell cytokines following 
DC-driven activation in vitro. Moreover, UDCA treatment in vivo in the lung reduces tissue 
eosinophilia in mice in an allergic airway inflammation model. Ursodeoxycholic acid affects DCs 
and supports the production of IL-12 (Fig. 3A), suggesting that it is responsible for a pro-Th1 T-
cell cytokine induction, in a process requiring the FXR (25). Previous studies in our group have 
identified that high-level production of IL-12 by GM-CSF-cultured DCs abolished their potential 
to induce Th2 immunity, via promotion of a counter-regulatory Th1 response (18, 19). Higher 
numbers of intracellular IFN-γ-positive CD4 T cells in MLN suggest a change in favor of Th1 
balance because of the UDCA treatment. This is supported by in vitro data that DCs treated 
with UDCA are less capable to induce IL-13 (Th2) response and that low concentrations of 
UDCA had similar effects on IFN-γ but higher concentrations induce and support IFN-γ. 
Intratracheal administration of UDCA could also act on structural cells of the airways that are 
responsible for the production of IL-25 and IL-33, both important for the recruitment of 
eosinophils (26) independent of T cells, and these cytokines are as well important for the 
recruitment of type 2 innate lymphoid cells (ILC2) (27) and may also act indirectly to suppress 
T-cell activation. However, in the in vitro experiments, we observed lower levels of Th2 (IL-13) 
and increasing Th1 (IFN-γ) cytokines, suggesting a direct immunosuppressive effect of UDCA on 
DC-driven activation of T cells. This is in line with previous observations (6). Somewhat 
surprisingly, there was a change in the balance of polarizing cytokine production in favor of IL-
12, because the levels of IL-10 measured in DC supernatants were at the detection limit of the 
ELISA. The most likely explanation for the observed reduction in Th cytokine production was 
that the duration of the interaction between T cells and DCs was significantly reduced when 
DCs were treated with UDCA. This supports the idea that UDCA targets the DC. The outcome of 
an immune response after T cell/DC interaction is dependent on its duration, Ag levels, and T-
cell numbers as recently shown using drugs that block the interaction between DCs and T cells 
(28). The effect of UDCA on suppressing allergic eosinophilic inflammation could be very well 
explained by the effects on DCs. Allergic airway inflammation is highly DC dependent, DCs 
playing an important role in the induction and maintenance of allergic airway inflammation 
(22, 29, 30). Another good target candidate for UDCA could be the eosinophils. In humans, 
there is strong evidence that UDCA prevents the degranulation of eosinophils in patients with 
PBC after 4 weeks of UDCA (10). Evidence from mouse eosinophils suggests that they do not 
degranulate in OVA-driven allergic airway inflammation models (31). We failed to see an effect 
of UDCA on eosinophil degranulation (data not shown). The effect of UDCA on DCs required 
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the nuclear FXR. This receptor has been described in peripheral blood mononuclear cells 
(PBMCs), including T cells and monocytes at the protein level and mRNA level, and it is 
inhibited by pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α and IL-1 release 
during the acute phase response (32). Farnesoid X receptor is known as a receptor for bile acid 
metabolism, and our finding of FXR expression on bone marrow-derived DCs strongly supports 
the idea that DCs are targets for UDCA. Ursodeoxycholic acid activates the FXR and may be 
either an agonist or an antagonist (23, 24). To prove the functionality of FXR, we used FXR-
deficient bmDCs or WT bmDCs and showed that sensitization with either FXR-KO bmDCs or WT 
bmDCs has the capacity to induce eosinophilic inflammation in C57bl/6 animals. However, the 
UDCA-induced promotion of Th1 responses by DCs required the FXR. We failed, however, to 
observe a direct immunosuppressive effect of UDCA on eosinophil counts in WT DCs in C57bl/6 
mice. This could be because of strain differences between C57bl/6 and Balb/c (33). Other 
ligands of the FXR are chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA). However, we 
found that these compounds were cytotoxic for DCs and for T cells (our unpublished 
observations). This cytotoxic effect was already reached at concentrations of 10 and 50 µM 
(data not shown). Our present results are another example of an unexpected orphan nuclear 
receptor–ligand interaction that has the capacity to suppress allergic inflammation. Other  
possible receptors are the PPAR-gamma receptor (34), the vitamin D receptor, and the aryl 
hydrocarbon receptor (35). As these nuclear receptors often form heterodimers with each 
other and other nuclear transcription factors, it will be very interesting to see how the FXR is 
regulated in DCs. Although UDCA has been shown to reduce eosinophilic functions in humans 
with PBC, our data suggest that UDCA might also affect DC function in the gut. Particularly in 
disease states of the GI tract that are dominated by eosinophils, such as eosinophilic gastritis 
and esophagitis, it will be interesting to study whether UDCA has the same potential to 
suppress tissue eosinophilia as reported in our lung inflammation model. This approach might 
be more amenable to therapeutic intervention as UDCA is available in an oral formulation. In 
conclusion, our study shows that UDCA has immunomodulatory capacities to suppress 
eosinophilic inflammation outside the GI tract, via modulation of DC function. 
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Methods 
Mice 
Six- to 8-week-old Balb/c and C57bl/6 female mice were obtained from Harlan (Zeist, the Netherlands). Bone 
marrow was harvested from farnesoid X receptor (FXR)-deficient (14) mice, and OTII lymphocytes (all C57bl/6 
background) were obtained from Erasmus MC or UMC Groningen. The mice were housed under specific pathogen 
free (SPF) conditions at the animal care facility of the Erasmus MC Rotterdam with the approval of the local animal 
ethics and welfare committee. The bronchial hyperreactivity (BHR) experiments were performed at the VIB, Ghent, 
Belgium, with the approval of the local animal ethics and welfare committee. 
 
A mouse model of airway inflammation 
To induce airway inflammation, we immunized Balb/c mice with ovalbumin (OVA) (10 µg OVA, grade V from Sigma 
Aldrich, Zwijndrecht, the Netherlands) emulsified in 2 mg AL(OH)3 (OVA/alum) or as a control with phosphate-
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buffered saline (PBS) in alum. Six days later on three consecutive days, mice anesthetized with isoflurane were 
treated with UDCA 30 µg/animal or diluent intratracheally (i.t.). After recovery, they were challenged by exposure 
to OVA aerosols 10 mg/ml or PBS during 30 min. Twenty-four hours after the last aerosols, the mice were killed 
using an anesthetic overdose followed by bleeding from the vena inguinalis and bronchoalveolar lavage (BAL). The 
lungs were snap-frozen in OCT freezing solution (TissueTek, Zoeterwoude, the Netherlands). The mediastinal lymph 
nodes were collected and stimulated with OVA. Bronchial hyperreactivity was analyzed 24 h after the last aerosols 
using Flexivent invasive measurement of dynamic resistance (SCIREQ). Mice were anesthetized with urethane, 
paralyzed using d-tubocurarine, and tracheotomized, followed by mechanical ventilation. Increasing concentrations 
of methacholine (MCH) (0–100 mg/ml) were nebulized using Aeroneb (SCIREQ). Dynamic resistance and compliance 
were recorded after a standardized inhalation maneuver given every 10 s for 2 min. Baseline resistance was 
restored before administering the subsequent doses of MCH. In some experiments, we performed an adoptive 
transfer of dendritic cell (DCs) to induce asthma. In brief, myeloid DCs were grown for 8 days from the bone marrow 
(Balb/c or in case of WT and FxR-KO C57bl/6) in recombinant murine granulocyte macrophage–colony-stimulating 
factor (rmGMCSF) 20 ng/ml, were subsequently pulsed with OVA or OVA in the presence of UDCA or PBS, and then 
1x10
6
 DCs were injected (i.t.). After this treatment, mice were given three additional OVA aerosol challenges. 
 
Bronchoalveolar lavage fluid (BALF) 
Bronchoalveolar lavage was performed, and cells were collected for cellular differentiation by flow cytometry using 
a method described elsewhere (15). Antibodies for CD3 labeled with PeCy
5
 (clone 145-2C11; BD Biosciences, Breda, 
the Netherlands), CD19 labeled with PeCy5 (clone 1D3; eBiosciences, Vienna, Austria), CD11c labeled with PeCy
7
 
(clone N418; eBiosciences), MHCII labeled with Fitc (M5/114.15.2; eBiosciences), and CCR3 labeled with APC (clone 
FAB729A; R and D systems, Abingdon, UK). In some experiments, when C57bl/6 animals were used, half of the BAL 
cells were stimulated with ionomycin (Sigma), phorbol 12-myristate 13- acetate (PMA; Sigma), and Golgiplug (BD 
Biosciences); incubated at 37°C for 4 h; and subsequently stained with the following antibodies: CD3 APC cy
7
 (clone 
145-2C11; BD Biosciences), CD4 PeCy
5
 RM4-5 (eBiosciences), interleukin (IL)-4 (clone 11B11; BD Biosciences), and 
interferon (IFN)-γ (clone XMG1.2; BD Biosciences). Fixable Aqua Dead Cell Stain kit for 405 nm (Invitrogen, 
Molecular Probes, Life Technologies Europe BV, Bleiswijk, the Netherlands) was used as a live–dead marker. Cells 
were measured on a Flowcytometer LSRII (BD Biosciences) and analyzed with FLOWJO software. Bronchoalveolar 
lavage fluid and supernatants of the OVA-stimulated lymph nodes (LN) cell suspensions were assayed with enzyme-
linked immunosorbent assay (ELISA) for the quantification of IL-4, IL-5, IL-10, IL-13, and IFN-γ. T-cell stimulation and 
eosinophil culture Lymphocytes obtained from animals that were sensitized against OVA were stimulated in vitro in 
a nonspecific way with culture plate–coated antibodies against CD3 (overnight 1 µg/ml) and antibodies against 
CD28 in solution (2.5 µg/ml) for 4 days. Ursodeoxycholic acid was present during the whole culture period. To 
generate eosinophils, bone marrow cells (0.2x10
6
/well) were cultured in 30% fetal bovine serum (FBS) and IL-5 25 
ng/ml, as described (15). Ursodeoxycholic acid was added on day 5. Twenty-four hours later, cells were counted and 
stained for the eosinophil-specific marker CCR3 (eotaxin receptor) and for live–dead with PI. 
 
Bone-marrow-derived myeloid DCs 
To generate mDCs, bone marrow cells were collected from naive mice and cultured in 5% FBS and rmGM-CSF 
(kindly provided by Dr. K. Thielemans, Belgium) for 9 days as described (16). At day 9, they were exposed to a 
different concentration of UDCA and pulsed in vitro overnight with 100 µg/ml OVA or sham-pulsed with PBS. 
Supernatants of DC medium were stored for IL-10 and IL-12 ELISA (BD Biosciences). Visualization of DC/T cell 
interaction For visualizing dynamic interactions between DCs and specific T cells, OVA-specific T cells obtained from 
OTII TCR Tg (H-2b) mice were co-cultured with unpulsed bone marrow derived dendritic cells (BMDCs), OVA 
protein–pulsed BMDCs (100 µg/ml), or OVA peptide (323–339)–pulsed BMDCs (1 µg/ml) treated or not treated with 
10 µM UDCA overnight. Prior to incubation, DCs were stained with an fluorescein isothiocyanate (FITC)-labeled 
antibody to I-Ak,b (M5/114), and T cells were stained with biotin-tagged TCR Vα2 antibodies, followed by Qdot 655 
streptavidin conjugates (Invitrogen) essentially as described (17). Stained DCs adhere in a poly-L-lysine (PLL)-coated 
imaging chamber at 37°C in an atmosphere of 5% CO2. After 1h, T cells were added in a ratio of 1 DC to 10 T cells. 
Interactions were visualized with an LSM 510 confocal microscope (Zeiss, Sliedrecht, the Netherlands) equipped 
with 488- and 633-nm lasers. Time-lapse images were collected every 20 s for 40 min. Interactions were quantified 
using IMARIS software (version 5.0; Bitplane AG, Zurich, Switzerland) (17). 
 
Statistical analysis 
For statistical analysis, Kruskal–Wallis one-way ANOVA was used to calculate the overall P-value. A P-value of <0.05 
was considered a significant difference between groups. The nonparametric Mann–Whitney U-test was performed 
to analyze each group with respect to each other. The Pearson correlation test was used to indicate a significant 
concentration dependency. 
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Recent findings 
An interesting finding was published by Kollerov (36) showing that various fungi causing lung 
diseases are secreting bile acids such as DCA and UDCA. It could be interesting to investigate if 
these fungi reduce inflammation to itself by release of UDCA in the lung and are thereby 
capable to cause fungal infections. Presence of fungi in the lung can act as alarmins enhancing 
asthmatic responses (37). 
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Supporting material 
 
UDCA is not cytotoxic for eosinophils 
UDCA treatment reduces eosinophilic airway inflammation, however without affecting the 
major eosinotrophic cytokine IL-5 or the production of the eosinophil specific chemokine 
eotaxin. To exclude the possibility of a direct cytotoxic effect of UDCA on eosinophils, that 
could cause the reduction in eosinophils in UDCA-treated group, we grew eosinophils in vitro 
and exposed them to varying concentrations of UDCA. Bone marrow cells were isolated from 
mice and cultured in the presence of IL-5 to promote eosinophil differentiation. On day 5, 
these cells were treated with UDCA and analyzed the next day. The viability of eosinophils, 
identified as CCR3-positive cells with high scatter characteristics, was analyzed using propidium 
iodide (PI) exclusion staining. No toxic effect was measured in eosinophils up to a 
concentration of 1000 µM UDCA (390 µg/ml) (supplementary figure 1a, indicating the 
percentage of total live eosinophils in culture), which is the dose that was given i.t. in the 
previous in vivo experiments. Higher UDCA concentrations induced eosinophil death.  Thus, we 
applied non-toxic UDCA concentrations in our in vivo experiments excluding direct cytotoxic 
effects of UDCA on eosinophils.   
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Supplementary figure 1. UDCA has no toxic effect on eosinophil 
and DC survival T cell cytokine production UDCA has no toxic 
effects on eosinophils (a) or DCs (b) at concentrations of less than 
1000µM. UDCA has no direct effect on cytokine production of 
IFN-γ (c), IL-2 (d) and IL-4 (e) of non-specifically stimulated (with 
anti-CD28 and anti-CD3) lymphocytes obtained from OVA-
sensitized mice. The migratory capacity of UDCA-treated DCs is 
elevated compared to saline-treated DCs (f). 
 
f
0
500
1000
1500
2000
PBS UDCA
CS
FE
 
la
be
le
d 
D
Cs
*
61 
 
 
UDCA does not influence T cells directly 
UDCA treatment of OVA-immunized mice during OVA challenge also resulted in a reduced 
cytokine production that is classically associated with Th2 responses, e.g. the increased IL-13 
concentration. To address whether UDCA directly suppresses the cytokine production of T-
cells, we stimulated T-cells from OVA-immunized mice and challenged these cells non-
specifically with plate bound anti-CD3 and with anti-CD28 in suspension. Supplementary 
figures 1b-d show that no differences in T-cell cytokine IL-2, IL-4 and IFN-γ production were 
observed upon increasing UDCA concentrations. Thus, the cytokine production via non-specific 
T-cell stimulation was not abrogated by UDCA.  
 
No cytotoxic effect of UDCA on DCs 
To exclude the possibility of a direct cytotoxic effect of UDCA on DCs, that could cause the 
reduction in DCs in UDCA-treated group, we grew DCs in vitro and exposed them to UDCA. 
CD11c-positive GM-CSF-cultured bone marrow cells (bone marrow-derived DCs) were exposed 
to various UDCA concentrations on day 8 of culture and were subsequently exposed to OVA on 
day 9 and analyzed on day 10. There was no cytotoxic effect of UDCA on bone marrow DCs 
(Supplementary figure 1e). UDCA-treated DCs have an enhanced migratory activity in vivo. 
Prior overnight incubation with UDCA did not abolish the potential of DCs to migrate from the 
trachea to the draining mediastinal lymph nodes, yet even enhanced it (Supplementary figure 
1f), showing the number of labeled DCs reaching the mediastinal nodes 24h after intratracheal 
injection). 
 
UDCA induces an increased IL-12 production by DCs, promotes induction of IFN-γ in 
responding T cells while suppressing induction of Th2 cytokines  
The experiments employing UDCA demonstrated that intratracheal administration of UDCA 
reduces the number of DCs in allergen challenged lungs. In previous studies, we identified lung 
DCs as key pro-inflammatory cells that are necessary and sufficient for Th2 cell stimulation 
during ongoing airway inflammation (Hammad et al. Nat Rev Imm 2008). CD11c-positive cells 
(DCs) showed slightly less MHC II staining for UDCA (highest dose) treated DCs than DCs 
treated with PBS. The phenotype of DCs exposed to UDCA was only slightly less mature 
(Supplementary figure 2a). No significant alteration in costimulatory molecules was observed 
at  different UDCA concentrations (Supplementary figure 2b). Activation of bone marrow-
derived DCs from MyD88 deficient mice, e.g., mice that lack Toll-like receptor signaling, and 
their wild-type littermates WT controls with UDCA showed similar results (Supplementary 
figure 2c), confirming that the effects of UDCA are mediated via Toll-like receptor independent 
mechanism.  
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Supplementary figure 2 UDCA doesn’t affect DC phenotype. CD11c-positive cells (DCs) showed slightly less (but not 
significantly less) MHC II staining (MFI and percentages) for UDCA-treated OVA-pulsed DCs than OVA-pulsed DCs 
treated with PBS. DCs showed only a slightly less mature phenotype subsequent to exposure to UDCA. The 
expression of CD40, CD80 and CD86 does not differ between OVA-pulsed DCs that are sham treated or those 
treated with 300µM or 450µM of UDCA (a). No significant alteration in costimulatory molecules was observed at 
different UDCA concentrations. Bone-marrow-derived DCs from MyD88 (in the absence of signalling from Toll-like 
receptors) and WT controls showed similar results for MHCII and isotype and CD86 and isotype (b), which confirms 
that the effect of UDCA is independent of Toll-like receptors. There is no difference between WT and MyD88 bone-
marrow-derived DCs regarding co-stimulatory molecules (c). 
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Uric acid is found to be increased in various inflammatory disorders. Previously, we have 
shown that uric acid crystals (formed at high levels of uric acid) have adjuvant properties 
enhancing Th2 responses. Here we present for the first time that uric acid is released in the 
lungs upon allergen challenge favouring a Th2 response. Uricase treatment reduces 
characteristics of asthma. 
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An Unexpected Role for Uric Acid as an Inducer of T Helper 2 Cell 
Immunity to Inhaled Antigens and Inflammatory Mediator of 
Allergic Asthma 
 
Summary 
Although deposition of uric acid (UA) crystals is known as the cause of gout, it is unclear 
whether UA plays a role in other inflammatory diseases. We here have shown that UA is 
released in the airways of allergen-challenged asthmatic patients and mice, where it was 
necessary for mounting T helper 2 (Th2) cell immunity, airway eosinophilia, and bronchial 
hyperreactivity to inhaled harmless proteins and clinically relevant house dust mite allergen. 
Conversely, administration of UA crystals together with protein antigen was sufficient to 
promote Th2 cell immunity and features of asthma. The adjuvant effects of UA did not require 
the inflammasome (Nlrp3, Pycard) or the interleukin-1 (Myd88, IL-1r) axis. UA crystals 
promoted Th2 cell immunity by activating dendritic cells through spleen tyrosine kinase and 
PI3-kinase δ signaling. These findings provide further molecular insight into Th2 cell 
development and identify UA as an essential initiator and amplifier of allergic inflammation. 
 
Introduction 
Allergic asthma is caused by an inappropriate adaptive T helper 2 (Th2) cell-mediated immune 
response to innocuous antigen, leading to eosinophilic airway inflammation, mucus 
hypersecretion, structural changes to the airway wall, and variable airway obstruction (Barnes, 
2008). The cytokines produced by allergen-specific Th2 cell-type lymphocytes are held largely 
responsible for orchestrating the many features of asthma. Sensitization results from allergen 
recognition by structural cells of the airways and innate immune cells like basophils and 
dendritic cells (DCs) that induce and amplify adaptive Th2 cell-mediated immune responses 
(Barrett and Austen, 2009; Hammad et al., 2009, 2010; Lambrecht and Hammad, 2009; Sokol 
et al., 2008). The precise molecular mechanisms involved in allergenicity and Th2 cell response 
induction by DCs are incompletely understood (Paul and Zhu, 2010). Allergens have a complex 
molecular structure and often display enzymatic activity that stimulates epithelial and innate 
immune cells through protease-activated receptors (Hammad and Lambrecht, 2008; Sokol et 
al., 2008; Tang et al., 2010), whereas others like house dust mite (HDM) contain endotoxin or 
other pathogen-associated microbial patterns (PAMPS) that trigger epithelial cells and/or DCs 
in a toll-like receptor 4 (TLR4)- or C-type lectin receptor-dependent manner (Hammad et al., 
2009; Nathan et al., 2009; Trompette et al., 2009). Triggering of PAMP receptors on epithelial 
cells and/or basophils subsequently leads to release of innate pro- Th2 cell cytokines like 
thymic stromal lymphopoietin (TSLP), granulocyte-macrophage colony stimulating factor (GM-
CSF), IL-25, and IL-33 that instruct DCs to promote Th2 cell-type immunity in the mediastinal 
lymph nodes (Hammad and Lambrecht, 2008;Hammad et al., 2009, 2010; Rank et al., 2009; 
Sokol et al., 2008; Zhou et al., 2005). Although contamination of allergens with PAMPs that 
stimulate pattern recognition receptors provides a good explanation for how immunity can be 
induced to harmless allergens, another could be that allergens trigger release of damage-
associated molecular patterns (DAMPs) that occur intracellularly in homeostasis but are 
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released extracellularly upon physical or metabolic stress (Matzinger, 2002). A well-known 
DAMP is uric acid (UA) released from dying or stressed cells (Shi et al., 2003; Vorbach et al., 
2003). Uric acid crystals potently trigger acute neutrophilic inflammation through stimulation 
of the NLRP3 inflammasome and release of interleukin-1β (Chen et al., 2006; Martinon et al., 
2006). This pathway is at the heart of gouty inflammation, as supported by the absence of UA-
induced neutrophilic inflammation in mice lacking the NLRP3, ASC (Pycard), IL-1R, or its 
downstream adaptor MyD88 and by the success of IL-1 receptor antagonist (IL-1RA) treatment 
for gout (So et al., 2007; Ghosh et al., 2013). We have reported recently that UA is released in 
the peritoneal cavity after injection of the Th2 cell adjuvant aluminum hydroxide or alum, 
commonly co- injected with harmless antigens intraperitoneally to induce allergic sensitization 
and asthma (Kool et al., 2008b). In addition to inducing release of UA, alum can also directly 
trigger the NLRP3 inflammasome and stimulate secretion of bioactive IL-1β (Eisenbarth et al., 
2008; Kool et al., 2008a; Li et al., 2008; McKee et al., 2009). These studies have aroused 
interest in the UA-inflammasome-IL-1 axis as a trigger of Th2 cell development. Here, we 
hypothesized that uric acid is a general inducer and amplifier of Th2 cell immunity. By using 
models of intraperitoneal injection, as well as airway exposure of HDM allergen in mice and 
patients, we found that UA is present at sites of Th2 cell development, where it is necessary 
and sufficient for induction of Th2 cell immunity. Contrary to expectation, this Th2 cell adjuvant 
effect did not require triggering of the NLRP3-ASC complex, nor signaling through the IL-1R. 
Rather, UA induced Th2 cell immunity by triggering DC activation in a spleen tyrosine kinase 
(Syk)- and PI3-kinase δ-dependent manner. These findings identify UA as an unexpected 
initiator and amplifier of Th2 cell immunity and allergic inflammation. 
 
Results 
Uric Acid Is Necessary and Sufficient for Induction of Th2 Cell Immunity to Harmless Antigen 
We have reported that UA is released in the peritoneal cavity after injection of alum (Kool et 
al., 2008b) and is a necessary intermediate for early DC activation in vivo, whereas others 
argued that the immunostimulatory effects of alum did not require UA (Franchi and Nunez, 
2008). As shown in Figure 1A, the degradation of UA by uricase treatment reduced secretion of 
bioactive IL-1β into the peritoneal cavity, whereas production of IL-1β by DCs in vitro did not 
require endogenous release of UA. Therefore, the important role of UA in mediating the 
adjuvant activity of alum is mainly revealed in vivo. The increased UA production after injection 
of OVA in alum was found to be intact in Tlr4
-/-
, Myd88
-/-
, and Casp1
-/-
 mice, excluding an 
important role for the TLR4 or inflammasome-IL1β axis in its induction (Figure S1 available 
online). Because alum is frequently used to induce allergy in animal models of asthma, we 
hypothesized that UA is necessary for promoting adaptive Th2 cell immunity to OVA+alum. 
Injection of OVA+alum into BALB/c mice led to an increased concentration of UA in the 
peritoneal cavity, which could be neutralized by treatment with uricase (Figure 1B). Uricase 
treatment during priming to OVA+alum eliminated Th2 cell-dependent bronchoalveolar lavage 
(BAL) fluid eosinophilia (Figure 1C), peribronchial inflammation and goblet cell hyperplasia 
(Figure 1D), secretion of IL-5 in the BAL fluid (Figure 1E), production of IL-4, IL-5, IL-10, and IL-
13 (but not IFN-g) in mediastinal LN (MLN) cultures restimulated with OVA antigen for 3 days 
ex vivo (Figure 1F), and production of serum OVA-specific IgE and IgG1 (Figure 1G). There was 
also a trend toward reduced production of IgG2a by uricase treatment. OVA+alum injection also  
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Figure 1. UA Is Necessary and Sufficient for Th2 Cell Response Induction to Ovalbumin 
(A) In vitro bone marrow-derived GM-CSF-cultured DCs were stimulated with OVA or OVA+alum in the presence or 
absence of uricase (0.1 U/ml). In vivo, OVA or OVA+alum with or without 50U uricase was injected intraperitoneally 
(i.p.). Bioactive IL-1β was measured in the supernatant or the peritoneal lavage 2 hr after exposure. (B) UA in the 
peritoneal lavage 2 hr after injection of OVA or OVA+alum in mice treated or not with uricase. (C) BALB/c mice were 
treated with PBS or uricase 5 min before sensitization with OVA or OVA+alum i.p. on day 0. On day 7, mice were 
boosted with OVA i.p. and challenged with OVA aerosols on days 17–19. On day 20, BAL was analyzed for the 
presence of eosinophils. (D) Lung sections were stained with periodic acid Schiff (PAS) reagent to visualize goblet 
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cell metaplasia. Scale bars represent 100 µm. (E) IL-5 concentration in BAL supernatants of mice treated as 
described in (C). (F) Cytokine production of in vitro restimulated MLN cells taken on day 20 and cultured for 3 days 
in vitro in the presence of OVA. (G) Serum OVA-specific Igs were determined by ELISA. (H) Mice were sensitized with 
OVA or OVA mixed with different doses of UA crystals i.p. on day 0. On day 7, all mice were boosted with OVA i.p. 
and challenged with OVA aerosols on days 17–19. On day 20, the number of eosinophils was assessed in BAL. (I) 
Lung sections stained with PAS. Scale bar represents 100 mm. (J) IL-5 in BAL supernatant. (K) Serum OVA-specific Igs 
determined by ELISA. Data are shown as mean ± SEM, *p < 0.05, **p < 0.01, n = 4–8 mice/group. Experiments were 
repeated twice; data shown are representative of all experiments. 
 
led to release of extracellular ATP, another DAMP known to activate the NLRP3 inflammasome 
via the P2X7 receptor (Mariathasan et al., 2006) and promote Th2 cell immunity (Idzko et al., 
2007), yet its neutralization or use of P2X7R
-/-
 mice did not reveal a contribution to Th2 cell 
immunity (Figure S2). To address whether UA was also sufficient to induce Th2 cell immunity, 
we injected OVA mixed with UA crystals. Compared with control mice receiving OVA, this 
treatment dose dependently increased airway eosinophilia (Figures 1H and 1I), goblet cell 
hyperplasia (Figure 1I), IL-5 in BAL fluid (Figure 1J), and production of OVA- specific IgE, IgG1, 
and IgG2a (Figure 1K). Injection of OVA+UA also led to increased production of IL-4, IL-5, and IL-
10, but not IFN-γ, in MLN cells (data not shown). These responses were of similar strength as 
those induced by injection of OVA+alum (Figures 1C–1E). Therefore, UA is necessary and 
sufficient for Th2 cell response development to intraperitoneal injection of harmless antigen, 
identifying it as a potent Th2 cell adjuvant.  
 
Endogenous UA Is Necessary for Development of Th2 Cell Immunity to HDM Allergen in the 
Absence of Adjuvant 
We next investigated the involvement of endogenous UA in response to complex and relevant 
allergens in the airways. A single intranasal HDM administration in naive mice resulted in a 
rapid increase in UA concentration in BAL fluid and lung (Figure 2A) compared with PBS. Mice 
sensitized and challenged with HDM developed features of allergic asthma, like BAL fluid and 
lung eosinophilia, lymphocytosis, goblet cell hyperplasia (Figures 2B and 2D), and airway 
hyperresponsiveness (AHR) to increasing doses of methacholine (Figure 2C). Intratracheal 
administration of uricase on day 0 at the time of sensitization neutralized the increase in UA 
(Figure 2A) and strongly reduced airway lymphocytosis and eosinophilia and AHR (Figures 2A–
2D). To explain the mechanism of action, we evaluated the production of cytokines known to 
promote eosinophilic inflammation and Th2 cell immunity (Hammad and Lambrecht, 2008; 
Saenz et al., 2008). As already reported, the concentration of GM-CSF, TSLP, and IL-25 (Figure 
2E) were increased in the lungs of animals exposed to a single HDM injection, compared with 
PBS (Hammad et al., 2009). However, this innate cytokine response was severely reduced in 
mice treated with uricase. House dust mite-driven Th2 cell development relies on antigen 
presentation by inflammatory Ly6C
hi
CD11b
+
 DCs that take up antigen in the lung and migrate 
to the MLN (Hammad et al., 2010). To address antigen uptake and migration of these 
inflammatory DCs, we injected fluorescent OVA together with HDM allergen. In mice injected 
with OVA+HDM, migratory DCs carrying fluorescent cargo were easily identified in the MLN. 
After uricase treatment, this migration was strongly reduced (Figure 2F). We next searched for 
the source of increased UA production. Within 2 hr after HDM administration, there was 
increased immunoreactivity for UA in airway epithelial cells and major histocompatibility 
complex II (MHCII) positive alveolar macrophages and recruited monocytes (Figures 2G)  
68 
 
  
 
Figure 2. Uric Acid Plays a Key Role in Sensitization to House Dust Mite Allergen via the Airways 
(A) C57BL/6 mice were sensitized i.n. with PBS or HDM and treated or not with uricase, and UA concentration was 
determined 2 hr later in the BAL and lung homogenates. (B) Mice were sensitized i.n. on day 0 with PBS, HDM, or 
HDM+uricase and challenged i.n. with HDM on days 7–11. On day 14, BAL was examined for the presence of 
eosinophils and lymphocytes. (C) Lung function, as determined by invasive measurement of airway resistance (R) in 
response to increasing concentrations of methacholine. #p < 0.05 compared with untreated, HDM-sensitized group; 
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*p < 0.05 compared with nonsensitized group. (D) PAS staining of lung sections. Scale bars represent 100 µm. (E) 
Production of GM-CSF, IL-33, TSLP, and IL-25 in lung homogenates of mice 2 hr after the i.n. administration of PBS, 
HDM, or HDM+uricase. (F) Antigen uptake and migration of inflammatory CD11b
+
Ly6C
+
 DCs to the mediastinal LN, 
24 hr after intranasal injection of OVA-AF647 in the presence or absence of HDM, and effect of treatment with 
uricase. ***p < 0.005 compared with OVA; **p < 0.05 compared with OVA+HDM. (G) Fluorescence staining of uric 
acid (red) and MHCII (green) in lungs of animals exposed for 2 hr to HDM or PBS. Nuclei were counterstained with 
DAPI (blue). Scale bars represent 10 µm. (H) Fluorescence staining of the peroxisomal marker PMP70 (red) and 
MHCII (green) in lungs of animals exposed for 2 hr to HDM or PBS. Nuclei were counterstained with DAPI (blue). 
Scale bars represent 20 µm. (I) Expression of XOR mRNA normalized for HPRT by real-time quantitative RT-PCR. (J) 
Increased production of UA depends on TLR4 triggering by HDM. In this experiment C57BL/6 WT or Tlr4
-/-
 mice 
received HDM, and UA concentration was measured 2 hr later. Data are shown as mean ± SEM, *p < 0.05, n = 4–8 
mice/group. Experiments were repeated twice. Data shown are representative of all experiments. 
 
compared to mice administered PBS. Strong UA immunoreactivity was seen along the 
basement membrane of HDM-exposed mice. Although UA release occurs in response to 
necrotic cell death, UA is also produced as a pulmonary defense mechanism to oxidative 
damage, through increased xanthine oxidoreductase (XOR) enzyme activity inside peroxisomes 
(Vorbach et al., 2003). In bronchial epithelial cells and MHCII-positive cells, HDM exposure 
induced enhanced staining for the 70 kDa peroxisomal marker PMP70, suggestive of 
peroxisomal biogenesis (Figure 2H; Imanaka et al., 1999). The expression of XOR was increased 
in BAL cells of HDM-exposed mice 2 hr after instillation compared with PBS (Figure 2I). We 
(Hammad et al., 2009) and others (Phipps et al., 2009; Trompette et al., 2009) recently 
identified TLR4 signaling as a crucial early trigger for the innate pro-Th2 cell immune response 
to allergens. In contrast to the alum-induced increase of UA in the peritoneal lavage (Figure 
S1), HDM-driven production of UA was severely reduced in C57BL/6 Tlr4
-/-
 mice (Figure 2J), 
suggesting that triggering of TLR4 by HDM is necessary for activation of XOR and UA 
production in the airways in response to allergens.  
 
Uric Acid Is Increased in Allergen-Challenged Human Asthmatics and Mice  
To study whether our findings had any bearing on human asthma, BAL fluid was collected from 
21 asthmatic subjects, 10 min and 24 hr after segmental challenge with saline or specific 
allergens (rye, birch, or HDM). There was no difference in the concentration of UA between 
saline- and allergen-challenged segments after 10 min. In contrast, 24 hr after allergen 
provocation, the UA concentration was markedly elevated in the BAL fluid from allergen- 
compared to saline-challenged segments (Figure 3A). This increase in UA concentration 
correlated with the influx of eosinophils and lymphocytes into the BAL (Figures 3B and 3C). 
Subgroup analysis of patients showing a minor rise in UA showed that this was not correlated 
with the type of allergen used nor the concentration of IgE in the serum, but rather on 
maintenance inhaled corticosteroid (ICS) therapy up to 7 days prior to allergen challenge 
(Figure S3). To test whether UA neutralization would have any therapeutic potential, we again 
turned to the mouse model of HDM-induced asthma. Mice were first sensitized to HDM and 
were treated with uricase prior to each allergen challenge. HDM challenge induced a rise in UA 
in BAL fluid, still measurable 3 days after the last of five challenges (Figure 3D), and uricase 
treatment during challenge reduced airway eosinophilia (Figure 3E), methacholine-induced 
AHR, and IL-13 concentration in the BAL fluid (Figures 3F and 3G). Allergen challenge induced 
high numbers of eosinophils in the BAL fluid, which indicates that cellular death of recruited 
eosinophils could be a trigger for UA production. Uricase treatment had similar effects in a  
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Figure 3. Involvement of UA in Ongoing Allergic Airway Inflammation in Human and Mouse 
(A) UA concentration in BAL of asthmatic patients 10 min or 24 hr after segmental bronchial allergen or saline 
challenge. (B and C) Correlation of UA concentration with the number of BAL eosinophils (B) or lymphocytes (C) 24 
hr after allergen challenge. (D) Concentration of UA in BAL 3 days after the last of five HDM challenges in HDM-
sensitized mice. (E) Treatment of HDM-sensitized mice with uricase (10 U) concurrent with each allergen challenge 
reduced airway eosinophilia, measured 3 days after the last challenge. (F) Effect of uricase treatment prior to 
allergen challenge on AHR to increasing doses of metacholine. (G) Concentration of IL-13, a cytokine associated with 
induction of AHR, in BAL. Data are shown as mean ± SEM, *p < 0.05, **p < 0.01, n = 4–8 mice/group. Experiments 
were repeated twice. Data shown are representative of all experiments. 
 
milder sensitization model in which only 20% of the number of eosinophils was recruited 
compared with the high dose sensitization model (Figure S4), arguing against the idea that  UA 
plays a role only when there would be massive cellular recruitment and death. 
 
UA Crystals, Alum, and HDM Promote Th2 Cell Immunity in the Absence of NLRP3 
Inflammasome Activation 
Although UA is the prototypical activator of the NLRP3 inflammasome and several groups 
(Eisenbarth et al., 2008; Franchi and Nunez, 2008; Hornung et al., 2008; Kool et al., 2008a; 
McKee et al., 2009) have shown that alum directly triggers NLRP3 in vitro, there is considerable 
controversy whether the inflammasome-IL-1β pathway is necessary for adjuvanticity in vivo  
71 
 
A         B
C          D
O
VA
O
V
A+
U
A
O
VA
O
VA
+U
A
0
1
2
3
4
5
WT Pycard-/-
E
o
s
in
o
p
h
ils
(x
1
0
5
)
* 
* 
O
VA
O
VA
+U
A
O
VA
O
V
A+
U
A
0
1
2
3
4
5
L
ym
p
h
o
cy
te
s
 (
x
1
0
4
) * 
* 
WT Pycard-/-
O
VA
O
VA
+U
A
O
V
A
O
VA
+U
A
0.0
2.5
5.0
7.5
WT Tlr4-/-
E
o
s
in
o
p
h
il
s
 (
x
1
0
5
)
** 
* 
O
VA
O
VA
+U
A
O
VA
O
VA
+U
A
0
5
10
15
L
ym
p
h
o
cy
te
s
 (
x
1
0
4
)
WT Tlr4-/-
* 
* 
O
VA
O
VA
+U
A
O
VA
O
VA
+U
A
0
1
2
3
E
o
si
n
o
p
h
il
s
 (
x
1
0
5
)
WT Myd88-/-
O
VA
O
VA
+U
A
O
VA
O
VA
+U
A
0
1
2
3
4
5
L
y
m
p
h
o
cy
te
s
 (
x
1
0
4
)
WT Myd88-/-
* * 
** ** 
E
O
VA
O
VA
+U
A
O
VA
O
VA
+U
A
0
1
2
3
4
WT Nlrp3-/-
E
o
si
n
o
p
h
ils
(x
1
0
5
)
O
VA
O
VA
+U
A
O
VA
O
VA
+U
A
0
1
2
3
4
WT Nlrp3-/-
L
y
m
p
h
o
cy
te
s
(x
1
0
4
)
* 
* 
* 
* 
O
VA
O
VA
+U
A
O
VA
O
VA
+U
A
0
2
4
6
8
WT Il1r1-/-
p=0.057
*
E
o
s
in
o
p
h
ils
(x
1
0
5
)
O
VA
O
VA
+U
A
O
VA
O
VA
+U
A
0
2
4
6
8
10
WT Il1r1-/-
L
ym
p
h
o
cy
te
s
(x
1
0
4
)
 
Figure 4. Uric Acid-Mediated Adaptive Th2 Cell Responses Do Not Require the IL-1-Inflammasome Axis C57BL/6 
mice were administered OVA mixed or not with UA crystals (UA) on day 0, boosted on day 7 with OVA 
intraperitoneally (i.p.), and challenged with OVA aerosols on days 17–19. (A) Cellular composition in the BAL of WT 
and Nlrp3
-/-
 mice. (B) Cellular composition in the BAL fluid (BALf) of WT and Pycard
-/-
 mice. (C) Cellular composition 
in the BALf of WT and Tlr4
-/-
 mice. (D) Cellular composition in the BALf of WT and Myd88
-/-
 mice. (E) Cellular 
composition in the BAL of WT and Il-1r
-/-
 mice. Data are shown as mean ± SEM, *p < 0.05, **p < 0.01, n = 4–6 
mice/group. Experiments were repeated 2–3 times. Data shown are representative of all experiments. 
 
(Franchi and Nunez, 2008; Williams et al., 2010). We therefore studied the involvement of this 
pathway in UA-driven Th2 cell immunity in vivo. Wild-type C57BL/6 mice immunized with 
OVA+UA showed a marked increase in eosinophilia and lymphocytosis in BAL (Figures 4A–4E), 
and this response was not affected in Nlrp3
-/-
 or Pycard
-/-
 mice, lacking essential components of 
the inflammasome complex (Martinon et al., 2006). Because there might be inflammasome-
independent pathways to generate IL-1β, we also immunized mice lacking the IL-1R or mice 
lacking the critical IL-1R signaling intermediate MyD88. It has also been suggested that UA 
crystals signal via TLR4, although this could be due to contaminating endotoxin. Strikingly, Il1r
-/-
, Tlr4
-/-
, and Myd88
-/-
 mice all developed normal Th2 cell immunity to OVA+UA (Figures 4C– 4E). 
We also studied whether development of Th2 cell immunity and asthma in response to 
OVA+alum relied on Nlrp3. Contrary to a recent report (Eisenbarth et al., 2008), we observed  
72 
 
 
 
 
 
Figure 5. Inflammatory Monocytes and Dendritic Cells Are Critical for the Uric Acid-Mediated Adaptive Th2 Cell 
Responses (A) C57BL/6 mice received OVA-AF647 mixed or not with UA crystals intraperitoneally (i.p.), and 24 hr 
later the peritoneal lavage was examined for the presence of OVA
+
CD11b
+
Ly6C
hi
 inflammatory monocytes and DCs. 
(B) OVA
+
 inflammatory monocytes and DCs were analyzed for the expression of CD86. (C) C57BL/6 mice were 
treated with Gr-1 or control antibodies (500 µg/mouse) on day -1, 0, 1, 2. On day 0, mice were treated with OVA 
mixed or not with UA crystals (UA), boosted on day 7 with OVA i.p., and challenged with OVA aerosols on days 17–
19. Cellular composition in the BALf is shown. (D) C57BL/6 Cd11c-DTR mice were treated with diphtheria toxin (100 
ng/mouse i.p.) on day -1. On day 0, mice were treated with OVA mixed or not with UA crystals, boosted on day 7 
with OVA i.p., and challenged with OVA aerosols on days 17–19. Cellular composition in the BALf was determined by 
flow cytometry. (E) BALB/c mice were sensitized by intratracheal instillation of 1 x 10
6
 unpulsed or OVA-pulsed bone 
marrow-derived GM-CSF DCs with or without uricase. On days 10–12, mice were challenged with OVA aerosols. 
Cellular composition in the BAL is shown. Data are shown as mean ± SEM, *p < 0.05, **p < 0.01, n = 4–6 
mice/group. Experiments were repeated 2–3 times. Data shown are representative of all experiments. 
 
that Th2 cell-dependent asthmatic airway inflammation developed normally in Nlrp3
-/-
 mice 
immunized with OVA+alum (Figure S5). To address whether HDM-driven asthma was 
dependent on these pathways, Nlrp3
-/-
, Pycard
-/-
, and P2X7R
-/-
 mice were sensitized and 
challenged with HDM via the airways but showed no reduction in Th2 cell-dependent 
eosinophilia (Figure S6). As already reported, Myd88
-/-
 and Tlr4
-/-
 mice had reduced HDM-
driven airway inflammation (data not shown; Hammad et al., 2009, 2010). In conclusion, the 
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prototypical Th2 cell stimuli alum and HDM, like UA crystals, do not rely on the NLRP3 
inflammasome to induce Th2 cell adaptive immunity leading to allergic airway inflammation. 
 
UA Crystals Recruit Inflammatory DCs that Are Necessary and Sufficient for Th2 Cell 
Immunity 
Twenty-four hours after injection of OVA-Alexa Fluor 647+UA, there was a strong increase in 
the number of inflammatory Ly6C
hi
CD11b
+
 monocytes and inflammatory Ly6C
+
CD11b
+
 DCs that 
had ingested OVA in the peritoneal cavity compared with mice injected with OVA-AF647 alone 
(Figure 5A), and these recruited cells had higher expression of the co-stimulatory molecule 
CD86 (Figure 5B). Although recruitment and activation of DCs suggests a functional role for 
these cells in the UA effect, we still wanted to address whether DCs are really necessary for 
mediating Th2 cell immunity, because recent work suggested that DCs are poor inducers of Th2 
cell immunity, whereas basophils readily are (Perrigoue et al., 2009; Sokol et al., 2009; 
Yoshimoto et al., 2009). We therefore injected OVA+UA in Cd11c-DTR C57BL/6 mice, together 
with diphteria toxin (DT) to deplete DCs (Jung et al., 2002). DT injection in Tg mice abolished 
airway eosinophilia induced by OVA+UA (Figure 5D). This effect was also seen when we 
injected an antibody to Ly6C/G (Gr1) that depletes inflammatory monocytes (Figure 5C), but in 
this setting one cannot exclude that neutrophils play an additional role. To finally demonstrate 
that inflammatory DCs are sufficient to induce Th2 cell immunity, we injected GM-CSF-cultured 
OVA-pulsed DCs (a model to generate inflammatory type DCs) into the peritoneal cavity, 
followed by OVA challenge to the lung. Intraperitoneal injection of OVA-pulsed DCs, but not 
unpulsed DCs, was able to prime for an eosinophilic Th2 cell response (Figure 5E). However, 
treatment with uricase did not inhibit Th2 cell development induced by DC injection, 
demonstrating that the immunostimulatory effects of UA are upstream of DC activation in 
vivo. These experiments also demonstrate that uricase treatment does not have a generalized 
off-target suppressive effect on Th2 cell polarization, but rather inhibits inflammatory type DC 
recruitment and activation.  
 
UA Activates DCs and Th2  Cell Immunity in a Syk- and PI3-Kinase δ-Dependent Manner 
The above data implied that DCs are a crucial intermediate cell type in mediating the Th2 cell 
immune response to OVA+UA (Figure 5) but also that the NLRP3-ASC-IL1R axis were not 
involved in this process in vivo (Figure 4). UA crystals mixed with OVA in vitro were able to 
induce the secretion of bioactive cleaved IL-1β in inflammatory DCs, and this effect was 
completely absent in cells of Nlrp3-/- mice, essentially showing that UA does trigger this 
inflammasome pathway in DCs. However, OVA+UA also induced secretion of IL-6 and TNF-α in 
inflammatory DCs and these responses were not abolished in Nlrp3-/- mice. Strikingly, 
OVA+UA did not induce production of the Th1 cell instructive cytokine IL-12. Recently, via 
atomic force microscopy, UA crystals were shown to directly engage cholesterol-rich cellular 
membranes of DCs in a receptor-independent manner, leading to recruitment and activation 
of spleen tyrosine kinase (Syk) on membrane-associated immunoreceptor tyrosine activation 
motifs (Ng et al., 2008). Other studies have also identified Syk signaling and downstream PI3-
kinase activation as an essential intermediate of UA-induced human neutrophil activation 
(Desaulniers et al., 2001; Popa-Nita et al., 2007). When the in vitro Syk inhibitor piceattanol 
was added, UA+OVA no longer induced IL-1β, IL-6, or TNF-α production in inflammatory DCs,  
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Figure 6. UA Crystals Induce Th2 Cell Immunity through Spleen Tyrosine Kinase and PI3-Kinase δ (A) Bone marrow-
derived DCs were cultured in GM-CSF from WT and Nlrp3
-/- 
mice and pre-incubated with the Syk inhibitor 
piceatennol for 30 min (50 mM), then pulsed with OVA (100 µg/ml) with or without UA crystals (250 µg/ml) for 3 hr, 
after which cytokine concentration was determined in the cell supernatant. (B) C57BL/6 mice were treated twice a 
day on days -1 and -2 orally with the specific Syk inhibitor BAY61-3606 (Yamamoto et al., 2003) and injected on day 
0 with OVA-AF647 mixed or not with UA crystals intraperitoneally (i.p.). 24 hr later, the peritoneal lavage was 
examined for the presence of OVA
+
 inflammatory monocytes. (C) Pik3cdD910A or WT C57BL/6 mice were injected 
with OVA-AF647 mixed or not with UA crystals (UA) i.p., and 24 hr later the peritoneal lavage was examined for the 
presence of OVA
+
 inflammatory monocytes. (D) C57BL/6 mice were treated twice a day on days -1 and -2 orally with 
the specific Syk inhibitor BAY61-3606 . On day 0, mice were treated with OVA mixed or not with UA crystals, 
boosted on day 7 with OVA i.p., and challenged with OVA aerosols on days 17–19. Cellular composition in the BAL is 
shown. (E) Cellular composition in the BALf of WT and Pik3cdD910A mice, which have been sensitized with OVA+UA 
crystals and challenged with OVA aerosol as described in (D), is depicted. (F) Cellular composition in the BAL of Sykb
-
/-
 DC and Sykb+/+ DC chimeric mice, which were sensitized with OVA+UA crystals and challenged with OVA as 
described in (D). Data are shown as mean ± SEM, *p < 0.05, **p < 0.01, n = 4–6 mice/group, representative of at 
least two experiments per panel. 
 
suggesting that this pathway was more broadly involved in inducing cytokine production in DCs 
(Figure 6A).  Oral administration of the Syk inhibitor BAY61-3606 reduced influx of OVA-
positive inflammatory Ly6C
+
CD11b
+
 monocytes in the peritoneum 24 hr later (Figure 6B). 
Signaling downstream of Syk has been shown to involve interaction of p85 with p110d 
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subunits of PI3-kinase (Popa-Nita et al., 2007). The number of OVA
+
Ly6C
+
CD11b
+
 monocytes 24 
hr after injection of OVA+UA was strongly reduced in mice expressing a catalytically inactive 
form of the p110d subunit of PI3-kinase (D910A) (Figure 6C). We finally addressed whether Syk 
and downstream PI3-kinase δ signaling was important for development of adaptive Th2 cell 
immunity to OVA+UA. Oral administration of BAY61-3606 compound strongly reduced airway 
lymphocytosis and eosinophilia (Figure 6D). Accordingly, OVA+UA did not induce Th2 cell 
immunity in Pik3cdD910A mice (Figure 6E), although this finding could also reflect effects on 
other cells like mast cells (Ali et al., 2004). To address whether the inhibition of Syk was 
specifically acting at the level of DCs, we took a genetic approach and immunized Cd11c-Cre x 
Sykb 
fl/fl 
 mice specifically lacking Syk in CD11c
hi
 cells (unpublished observations) or control mice 
with OVA or OVA+UA crystals. Upon OVA challenge, the degree of reduction in airway 
eosinophilia in these Sykb
-/-
 DC mice was of similar magnitude as those treated with a 
pharmacological Syk antagonist, suggesting indeed that Syk triggering in DCs is crucial for 
mounting Th2 cell immunity to UA (Figure 6F).  
 
Discussion 
Although UA is a known trigger for acute neutrophilic inflammation (Martinon et al., 2006), we 
here identified its role as a promotor of Th2 cell-dependent allergic inflammation. The release 
of UA was seen in patients with allergic asthma challenged with relevant allergen, in naive and 
sensitized mice exposed to the prototypical Th2 cell inducer and relevant HDM allergen, and 
after injection of the prototypical Th2 cell adjuvant alum. The Th2 cell-inducing capacity of UA 
occurred independently from its actions on the NLRP3-ASC-IL-1-MyD88 axis. UA is released 
upon alum administration in vivo, but not in vitro, so these findings could explain the 
controversy that has arisen as to whether triggering NLRP3 inflammasome activation is crucial 
for alum adjuvanticity (Marrack et al., 2009). All authors that have studied the involvement of 
NLRP3 agree that NLRP3, PYCARD (ASC), and caspase-1 are crucial for alum-induced IL-1β 
secretion in vitro and in vivo, but this does not automatically imply that all adjuvant effects of 
alum must therefore occur via this pathway (Franchi and Nunez, 2008; Li et al., 2007, 2008; 
McKee et al., 2009). Our findings suggest that UA released upon alum injection in vivo is by 
itself sufficient to induce Th2 cell adjuvant effects that do not depend on the inflammasome-IL-
1R pathway. It has indeed long been known that alum-induced asthma models do not rely on 
IL-1R signaling (Piggott et al., 2005; Schmitz et al., 2003) nor on the downstream essential 
adaptor molecule MyD88 (Piggott et al., 2005). One report has suggested that Nlrp3 is 
absolutely required for alum to induce Th2 cell immunity to OVA and subsequent development 
of allergic type inflammation of the lung (Eisenbarth et al., 2008), at odds with findings in the 
current report. These authors, however, also demonstrated that the effects of alum were 
MyD88 independent, arguing against a role for IL-1R signaling, given the crucial role of MyD88 
as a signaling intermediate of the IL-1R pathway. These differences could be explained best by 
subtle differences in antigens used, type of alum used, and timing of analysis. Also we have 
described previously that NLRP3, IL-1, and MyD88 are involved in the early innate response of 
DCs to alum injection in the peritoneal cavity, but clearly these reactions are redundant with 
other pathways to induce Th2 cell immunity to OVA (Figure 4), and their elimination never 
leads to complete abolition of DC activation or subsequent T cell activation (Kool et al., 2008a, 
2008b). The most striking finding of our paper is that UA is also released upon primary 
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exposure of the lung to HDM, as well as upon allergen challenge in already sensitized human 
asthmatics and mice. Experiments with the UA-degrading enzyme uricase furthermore showed 
that endogenously released UA promotes Th2 cell sensitization by amplifying the production of 
innate pro-Th2 cytokines that instruct DCs to induce Th2 cell immunity, like TSLP, GM-CSF, and 
IL-25 (Barrett and Austen, 2009; Lambrecht and Hammad, 2009), as well as stimulating the 
activation of inflammatory DCs. Many reported that this innate pro-Th2 cytokine release and 
DC activation depends on TLR4 triggering on lung epithelial cells via endotoxin contained in the 
HDM allergen (Hammad et al., 2009, 2010; Trompette et al., 2009). We now show that TLR4 
triggering is functionally connected to the induction of UA production in epithelial cells and 
macrophages. Most probably this occurs via induction of the enzymatic activity of the rate-
limiting uric acid-synthesizing enzyme xanthine oxidoreductase, leading to production of UA 
inside peroxisomes. Alternatively, increased UA concentration could also result from reduced 
catabolism from urate oxidase. Although we have not formally investigated the mechanisms of 
TLR4-driven induction of UA production, it is known that UA is found in the lining fluid of the 
airway epithelial layer in vivo and is induced in response to various types of oxidative stress 
like ozone exposure or respiratory viral infection (Akaike et al., 1990; Papi et al., 2008). The 
xanthine oxidoreductase gene is induced as part of an innate immune response to various 
stimuli like LPS, tissue hypoxia, and early innate cytokines like IL-1, and the promotor region 
contains an NF-κB control element (Hassoun et al., 1998; Vorbach et al., 2003). How exactly 
locally released UA affects the innate cytokine production by epithelial cells is at present 
unclear, nor do we have any indication that UA concentration would be so high that UA 
crystals are formed in the lung lining fluid. Because of physicochemical constraints, we have 
been unable to transfer UA crystals to the lungs of mice to directly probe for effects on 
epithelial cells without mortality of the mice. One possibility that needs further exploration is 
the fact that the antioxidant properties of UA in the lung lining fluid affect the potential of 
bronchial epithelial cells to synthesize, correctly fold, and secrete proteins, processes sensitive 
to oxidative stress (Santos et al., 2009). We have also reported previously that ATP is released 
in the airways of OVA-challenged sensitized mice, as well as allergen-challenged patients, 
indicating that a DAMP can contribute to asthma pathogenesis (Idzko et al., 2007). Because 
ATP is a well-known activator of the NLRP3 inflammasome (Franchi et al., 2007), acting via the 
P2X7 purinergic receptor that is a potassium efflux channel, it made sense to address whether 
either alum-induced or HDM-induced asthma relied on P2X7. Experiments in P2x7R
-/-
 mice did 
not, however, reveal a crucial role of this receptor in asthma development, again arguing 
against a predominant role of NLRP3 in asthma. However, there are many ways by which ATP 
can activate innate and structural cells of the lung to promote asthma and Th2 cell 
development, because the purinergic receptor family is very broad and widely expressed 
among others on eosinophils (Kobayashi et al., 2010). Recently, several groups studying Th2 
cell response induction to the protease allergen papain or to gastrointestinal parasites have 
reported that DCs are poor inducers of Th2 cell immunity that are neither sufficient nor 
required for Th2 lymphocyte differentiation, basophils being clearly superior (Perrigoue et al., 
2009; Sokol et al., 2009; Yoshimoto et al., 2009). However, it was recently also shown that for 
HDM sensitization, inflammatory DCs are the antigen-presenting cells that provide the first 
instruction to Th2 cell development, whereas basophils act to enhance these responses 
(Hammad et al., 2010). Given the fact that the relative contribution of DCs versus basophils 
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seems to depend on the type of Th2 cell stimulus or the route of injection (Tang et al., 2010), it 
was therefore of interest to study the involvement of DCs in mediating the Th2 cell adjuvant 
activities of UA injected into the peritoneal cavity. Employing the logic of Koch’s postulates, we 
first found that inflammatory type DCs and their monocytic precursors were recruited to the 
site of UA injection, that depletion of CD11c
hi
 dendritic cells abolished UA-driven Th2 cell 
responses, and that adoptive transfer of inflammatory DCs to the peritoneal cavity was 
sufficient to induce Th2 cell immunity. Moreover, because we did not observe basophil 
recruitment to the draining lymph nodes of the peritoneal cavity (data not shown), we believe 
that these experiments are sufficient proof that DCs are the cells driving Th2 cell immunity to 
OVA+UA. Recently, UA crystals were shown to directly engage cholesterol- rich cellular 
membranes of DCs in a receptor-independent manner, leading to activation of Syk and 
downstream PI3K signaling (Ng et al., 2008). Experiments with in vitro and in vivo Syk 
inhibitors, as well as kinase-dead Pik3cdD910A mice, revealed that this pathway was relevant 
for early in vivo recruitment of inflammatory DCs to the site of injection and in vivo 
development of Th2 cell immunity to OVA+UA. Although these manipulations could also affect 
other cells, the use of mice specifically lacking Syk expression in DCs allowed us to conclude 
that at least the DC is a predominant sensor of UA crystals. How exactly DCs exposed to UA 
subsequently polarize Th2 cell immune responses is more speculative, but again probably 
involves Syk signaling. We observed that DCs exposed to OVA+UA produced IL-1β, IL-6, and 
TNF-α in the absence of the polarizing cytokine IL-12, in a Syk-dependent manner. We and 
others have previously reported that absence of IL-12 production is a prerequisite for 
inflammatory DCs to be able to induce Th2 cell immunity, because retroviral overexpression of 
IL-12 abolishes DC-driven Th2 cell development and subsequent asthma (Eisenbarth et al., 
2002; Kuipers et al., 2004), whereas others reported that IL-6 and TNF-α are all involved in 
promoting DC-driven Th2 cell development in asthma (Dodge et al., 2003; Ebeling et al., 2007; 
Eisenbarth et al., 2002; Rincon et al., 1997). One report demonstrated that Syk signaling in DCs 
is crucial for Th2 cell-dependent asthma development driven by adoptive transfer of DCs, but it 
is unclear how this relates to polarizing cytokine secretion (Matsubara et al., 2006). Further 
definitive experiments will involve neutralization of individual cytokines to address these 
issues in detail. In conclusion, we have identified an unexpected role for UA as a crucial 
initiator and amplifier of Th2 cell immunity and allergic inflammation in the mouse by 
activating inflammatory DCs. At the same time we have identified a pathway of immune 
activation by UA crystals that is independent of their well-known capacity to trigger the NLRP3 
inflammasome. The fact that neutralization of uric acid at the time of allergen challenge 
reduces the salient features of asthma, and the fact that increased UA concentrations are 
found in patients after allergen challenge, open up the prospects that this pathway could be 
used for novel therapeutics in asthma. 
 
Experimental procedures 
Human Subjects Twenty-one nonsmoking patients with mild allergic asthma (Table S1) were recruited based on 
airway hyperresponsiveness, positive allergen skin prick tests, elevated total or specific IgE concentrations, and a 
dual reaction after allergen challenge (Lommatzsch et al., 2006). The calculation of the individual provocation dose 
was performed based on responsiveness to inhalation allergen challenge (Lommatzsch et al., 2006). Inhaled and 
segmental allergen challenges were separated by at least 4 weeks. Segmental allergen challenge was performed as 
described (Lommatzsch et al., 2006). Corticosteroids were withdrawn at least 7 days before challenge. Patients gave 
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their written informed consent, and he study was approved by the local ethics committee of the University Hospital 
Rostock, Germany. 
 
Mice BALB/c mice and C57BL/6 mice (6–9 weeks old) were purchased from Harlan (Zeist, The Netherlands). Nalp3
-/-
, 
Pycard
-/-
, Tlr4
-/-
, P2x7R
-/-
, Myd88
-/-
, Il1r
-/-
, and WT C57BL/6 mice (6–10 weeks old) were kindly provided by J. Tschopp 
(University of Lausanne, Swizterland) and B. Ryffel (University of Orleans, France). Pik3cdD910A were kindly 
provided by B. Vanhaesebrouck (Queen Mary University London). To generate mice lacking Syk specifically in DCs, 
Cd11c-Cre mice were crossed to Sykb 
fl/fl
 mice (unpublished observations). Bone marrow of these mice was used to 
generate chimeric mice, by sublethally irradiating C57BL/6 mice (5Gy), followed 4 hr later by intravenous (i.v.) 
injection of 2 x 10
6
 BM cells. Chimeric mice were used 10 weeks after hematopoietic reconstitution. All experiments 
were approved by the animal ethics committee at Ghent University and Erasmus University Medical Center. 
 
Monosodium Urate Crystal Preparation MSU crystals were prepared as described (Chen et al., 2006). In brief, 
saturated uric acid (5 mg/mL, Sigma) in 0.1M borate buffer (pH 8.5) was incubated at room temperature for 48 hr. 
After harvesting the crystals, they were washed with alcohol and acetone and air-dried for at least 2 days. Crystals 
were between 5 and 25 µm long and contained <0.005 EU/mL endotoxin. 
 
Treatment with Uricase For intraperitoneal injections, mice received 50 U of uricase (Sigma-Aldrich) 
or rasburicase (Sanofi-Synthelabo) in 100 ml PBS 5 min prior to injection of OVA+alum. For intrapulmonary 
administration, HDM was mixed with 10 U uricase and injected intranasally into 40 ml. 
 
Induction of Allergic Airway Inflammation To test the adjuvant properties of MSU crystals, mice were injected 
intraperitoneally (i.p.) with 10 µg of OVA (Worthington) mixed with increasing amounts of MSU crystals (1–7.5 mg 
in 500 ml). Mice were boosted i.p. on day 7 with OVA and challenged with OVA aerosols (Sigma, 1% for 30 min) on 
days 17–19. On day 20, mice were analyzed for the presence of Th2 cell-dependent eosinophilic airway 
inflammation. To induce HDM-driven eosinophilic airway inflammation, anesthetized mice were administered 
intranasaly (i.n.) with 40 µl of house dust mite extracts (100 µg, Greer Laboratories) on day 0 and challenged on 
days 7–11 with HDM. On day 14, mice were sacrificed and different parameters were analyzed. Assessment of 
bronchial hyperreactivity and histological analysis of goblet cell hyperplasia was measured as described previously 
(Hammad et al., 2009). 
 
Immune Analysis To determine the degree of airway eosinophilia, bronchoalveolar lavages (BAL) were performed 
by injecting 1 ml of PBS containing 0.01mM EDTA. Cells were stained with FITC anti-I-Ad and I-E
d
, PE-labeled anti-
SiglecF, PerCp-labeled anti-CD3 and anti-CD19, and APC-labeled anti-CD11c (all from BD Biosciences). Peritoneal 
inflammatory cells were stained as described (Kool et al.,2008b). Data were collected on a FACS Aria II (Becton 
Dickinson) and were analyzed with FlowJo software (Treestar, Inc.). The concentration of UA (Amplex Red Uric Acid; 
Uricase assay, Invitrogen), GM-CSF, IL-33, TSLP, and IL-25 (all R&D Systems) was measured in BAL fluid and lung 
homogenates by ELISA 2 and 24 hr after HDM administration. The concentration of Th2 cytokines in BAL fluids was 
measured 24 and 72 hr after the last challenge, respectively. OVA-specific IgG1, IgE, and IgG2a were measured in 
sera of mice sensitized and challenged with OVA by ELISA (antibodies from R&D Systems). 
 
Uric Acid Staining in the Lung Two hours after the i.n. administration of PBS or HDM, lungs were inflated with PBS 
and OCT and frozen at -80°C. Ten mm thick sections were fixed with 4% formaline for 10 min and stained with 
rabbit anti-uric acid antibodies (Abcam) followed by Cy3-labeled goat anti-rabbit antibodies (Jackson Laboratories), 
blocking with rabbit serum, biotin-labeled anti-peroxisomal membrane protein 70 (Genetex), and FITC-labeled anti-
MHCII (BD Bioscience), followed by streptavidin Alexa Fluor 647. Nuclei were counterstained with 40,60 diamidino-
2-phenylindole (DAPI). Images were collected on a Zeiss LSM 710 equipped with a Ar 488 nm laser, a He-Ne 561 nm 
laser, a He-Ne 633 nm laser, and a Mai Tai femtosecond-pulsed laser tuned at 800 nm to excite DAPI. Images were 
analyzed with Imaris (Bitplane). 
 
qPCR on Xanthine Oxido Reductase RNA was isolated from BAL cells with High Pure RNA Isolation Kit (Roche) with 
on-column DNase I treatment. 100 ng RNA was reverse transcribed with Transcriptor High Fidelity cDNA Synthesis 
Kit (Roche). Quantitative PCR was performed with LightCycler 480 Probes Master (Roche) and primers (xanthine 
oxidoreductase; forward, AGGGATTCCGGACCTTTG; reverse, GCAGCAGTTTGGGTTGTTTC) and probe mixes (probe 
69; Roche). PCR conditions were 10 min at 95°C, followed by 45 cycles of 10 s at 95°C and 50°C for 1 min with a 
LightCycler 480 Instrument (Roche). PCR amplification of the housekeeping gene hypoxanthine-guanine 
phosphoribosyl-transferase (HPRT) was performed during each run for each sample to allow normalization between 
samples. 
 
Statistical Analysis For all experiments unless stated otherwise, the difference between groups was calculated with 
the Mann-Whitney U test for unpaired data (GraphPad Prism version 4.0; GraphPad, San Diego, CA). Comparison of 
the human BAL fluid UA concentration was performed with the Wilcoxon-signed rank test. Correlations between 
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the human data were tested with Pearson’s correlation test. Differences were considered significant when p < 0.05 
(*), p < 0.01 (**), or p < 0.005 (***). 
 
 
Supplemental information 
Supplemental Information includes six figures and one table and can be found within this 
thesis and online at doi:10.1016/j.immuni.2011.03.015. 
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Recent findings 
A study on nasal secretion of chronic rhinosinusitis patients showed that uric acid was 
significantly increased after provocation and remained elevated during the observation period 
(Rank et al., 2013). If ozone was used to induce inflammation in asthmatics, no difference was 
seen on uric acid release (Esther et al., 2011). We found UA release to be dependent on TLR4 
signalling. The finding of Esther also points to a specific release of UA upon allergen exposure, 
rather than UA as an danger signal. 
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Supplemental information 
 
Table S1: Clinical characteristics of asthmatic patients The table displays sex and age (in years) of the patients, the 
pre-bronchodilator forced expiratory volume in the first second (FEV1, % predicted), the serum levels of total 
(normal range: < 100 kU l-1) and allergen-specific (normal range: < 0.7 kU l-1) Immunoglobulin E (IgE) levels, the 
asthma duration (in years), the allergen, and the dose (in allergen units, AU) used for segmental allergen challenge. 
Median age of the patients was 25 years old, range 20-31. 
 
 
Figure S1: OVA-alum induces UA independent of the TLR/IL-1R axis. Casp1-/-, Tlr4-/-, Myd88-/- mice and their 
control littermates were injected with OVA-alum or OVA alone. 2hrs later the peritoneal lavage was taken and UA 
levels were determined. 
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Figure S2: OVA-alum responses are independent of ATP or P2X7. (a) BALB/c mice were injected i.p. with OVA or 
OVA-alum and 2 hrs the levels of ATP were determined in the peritoneal lavage. (b) The peritoneal lavage was also 
examined for the levels of IL-1β, IL-6, IL-18, and MCP-1 by ELISA. (c) 2.5*10
6
 CFSE-labeled DO11.10 OVATCR Tg CD4
+
 
T cells were given to BALB/c mice one day prior to OVA-alum. Mice were treated 5 min before OVA-alum with 
apyrase. Four and 7 days later the mediastinal lymph node cells were collected and examined by flowcytometry for 
divisions. (d) Total numbers of OVA-TCR Tg cells are depicted. (e) WT or P2rx7-/- mice were sensitized on day 0 with 
alum (PBS) or OVA-alum (OVA), boosted on day 7 with OVA i.p., and challenged with OVA aerosols on days 17-19. 
Mice were sacrificed on day 20, and the cellular composition in the BALf is shown. (f) On day 20 the mediastinal 
lymphnode cells were restimulated with OVA (10 μg/ml) for four days. Cytokines were determined in the 
supernatant by ELISA. Data are shown as mean ± SEM, * p<0.05, n=4-6 mice/group. 
 
 
Figure S3: Uric acid levels are only elevated in patients not receiving inhaled corticosteroids. Uric acid levels in 
BALf of asthmatic patients 10 min or 24h after segmental bronchial allergen or saline challenge, defined as patients 
on ICS (inhaled corticosteroids) prior to segmental challenge or patients not on ICS. 
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Figure S4: Uricase treatment during challenge in a milder HDM model. 
Mice were sensitized i.n. on day 0 with PBS or 1 μg HDM. During challenge 
(day 7-11) with 10 μg HDM mice were treated with uricase. On day 14, BALf 
was examined for the presence of eosinophils and lymphocytes. 
 
 
 
Figure S5: OVA-alum driven Th2 development 
in a model of asthma develops normally in 
Nlrp3-/- mice. (a) WT C57BL/6 or Nlrp3-/- 
mice were immunized with OVA-alum i.p. on 
day 0. On day 7, mice were boosted with OVA 
i.p. and challenged with OVA aerosols on days 
17-19. On day 20, BALf was analyzed for the 
presence of eosinophils and lymphocytes. (b) 
MLN cytokine production was measured as in 
Supplementary Fig. 2. Data are shown as 
mean ± SEM, * p<0.05, ** p<0.01, n=4-6 
mice/group. 
 
 
 
 
 
 
 
 
 
 
Figure S6: HDM driven asthma 
develops normally in Nlrp3-/- , 
Pycard-/- , and P2rx7-/- mice 
WT C57BL/6 or Nlrp3-/- (a, b), 
Pycard-/- (c,d) or P2rx7-/- (e,f) 
mice were sensitized i.n on day 
0 with PBS or HDM, and 
challenged i.n with HDM on 
days 7-11. On day 14, BALf was 
examined for the presence of 
eosinophils and lymphocytes 
(a, c, e). MLN cytokine 
production was measured as in 
Supplementary Fig. 2 (b,d,f). 
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Various reports in the past studied the role of IL-1 in asthma, however none of these were 
done with protease containing allergens such as house dust mite. Here we showed for the first 
time the cytokine cascade following antigen exposure in the lung. This paper reveals an 
important role for epithelial cells and IL-1α in the sensitization to house dust mite.   
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Interleukin-1α controls allergic sensitization to inhaled house dust 
mite via the epithelial release of GM-CSF and IL-33 
 
Abstract 
House dust mite (HDM) is one of the most common allergens worldwide. In this study, we 
have addressed the involvement of IL-1 in the interaction between HDM and the innate 
immune response driven by lung epithelial cells (ECs) and dendritic cells (DCs) that leads to 
asthma. Mice lacking IL-1R on radioresistant cells, but not hematopoietic cells, failed to mount 
a Th2 immune response and did not develop asthma to HDM. Experiments performed in vivo 
and in isolated air–liquid interface cultures of bronchial ECs showed that TLR4 signals induced 
the release of IL-1α, which then acted in an autocrine manner to trigger the release of DC-
attracting chemokines, GM-CSF, and IL-33. Consequently, allergic sensitization to HDM was 
abolished in vivo when IL-1 α, GM-CSF, or IL-33 was neutralized. Thymic stromal lymphopoietin 
(TSLP) became important only when high doses of allergen were administered. These findings 
put IL-1α upstream in the cytokine cascade leading to epithelial and DC activation in response 
to inhaled HDM allergen. 
 
Introduction 
Allergic asthma is characterized by a Th2-dominated immune response to inhaled allergens like 
house dust mite (HDM), cockroach, and animal dander, which leads to eosinophilic 
inflammation of the airways, goblet cell metaplasia (GCM), and bronchial hyperreactivity 
(Barnes, 2008). The incidence of allergic sensitization to inhaled allergens has steadily risen 
over the last 60 yr, and in some countries up to one third of children have a positive skin prick 
test to environmental allergen (Umetsu et al.,2002). The various molecularly defined allergens 
found within the HDM Dermatophagoides pteronyssinus are the most common triggers of 
allergic asthma worldwide, which has led to the development of animal models that use 
inhaled HDM extracts to study the cellular and molecular mechanisms of allergic sensitization. 
Recent studies have shown that inhaled HDM extract stimulates Th2 immunity by acting on 
barrier epithelial cells (ECs), antigen-presenting DCs, and innate immune cells like basophils 
and mast cells (Hammad et al., 2010; Wills-Karp, 2010; Lambrecht and Hammad, 2012). One 
predominant way by which HDM induces Th2 immunity is by triggering the TLR4 receptor 
expressed on bronchial ECs, through its major allergen Der p 2 together with endotoxin 
contained in fecal pellets of the mite (Trompette et al., 2009). There is also evidence that 
components of HDM trigger C-type lectin or protease-activated receptors and thus contribute 
to the recruitment and activation of innate and adaptive immune cells (Barrett et al., 2009; 
Nathan et al., 2009; Lewkowich et al., 2011). Research from various laboratories has shown 
that triggering of pattern recognition receptors on ECs leads to release of innate pro-Th2 
cytokines like thymic stromal lymphopoietin (TSLP), GM-CSF, IL-25, and the IL-1 family member 
IL-33 that share the capacity of activating DCs (Hammad et al., 2009; Phipps et al., 2009; Kool 
et al., 2011). In this regard, TSLP has received much attention as it promotes Th2 development 
by DCs, activation of innate lymphoid cells, and basophil hematopoiesis (Kitajima et al., 2011; 
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Siracusa et al., 2011). Transgenic (Tg) overexpression of TSLP in lung ECs led to enhanced Th2 
responses to inhaled environmental antigens (Headley et al., 2009; Lei et al., 2011). Studies in 
human severe asthmatics demonstrated increased levels of TSLP messenger RNA and protein 
in bronchial biopsy specimens and identified associations between TSLP promoter region 
polymorphisms and risk of developing asthma (Harada et al., 2011; Shikotra et al., 2012). 
Although TSLP has become a prime target for intervention in allergic disease, other cytokines 
like IL-33, GM-CSF, or IL-25 could also control Th2 immunity to inhaled allergens (Fort et al., 
2001; Hurst et al., 2002; Cates et al., 2004; Besnard et al., 2011). The signals that control innate 
cytokine and chemokine release from bronchial ECs are poorly understood, and it is 
particularly unclear whether released cytokines could act as a cascade, with one cytokine 
stimulating the release of another, and thus acting as a controller of allergic sensitization. This 
possibility was raised when in vitro studies on cultured lung ECs found that IL-1 is a potent 
upstream inducer of TSLP production (Allakhverdi et al., 2007; Lee and Ziegler, 2007; Lee et al., 
2008). In this study, we have addressed the involvement of IL-1 in the interaction between 
HDM allergen, lung ECs, and DCs that leads to asthma. We found that mice lacking IL-1R on 
radioresistant cells, but not hematopoietic cells, were totally protected from mounting Th2 
immunity and asthma to low doses of HDM. Experiments performed in vivo and in isolated air–
liquid interface (ALI) cultures of bronchial ECs showed that this was caused by the TLR4-
mediated release of IL-1α, which acted in an autocrine manner on bronchial ECs to release DC-
attractive chemokines, GM-CSF, and IL-33 but not TSLP. Consequently, allergic sensitization to 
low-dose HDM was only abolished in vivo when IL-1α, GM-CSF, or IL-33 was neutralized. 
However, TSLP and its receptor became important when mice were exposed to high doses of 
HDM. These findings put IL-1α upstream in the cytokine cascade leading to epithelial and DC 
activation in response to inhaled HDM allergen. 
 
Results 
IL-1RI signaling is crucial for development of asthma to HDM 
IL-1α and IL-1β are closely related cytokines that share biological activity by acting exclusively 
on the IL-1R1 on various cell types. To address how these two cytokines affect development of 
asthma, we sensitized WT and Il1r1
-/-
 mice using 1 μg HDM or PBS as a control and challenged 
all mice intranasally 1 wk later on five consecutive days with 10 μg HDM. This protocol differs 
from previously published work on HDM-driven asthma, where we (Hammad et al., 2009) and 
others (Cates et al., 2004; Lewkowich et al., 2005; Phipps et al., 2009) administered higher 
doses of HDM. Using this protocol, we observed that HDM-sensitized WT mice developed signs 
of allergic asthma, such as influx of eosinophils and lymphocytes in the bronchoalveolar lavage 
(BAL) fluid (Fig. 1 A), peribronchial and perivascular infiltration of mononuclear cells, 
lymphocytes, and eosinophils, and GCM (Fig. 1 B), whereas sham PBS-sensitized mice exposed 
to HDM did not. In their serum, HDM-sensitized mice produced HDM-specific IgG1 and IgE, 
whereas Th1 cytokine–dependent IgG2a antibodies were not induced (Fig. 1 C). HDM-sensitized 
and challenged mice developed bronchial hyperreactivity to methacholine, whereas sham-
sensitized mice did not (Fig. 1 D). These features of asthma were accompanied by enhanced 
production of Th2 cytokines IL-13, IL-5, and IL-10 in the mediastinal LNs (MLNs; Fig. 1 E). The 
levels of IL-17 and IFN-γ were not induced significantly by active HDM sensitization. 
Importantly, when these experiments were performed in Il1r1
-/- 
mice, there was a strong 
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reduction in lung eosinophilia and lymphocytosis, GCM, HDM-specific IgG1 and IgE production, 
and bronchial hyperreactivity to methacholine. In addition to severely impaired Th2 cytokine 
production, we also noticed that production of IL-17 was impaired in Il1r1
-/- 
mice, consistent 
with a known role for this cytokine in Th17 development (Sutton et al., 2006).  
 
Figure 1. IL-1RI signaling is crucial for the development of HDM-induced asthma. (A–E) WT and Il1r1
-/-
 mice were 
sensitized on day 0 with HDM or PBS and were challenged with HDM on days 7–11. (A) Differential cell counts were 
determined by flow cytometry 72 h later. (B) PAS staining of lung sections. (C) Levels of serum HDM–specific Igs. (D) 
Airway resistance in response to increasing concentrations of methacholine. (E) Cytokine levels in MLN cells 
restimulated for 3 d with 15 μg/ml HDM. (F–H) C57BL/6 mice were sensitized with HDM in the presence or absence 
of blocking antibodies to IL-1α or IL-1β and were challenged with HDM. (F) Differential cell counts were determined 
by flow cytometry 72 h later. (G) IgG1 levels in sera. (H) IL-13 levels in MLN cells restimulated for 3 d with HDM. (I 
and J) C57BL/6 mice were sensitized with HDM or PBS and were administered blocking antibodies to IL-1α or IL-1β 
on the last 3 d of HDM challenge. (I) Differential cell counts were determined by flow cytometry 72 h later. (J) WT 
and Casp1
-/- 
mice were sensitized with HDM or PBS as a control and were re-challenged with HDM. Differential cell 
counts were determined by flow cytometry 72 h later. (K) WT mice were administered with PBS or HDM. IL-1α and 
IL-1β contents were determined in lung homogenates 2 and 24 h later. *, P < 0.05. Results show one representative 
experiment out of three. Five to six mice/group were used. Results are shown as mean ± SEM. 
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HDM sensitization depends mainly on IL-1α, not IL-1β.  
These experiments demonstrated that IL-1RI signaling is crucial for development of asthma but 
did not address whether IL-1 is required during sensitization (i.e., the first administration of 
HDM) or challenge phase (days 7–12) of the response. Also, as IL-1α and IL-1β both trigger the 
IL-1RI equally well, we addressed their relative contribution during sensitization or challenge. 
Neutralizing IL-1α with a blocking antibody during sensitization led to strongly reduced airway 
eosinophilia and lymphocytosis (Fig. 1 F), serum HDM–specific Ig levels (Fig. 1 G), Th2 cytokines 
(Fig. 1 H; only IL-13 shown as representative Th2 cytokine), and periodic acid-Schiff (PAS)–
positive GCM (not depicted). Neutralizing IL-1β during sensitization had no statistically 
significant effect on eosinophilic influx in the lung and on serum HDM–specific Igs (Fig. 1, F and 
G). IL-1β neutralization did reduce levels of Th2 cytokine production in the MLNs, however to a 
lesser extent than IL-1α blockade (Fig. 1 H). When either IL-1α or IL-1β was blocked during the 
challenge phase, there was no effect on BAL fluid cellular composition (Fig. 1 I) or any of the 
other parameters (not depicted). Caspase-1 (a.k.a. IL-1 converting enzyme 1) is necessary to 
process pro–IL-1β into biologically active secreted IL-1β, whereas it is not necessary for IL-1α 
biological activity (Dinarello, 2009). We therefore sensitized WT and casp1
-/-
 mice to HDM and 
challenged them with HDM. No differences on lung inflammation (Fig. 1 J) or any of the other 
parameters (not depicted) were observed in casp1
-/-
 mice, further supporting the idea that 
mainly IL-1α is necessary for HDM-induced Th2 immunity. One possible explanation for the 
differential effect of IL-1α versus IL-1β neutralization on development of HDM asthma could 
be different levels of production of either cytokine. We therefore measured the levels of IL-1α 
and IL-1β in lungs, 2 and 24 h after HDM administration of naive mice and found that IL-1α 
levels were strongly induced at 2 and 24 h, whereas IL-1β was barely detected (Fig. 1 K). 
 
IL-1RI is necessary on radioresistant cells of the lungs  
Because we observed that IL-1α was necessary for promoting Th2 immunity to natural 
allergens in the lung, we next questioned how it promoted Th2 immunity. The IL-1R1 is not 
only expressed on various immune cells like macrophages, DCs, T lymphocytes, mast cells, and 
eosinophils, but also on structural cells like fibroblasts and ECs. To address on which cell type 
IL-1R was necessary, we made a series of bone marrow chimeric mice. WT and Il1r1
-/-
 mice 
were sublethally irradiated and received donor WT or Il1r1
-/- 
bone marrow to allow for 
hematopoietic reconstitution. 10 wk later, we sensitized and challenged them with HDM. As in 
previous experiments (Fig. 1), WT → WT chimeric mice mounted higher degrees of airway 
eosinophilia and lymphocytosis (Fig. 2 A), serum HDM–specific IgG1 (Fig. 2 B), and GCM (Fig. 2 
C) compared with Il1r1
-/- 
→ Il1r1
-/- 
mice, essentially illustrating that the irradiation and 
chimerism procedure did not affect the fundamental outcome of the experiment previously 
performed in unmanipulated WT and Il1r1
-/- 
mice. We observed a similar reduction in BAL fluid 
eosinophilia and lymphocytosis, HDM-specific Igs, and GCM in mice that lacked the IL-1RI on 
radioresistant structural cells (WT → Il1r1
-/-
), whereas no reduction was seen in mice lacking IL-
1RI on hematopoietic cells (Il1r1
-/- 
→ WT).  
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Autocrine IL-1α acts on ECs to promote production of chemokines and innate pro-Th2 
cytokines 
Because of their exposed position as barrier cells of the lungs, bronchial ECs are prime 
candidates among radioresistant cells for producing IL-1, as well as responding to it. To address 
this possibility, we set up ALI cultures of primary ECs obtained from digested tracheas of 
various WT and gene- deficient mice. When these cultures were stimulated with HDM extract, 
they produced mainly IL-1α but not IL-1β (Fig. 2 D), reflecting the situation seen upon in vivo 
exposure of the lung to HDM (Fig. 1 K). We and others have previously reported that TLR4 
stimulation of ECs is a crucial event in the development of Th2 immunity to HDM (Hammad et 
al., 2009; Trompette et al., 2009). When ALI cultures were set up using tracheal ECs of Tlr4
-/- 
mice, HDM was less able to induce IL-1α production (Fig. 2 E). When ALI cultures were set up 
derived from Il1r1
-/- 
mice, however, HDM was however fully able to induce IL-1α production 
(Fig. 2 E). Moreover, in vivo, the levels of IL-1α were also increased in the BAL fluids of WT 
mice administered with HDM (Fig. 2 F). The HDM-induced production of IL-1α seen in the BAL 
of WT animals was absent in Tlr4
-/- 
mice (Fig. 2 F). In addition, we also found no increase in IL-
1α levels in the BAL of mice treated with uricase at the time of HDM administration (Fig. 2 F), 
indicating that uric acid (UA) produced in response to HDM exposure could induce IL-1α 
production. However, apyrase pretreatment to degrade any HDM-induced ATP production did 
not show an effect on IL-1α release (Fig. 2 F). Various pro-Th2 innate cytokines like TSLP, GM-
CSF, IL-33, and IL-25, as well as chemokines like KC and CCL20 that can be produced by lung 
ECs, have been found to be induced in the lungs of HDM-exposed mice in vivo (Hammad and 
Lambrecht, 2008). We next questioned whether epithelial IL-1α and IL-1RI signaling was 
involved in an autocrine loop influencing the production of these factors. When tracheal 
epithelial ALI cultures of WT mice were stimulated with HDM extracts, GM-CSF and KC were 
produced, in a process requiring TLR4 (Fig. 2 G). The levels of TSLP, IL-25, and IL-33 in ALI 
cultures were around the detection limit of the cytokine ELISA and were inconsistent between 
repeat experiments, so we focused our attention on the production of GM-CSF and 
chemokines. ALI cultures stimulated with rIL-1α produced GM-CSF, CCL20, and KC, and these 
effects were not seen in Il1r1
-/-
 mice, showing that these effects were not caused by some 
contaminant in the IL-1 preparations (Fig. 2 G). Strikingly, HDM was unable to induce GM-CSF 
and CCL20 production in ALI cultures generated from Il1r1
-/- 
mice, essentially demonstrating 
that autocrine release of IL-1α was inducing these factors in a process requiring TLR4 triggering 
by HDM. We next studied the in vivo production of early innate pro-Th2 cytokines and 
chemokines in WT and Il1r1
-/-
 mice by measuring their presence in lung homogenates 12 h 
after administration of HDM intratracheally (i.t.). As shown in Fig. 2 H, HDM administration in 
WT mice led to the production of GM-CSF, IL-33, CCL20, and KC, whereas TSLP and IL-25 were 
around the limit of detection in this assay (not depicted). The production of GM-CSF, IL-33, and 
KC but not that of CCL20 was severely reduced in Il1r1
-/- 
mice (Fig. 2 H), suggesting that these 
cytokines are downstream of IL-1. Moreover, the blockade of IL-33 at the time of HDM 
administration did not affect IL-1α production in the lung, showing that IL-1 is upstream of IL-
33 (Fig. 2 I). 
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Figure 2. IL-1RI is necessary on radioresistant structural cells of the lungs. (A–C) Various chimeric mice (coded as 
bone marrow donor → recipient) were sensinzed and challenged with HDM as described in Fig. 1. (A) Differential 
cell counts were determined 72 h later. (B) Levels of serum HDM–specific Igs. (C) PAS staining of lung sections. Five 
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to six mice/group were used. (D) ALI cultures of primary tracheal ECs from WT mice were exposed to HDM or PBS as 
a control. Levels of IL-1α and IL-1β were measured in supernatants. (E) ALI cultures of primary tracheal ECs from 
WT, Tlr4
-/-
, and Il1r1
-/-
 mice were exposed to HDM or PBS. Levels of IL-1α were measured in supernatants. (F) 
C57BL/6 WT mice were injected i.t. with PBS, uricase, or apyrase 30 min before exposure to PBS or HDM. Tlr4
-/-
 mice 
were exposed i.t. to PBS or HDM. BAL was collected after 2 h and was analyzed for the presence of IL-1α. (G) Levels 
of GM-CSF, CCL20, and KC were measured in BAL fluids 24 h after exposure to HDM, IL-1α, or PBS. (H) GM-CSF, IL-
33, CCL20, and KC levels in supernatants of ALI cultures of WT and Il1r
-/-
 mice exposed to PBS or HDM. (I) WT mice 
were injected i.p. with solST2r and with HDM i.t. IL-1α levels were measured in lung homogenates 24 h later. (J) 
Primary ECs from healthy donors (NBECs) and from asthmatic patients (DBECs) were exposed to HDM or PBS. Levels 
of IL-1α were measured 24 h later. (K) TSLP, IL-25, GM-CSF, and IL-33 levels in supernatants of NBEC and DBEC 
cultures exposed to HDM, IL-1α, or PBS. (L) Primary ALI cultures of human healthy donors (NBECs) were exposed to 
PBS or HDM in the presence or not of different doses of IL-1ra. GM-CSF was analyzed in the supernatant of these 
cultures after 24 h. *, P < 0.05. Results show one representative experiment out of three. Results are shown as 
mean ± SEM. 
 
Human ALI cultures produce IL-1 and GM-CSF in response to HDM allergen 
To investigate the translational aspect of these findings, we stimulated ALI cultures of 
commercially available primary human bronchial ECs (healthy: normal bronchial ECs [NBECs]; 
asthmatic: diseased bronchial ECs [DBECs]) with HDM allergen after three passages of culture. 
Exposure of these cultures led to increased IL-1α secretion on the apical side, particularly in 
ALI cultures set up from DBECs (Fig. 2 J). Exposure of the human ECs to HDM also led to GM-
CSF and TSLP secretion on the basolateral side but not of IL-25 (Fig. 2 K). Exposure of human 
ALI cultures to IL-1α also led to GM-CSF and IL-33 induction in NBEC cultures, but the GM-CSF 
response was significantly blunted in DBECs (Fig. 2 K). We next addressed whether human IL-
1RI signaling was also involved in an autocrine loop influencing the production GM-CSF, as 
shown previously in mice (Fig. 2 G). NBEC cultures were exposed to PBS or HDM in the 
presence of different doses of a blocking IL-1R antagonist. IL-1Ra did not induce any cell death 
in the cultures as assessed by the absence of tight junction disruption (not depicted). As shown 
in Fig. 2 L, the addition of IL-1Ra to the cultures decreased the production of GM-CSF induced 
by HDM, demonstrating that the autocrine release of IL-1α was inducing GM-CSF production in 
human ECs. 
 
Development of Th2 immunity to HDM depends on GM-CSF and IL-33 
GM-CSF, IL-33, and TSLP are potentially important cytokines that were produced in the 
epithelial ALI cultures and/or in vivo upon HDM exposure in an IL-1R1–dependent manner. To 
fully understand the importance of these cytokines in the process of sensitization to HDM, we 
first sensitized and challenged TSLP receptor–deficient (Crlf2
-/-
) and WT C57BL/6 control mice 
to HDM. Using a low dose of HDM to sensitize and challenge mice (1 μg for sensitization 
followed by 10 μg for challenge for 5 d, as in all experiments), we observed that TSLP receptor 
signaling was not necessary to induce sensitization to HDM because these knockout mice 
developed identical eosinophilic and lymphocytic influx in the lungs (Fig. 3 A) and identical 
HDM-specific IgG1 levels (Fig. 3 B) after HDM challenge and even increased cytokine levels 
after restimulation of MLN cells (Fig. 3 C). The levels of IL-17 were increased in Crlf2
-/-
 mice. In 
addition, the administration of a low dose of HDM did not induce TSLP production in the BAL 
fluids compared with mice exposed to PBS (Fig. 3 D). Similar results were obtained when Tslp
-/- 
C57BL/6 mice or BALB/c Crlf2
-/- 
were used for experiments, suggesting that these results hold 
true across two strains of mice and when either receptor or its ligand is inhibited (not 
depicted). However, when we used a higher dose of HDM (100 μg) to sensitize and challenge  
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Figure 3. Development of Th2 immunity to HDM depends on IL-33 and GM-CSF and not TSLP. (A–D) WT and Crfl2
-/-
 
were sensitized and challenged with HDM or PBS as described in Fig. 1. (A) Differential cell counts were determined 
72 h later. (B) Levels of serum HDM–specific Igs. (C) Cytokine levels in MLN cells restimulated for 3 d with HDM. (D) 
TSLP levels  in BAL fluids. (E–H) WT and Crfl2
-/- 
were sensitized and challenged with 100 μg HDM or PBS. (E) 
Differential cell counts were determined 72 h later. (F) Levels of serum HDM–specific Igs. (G) Cytokine levels in MLN 
cells restimulated for 3 d with HDM. (H) TSLP levels measured in BAL fluids. (I–K) C57BL/6 mice were injected i.p. 
with blocking soluble ST2 receptor or isotype control at the time of HDM sensitization. (I) Differential cell counts 
were determined 72 h after the last HDM challenge. (J) Levels of serum HDM–specific Igs. (K) Cytokine levels in MLN 
cells restimulated for 3 d with HDM. (L–N) C57BL/6 mice were injected i.p. with blocking anti–GM-CSF or isotype 
control antibodies at the time of HDM sensitization. (L) Differential cell counts were determined 72 h after the last 
HDM challenge. (M) Levels of serum HDM–specific Igs. (N) Cytokine levels in MLN cells restimulated for 3 d with 
HDM. *, P < 0.05. Results show one representative experiment out of at least three. Five mice/group were used. 
Results are shown as mean ± SEM. 
 
mice, Crlf2
-/-
 mice developed less airway eosinophilia (Fig. 3 E) accompanied by a reduced Th2 
cytokine production by MLN cells (Fig. 3 G) and showed increased IgG2a levels (Fig. 3 F), 
indicative of a switch to a Th1 type of immunity. Moreover, exposure to a high dose of HDM 
was accompanied by an increase in BAL fluid levels of TSLP (Fig. 3 H). These findings suggest 
that the role of TSLP in asthma is related to severity of the disease, as it is in humans. 
Interestingly, when Il1r1
-/-
 mice were administered the high dose of HDM, they still failed to 
develop asthma features (not depicted). To investigate the role of IL-33 in sensitization to low 
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dose HDM, we injected mice with recombinant soluble ST2 receptor (solST2r) to block IL-33 
signaling. We found that the administration of solST2r at the time of sensitization led to a 
decrease in the number of eosinophils and lymphocytes in the BAL (Fig. 3 I) and in HDM-
specific IgE and IgG1 in the serum (Fig. 3 J). rST2 did not significantly affect the levels of 
cytokines produced by MLNs (Fig. 3 K). Because GM-CSF–deficient mice spontaneously 
develop alveolar proteinosis, we were not able to analyze the contribution of genetic 
deficiency of GM-CSF on HDM-driven asthma (Stanley et al., 1994). To address the functional 
importance of GM-CSF, we administered a neutralizing GM-CSF antibody at the time of low-
dose sensitization to HDM. This lead to reduced eosinophilic influx in the lungs (Fig. 3 L), 
reduced HDM-specific IgG1 (Fig. 3 M), and Th2 cytokines in the MLNs (Fig. 3 N). 
 
Administration of IL-1α is sufficient to promote sensitization to inhaled protein antigens 
The aforementioned experiments demonstrated that IL-1α was necessary for inducing Th2 
immunity to HDM via activation of an epithelial cytokine cascade. As many parallel pathways 
might exist to induce Th2 immunity to natural allergens in the lungs, we next wanted to study 
whether IL-1α was also sufficient to induce Th2 immunity. To address this, we administered an 
otherwise tolerizing dose of harmless OVA antigen to the lungs of naive C57BL/6, in the 
presence or absence of rIL-1α. 10 d later, all mice were challenged with OVA aerosols. Addition 
of IL-1α resulted in a significant influx of eosinophils and lymphocytes in the BAL fluid 
compared with mice sensitized with only OVA or with PBS as a control (Fig. 4 A). Co-
administration of OVA and IL-1α also induced increased levels of Th2-dependent OVA-specific 
IgE and IgG1 in the serum (Fig. 4 B), a Th2 cytokine profile in MLNs (Fig. 4 C), GCM in lung ECs 
(Fig. 4 D), and bronchial hyperreactivity (Fig. 4 E). As in HDM-induced Th2 immunity, IL-1 had a 
mild stimulatory effect on IL-17 production, whereas IFN-γ was not induced. These stimulatory 
effects of IL-1α on Th2 immunity to OVA failed to develop in Il1r1
-/-
 mice, suggesting that they 
were not caused by some off-target contaminating moiety in the cytokine (not depicted). 
Similar results were obtained when we administered OVA together with recombinant IL-1β, 
consistent with the idea that IL-1RI is stimulated equally well by IL-1α and IL-1β (Fig. 3, A–D). 
Interestingly LPS, an innate adjuvant known to promote Th2 sensitization when administered 
at low dose, was able to increase bronchial hyperreactivity to the same extent as IL-1 (Fig. 3 E). 
We then addressed the relative contribution of TSLP and GM-CSF in mediating the Th2-
promoting effects of IL-1α. The induction of Th2 immunity to OVA + IL-1α (as shown in Fig. 4 F 
for BAL fluid cellular composition, representative of all other parameters) was unaffected in 
Crlf2
-/-
 mice lacking TSLPR. Moreover, the levels of TSLP measured in BAL fluids of the mice 
were very low and were not increased by IL-1α (not depicted). We also neutralized GM-CSF at 
the time of sensitization to OVA and IL-1α and subsequently challenged mice with OVA 
aerosol. Compared with mice receiving isotype antibody, GM-CSF neutralization reduced the 
influx of eosinophils and lymphocytes in the BAL fluid (Fig. 4 G), production of OVA-specific IgE 
and IgG1 (Fig. 4 H), and Th2 cytokines (Fig. 4 I). 
 
IL-1 induces Th2 sensitization via indirect effects on lung DCs 
As eosinophilic airway inflammation, GCM, and allergen-specific Ig production are all 
controlled by CD4 T cell responses, we next addressed how mucosal IL-1 and IL-1R signaling  
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Figure 4. IL-1α is sufficient to promote sensitization to inhaled protein antigens. (A–E) C57BL/6 mice were 
sensitized on day 0 with OVA in the presence of IL-1α, IL-1β, or PBS. Mice were challenged with OVA aerosols on 
days 10–12. (A) Differential cell counts were determined 24 h after the last challenge. (B) Levels of serum OVA–
specific Igs. (C) Cytokine levels in MLN cells restimulated for 4 d with OVA. (D) PAS staining of lung sections. (E) 
Bronchial hyperreactivity was analyzed in mice sensitized with OVA + IL-1 or OVA + LPS. (F) C57BL/6 and Crlf2
-/-
 mice 
were sensitized with OVA or with OVA + IL-1α and were exposed to OVA aerosols. Differential cell counts were 
determined 24 h after the last challenge. (G-I) C57BL/6 mice sensitized with OVA in the presence or absence of IL-
1α and injected with anti–GM-CSF or isotype control antibodies were challenged with OVA aerosols. (G) Differential 
cell counts were determined 24 h after the last challenge. (H) Levels of serum OVA-specific Igs. (I) Cytokine levels in 
MLN cells restimulated for 3 d with HDM. *, P < 0.05. Results show one representative experiment out of three. Five 
mice/group were used. Results are shown as mean ± SEM. 
 
could affect CD4 T cell activation and polarization. For that reason, we injected the model 
antigen OVA and measured T cell responses in the MLNs after first transferring a cohort of 
CFSE-labeled OVA-specific TCR Tg OTII cells. As the IL-1RI is also expressed on CD4 T cells and 
IL-1 was shown to directly affect T cell activation when given systemically or subcutaneously, 
some mice received IL-1RI–deficient OTII T cells (obtained from Il1r1
-/-
 × OTII mice). To 
eliminate the contribution of IL-1 on non-T cells and study whether mucosal IL-1 directly 
signals to T cells, WT OTII cells were also injected in Il1r1
-/-
 recipient mice. 1 d later, we instilled 
i.t. OVA ± IL-1α or PBS as a control and studied T cell activation 3 d later. In WT recipient mice, 
OVA-specific T cells had divided more vigorously when IL-1α was injected together with OVA, 
regardless of whether the OTII cells were responsive to IL-1 or not (Fig. 5 A). However, this 
effect was not observed in Il1r1
-/-
 recipient mice. Fig. 5 B shows increased IL-4, IL-5, and IL-17A 
expression in WT mice injected with WT or Il1r1
-/-
 OTII cells. However, if the recipient was  
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Figure 5. IL-1 induces Th2 sensitization through indirect effects on lung DCs. (A and B) C57BL/6 and Il1r1
-/-
 mice 
were injected with 10 × 10
6
 CFSE-labeled OVA-specific WT OT2 cells or Il1r1
-/-
 cells and were administered i.t. with 
PBS, OVA, or OVA + IL-1α. (A) Proliferation of CFSE-labeled T cells was determined by flow cytometry 4 d later. (B) 
Percentage of CFSE
+
 T cells positive for IL-4, IL-5, IL-17A, and IFN-γ was determined by flow cytometry. (C and D) 
MHCII
fl/fl
 × CD11c-Cre and WT mice were sensitized with OVA or OVA + IL-1α and were challenged with OVA 
aerosols. (C) Differential cell counts were determined 24 h after the last challenge. (D) Levels of serum OVA–specific 
Igs. (E) WT and Tlr4
-/-
 mice were administered fluorescent OVA i.t. The number of migrating OVA
+
 MHCII
hi
CD11c
+
 
DCs was determined in the MLNs 24 h later. (F) WT mice were administered i.t. with OVA, OVA + IL-1α, or PBS as a 
control. The levels of expression of CCR7, CD80, and CD86 were determined using flow cytometry. (G) WT mice 
were administered OVA i.t., OVA + IL-1α, or PBS. Mice were also injected with blocking antibodies to GM-CSF at the 
time of sensitization. The number of migrating MHCII
hi
CD11c
+
 DCs and their levels of CD86 expression were 
determined in the MLNs 24 h later. (H) WT and Il1r1
-/-
 mice were administered HDM or PBS. The number of 
MHCII
hi
CD11c
+
 DCs was determined in the MLNs 24 h later. *, P < 0.05. Results show one representative experiment 
out of at least two experiments. Four to five mice/group were used. Results are shown as mean ± SEM. 
 
deficient of IL-1RI, these cytokines were not increased above the level seen in mice receiving 
only OVA. These data show that mucosal IL-1α promotes Th2 immunity not by directly 
affecting antigen-specific CD4 T cells. As inhaled OVA is presented to CD4 T cells mainly by lung 
DCs and given the fact that CCL20 is a prototypical chemokine attracting immature DCs to the 
lungs and GM-CSF is an important development and maturation cytokine for DCs, we next 
studied whether IL-1 and the downstream cytokine cascade promoted development of Th2 
immunity by promoting the antigen-presenting function of lung DCs. To address this, we 
administered OVA + IL-1 to mice in which CD11c
+
 DCs do not express MHCII (MHCII
fl/fl
 × Cd11c-
Cre
+
). MHCII
fl/fl 
× Cd11c-Cre
-
 littermates served as controls. In control mice, OVA + IL-1 induced 
eosinophilia and lymphocytosis (Fig. 5 C), as well as serum Th2–dependent OVA-specific IgG1 
(Fig. 5 D), Th2 cytokines in MLN cultures (not depicted), and GCM (not depicted). These 
features of asthma were strongly reduced in mice lacking MHCII on CD11c
hi
 cells. We finally 
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wanted to address whether and how IL-1α affected DC function and activation in vivo. To trace 
DC migration, we injected mice with fluorescently labeled OVA with or without IL-1α. 1 d later, 
the MLNs were analyzed for the number of OVA-carrying DCs and their degree of maturation. 
Compared with OVA alone, the addition of IL-1α to OVA resulted in enhanced migration of DCs 
to the MLNs and increased expression of maturation markers CD80 and CD86 on the migrated 
DCs (Fig. 5, E and F). The effect was also observed in Tlr4
-/-
 mice, demonstrating that the effect 
of IL-1 was not caused by endotoxin contamination in the recombinant IL-1α. Enhanced DC 
migration and increased expression of maturation markers were inhibited if GM-CSF was 
neutralized at the time of OVA + IL-1α injection (Fig. 5 G). To study whether DC functions were 
also affected by endogenous IL-1R, we studied the migration of lung DCs to the MLNs in WT 
and Il1r1
-/-
 mice exposed to HDM, a trigger for IL-1α release. As shown in Fig. 5 H, HDM 
administration led to enhanced DC migration to the MLNs, an effect strongly reduced in Il1r1
-/- 
mice. 
 
Discussion 
In this study, we have uncovered a crucial role for IL-1R and IL-1α in causing Th2 sensitization 
to inhaled HDM. The precise role of IL-1α and IL-1β in development of allergy has been unclear 
and studied mainly using the model antigen OVA. In some experiments in which OVA alum was 
injected i.p., there was no role for either cytokine as Il1r1
-/-
 mice developed all features of 
asthma (Schmitz et al., 2003). However, the administration of recombinant IL-1α at the time of 
OVA/alum sensitization was shown to reduce asthma features (Caucig et al., 2010). In that 
study, IL-1α administration at later time points exacerbated the disease. In a milder model in 
which sensitization was induced in the absence of alum in Il1r1
-/-
 mice, asthma was reduced 
(Schmitz et al., 2003). The most logical conclusion from these conflicting data is that the 
strength of model, the route of administration, and the cell population targeted might 
determine the requirement for IL-1 in disease development. The i.p. injection of IL-1α 
primarily targets peritoneal macrophages and induces Th1 responses that can suppress Th2 
immunity (Caucig et al., 2010). In our study, the i.t. administration of the cytokine 
preferentially triggers lung ECs, thus favoring Th2 immunity. Using radiation bone marrow 
chimeric mice and exploiting the natural route of pulmonary exposure to HDM, we provide 
evidence that IL-1R triggering on radioresistant lung ECs promotes the innate immune 
response to natural allergens, a feature which was also observed in cigarette smoke–exposed 
mice (Botelho et al., 2011). Development of Th2 immunity to inhaled HDM or model antigens 
requires triggering of the TLR4 receptor on radioresistant cells (Hammad et al., 2009; Tan et 
al., 2010; Kool et al., 2011). This induces the release of epithelial cytokines (TSLP, GM-CSF, IL-
33, and IL-25) and chemokines (KC and CCL20) that promote Th2 immunity by activating 
basophils, eosinophils, and DCs (Fort et al., 2001; Hurst et al., 2002; Cates et al., 2004; Saenz et 
al., 2008; Besnard et al., 2011). We have set up ALI cultures of primary ECs from the 
conducting airways of mice and confirmed that GM-CSF, IL-1α, and KC were produced by 
HDM-stimulated ECs in a process requiring TLR4. We did not find consistent induction of TSLP, 
IL-33, and IL-25 in the ALI cultures, which does not exclude a role for them in vivo. Strikingly, 
the production of GM-CSF was impaired in ALI cultures set up from Il1r1
-/-
 mice, uncovering the 
presence of an endogenous autocrine loop of IL-1α acting on IL-1RI on ECs to promote 
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cytokine production. We also found evidence for this innate pro-Th2 amplification loop in vivo, 
as exposure of Il1r1
-/-
 mice to HDM led to significantly reduced production of GM-CSF, IL-33, 
and KC in lung homogenates, suggesting an important role for endogenous IL-1 in promoting 
Th2 immunity to allergens. Conversely, when we administered IL-1α to naive mouse lungs in 
vivo, we could induce production of GM-CSF and CCL20 (unpublished data). We have recently 
reported that endogenous danger signals like UA or ATP played an important role in the 
process of Th2 sensitization (Kool et al., 2011). In this study, we show that HDM-induced UA 
production was required for IL-1α production. However the neutralization of ATP with apyrase 
did not affect IL-1α secretion in vivo, indicating that ATP might be downstream of IL-1α 
production or might be involved in a different pathway. There are some subtle differences 
between the induction of cytokines and chemokines in the ALI cultures in vitro and the 
response seen in vivo. IL-33 was not induced by HDM in vitro but was consistently induced in 
vivo in a process requiring IL-1RI. This could be a potentially important observation, as IL-33 
has been shown to promote Th2 immunity to allergens by stimulating the function of DCs and 
innate lymphoid cells (Besnard et al., 2011; Eiwegger and Akdis, 2011). We have previously 
reported that Th2 immunity induced by inflammatory DCs is blocked when IL-33 signaling is 
blocked by administration of the soluble T1/ST2 receptor (Lambrecht et al., 2000). In support, 
we also observed a decrease in the number of BAL eosinophils and HDM-specific Igs when IL-
33 signaling was blocked at the time of sensitization in this HDM model. A central role has 
been attributed to TSLP in the process of allergic sensitization (Zhou et al., 2005; Liu et al., 
2007; Headley et al., 2009). Several groups have reported that IL-1 can induce TSLP 
(Allakhverdi et al., 2007; Lee and Ziegler, 2007), and a recent study demonstrated that lung 
DCs produce TSLP upon exposure to HDM (Kashyap et al., 2011). We found that the 
development of Th2 immunity driven by IL-1 or by a low dose of HDM did not require TSLP or 
its receptor. When a high dose of HDM (100 μg) was used to sensitize and challenge mice, 
airway eosinophilia was reduced in mice lacking TSLPR. Exactly why there is this allergen dose–
dependent effect of TSLP is unclear at present. In the high-dose model, IgG2a levels were 
increased, indicative of a mixed Th1 and Th2 response. As Th1 responses can counteract Th2 
immunity, we speculate that the absence of TSLP or of its receptor further shifts the immune 
response to Th1 response. In the low-dose model, the threshold for Th1 induction might be too 
high for TSLP blockade to have this enhancing effect. GM-CSF is a hematopoietic cytokine 
associated with Th2 immunity in the lung (Stämpfli et al., 1998; Ohta et al., 1999; Cates et al., 
2004; Bleck et al., 2006). This cytokine was reliably induced in vitro and in vivo by both HDM 
and IL-1α. Not surprisingly, neutralization of GM-CSF at the time of sensitization to HDM or 
OVA + IL-1α in vivo strongly reduced the salient feature of asthma. Human bronchial ECs have 
been shown to make IL-1α and IL-1β in an asthmatic setting and also express the IL-1RI 
(Mattoli et al., 1990; Marini et al., 1991). Our findings on cultures of human ECs demonstrated 
that IL-1α was increased after HDM exposure and that IL-1α could induce GM-CSF. It is 
therefore likely that the pathway that we discovered is also operative in humans exposed to 
allergens and could also help explain the adjuvant effects of air pollutants (Bleck et al., 2006). 
In the current study, we identify IL-1α and not IL-1β as the predominant IL-1 cytokine driving 
the innate cytokine cascade, but we have not studied how IL-1α is produced. IL-1α can be 
released as a cytokine by inflammatory cells or as an alarmin by dying cells (Chen et al., 2007; 
Dinarello, 2009). We have found it to be produced by bronchial ECs in ALI cultures and by 
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alveolar macrophages early in the response to HDM (unpublished data). However, we 
have never detected dying cells after HDM administration (unpublished data), but more 
studies are required to rule out the possibility that dying cells contribute to IL-1α 
release. Experiments with casp1
-/-
 mice did not support a role for IL-1β in Th2 immunity, in line 
with a previous publication on the lack of involvement of the NLRP3 inflammasome in HDM-
driven asthma (Kool et al., 2011). However, various papers show that IL-1β could be cleaved to 
its active form outside the cell by enzymes (proteinase3 and elastase) secreted by neutrophils 
(Joosten et al., 2009). We found no significant reduction in HDM-induced Th2 immunity when 
neutrophils were depleted using antibodies at the time of sensitization (unpublished 
data). DCs are necessary and sufficient to cause Th2 immunity to HDM (Hammad et al., 2010). 
We found that the type of Th2 immunity induced by IL-1α relied completely on antigen 
presentation by DCs and that IL-1α induced the migration and activation of DCs in a GM-CSF–
dependent way. Clearly, the process of Th2 development induced by mucosal administration of 
IL-1 or the enhanced proliferation of antigen-specific T cells seen did not require direct 
signaling of IL-1RI on T cells, as Th2 immunity was still induced when OVA and IL-1 were 
administered to the lungs of mice harboring OVA-specific TCR Tg T cells lacking IL-1RI. 
Strikingly, the same observation was made for induction of Th17 responses in the lung-draining 
nodes, which did not require IL-1RI on T cells. This is in contrast to studies in which IL-1 was 
given systemically or subcutaneously and promoted proliferation and Th2/Th17 immunity by 
directly acting on T cells (Sutton et al., 2006; Ben-Sasson et al., 2009). One explanation could 
be that administration to the lung does not allow sufficient IL-1α to reach the T cells. In our 
opinion, the promotion of enhanced T cell proliferation and Th2 immunity is best explained by 
effects of IL-1α and GM-CSF on DCs, which subsequently promote T cell expansion and 
differentiation. In parallel, other cytokines like IL-33 that are simultaneously induced could 
affect T cells directly. In conclusion, our experiments in mice and human bronchial ECs have 
unraveled a new mechanism that helps explain sensitization to HDM allergen. HDM triggers 
ECs to produce IL-1α in a TLR4-dependent manner. The IL-1α subsequently acts in an autocrine 
manner on the lung ECs, leading to secretion of pro-inflammatory chemokines, GM-CSF, and 
IL-33. Together, these recruit and activate inflammatory DCs that induce adaptive Th2 
immunity to the allergen. It will be interesting to study whether this cascade of innate 
cytokines programming adaptive immunity is induced by other natural allergens, 
environmental pollutants, and respiratory viruses that enhance the inflammatory response. 
 
Materials and methods 
Mice. TSLP receptor
-/-
  (Crlf2
-/-
) mice on C57BL/6 background (backcrossed for at least 10 generations to C57BL/6) 
were provided M. Comeau (Amgen, Thousand Oaks, CA); Il1r1
-/-
 mice (backcrossed for 8 generations to C57BL/6) 
were provided by B. Ryffel (University of Orléans, Orléans, France); Casp1
-/-
 mice were provided by T. Vandenberghe 
(Flanders Institute for Biotechnology, Zwijnaarde, Belgium); and Mhc2
fl/fl 
CD11c-Cre
+
 and Mhc2
fl/fl 
CD11cCre
-
 mice 
were provided by A. Liston (University of Leuven, Leuven, Belgium; backcrossed for at least 10 generations to 
C57BL/6). Female C57BL/6 WT mice were obtained from Harlan. Tlr4
-/-
 (backcrossed for eight generations to 
C57BL/6) mice and MHCII-restricted OVA-TCR Tg OTII mice were obtained from the Jackson Laboratory. Mice were 
housed under specific pathogen–free conditions in individually ventilated cages in a controlled day–night cycle and 
given food and water ad libitum. All experiments were approved by the animal ethics committee of Ghent 
University. 
 
Reagents. HDM extracts were obtained from Greer Laboratories. Recombinant soluble ST2 was provided by H. 
Braun (Flanders Institute for Biotechnology). Rasburicase (uricase) was purchased from Fasturtec, and human IL-1ra 
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(anakinra) was obtained from Amgen. For sensitization of mice, endotoxin low OVA was obtained from Hyglos and 
Worthington Biochemicals, whereas for use during antigen challenge, Grade III OVA and apyrase were obtained 
from Sigma-Aldrich. We obtained purified anti–IL-1α, recombinant mouse and human IL-1α, IL-1β, and IL-33, and 
ELISA Duoset for mIL-13, mKC, mCCL20, mIL-25, mIL-33, hIL-1α, hIL-1β, hIL-33, hTSLP, and hGM-CSF from R&D 
Systems. ELISA to detect hIL-25 was obtained from Wuhan EIAab Science. FITC-labeled antibody to MHCII, PE-Cy
5
–
labeled antibodies to CD3 and CD19, PE-Cy
7
–labeled antibody against CD49b, and APC-labeled antibody to CD11c, 
MHCII, and F4/80, and ELISA sets for mMCP1, mTSLP, and mIL-17A were acquired from eBioscience. FITC-labeled 
antibody to Ly6C, PE-labeled antibody against Siglec-F and Ly6G, Horizon V450–labeled antibody against CD11b, as 
well as mIL-1α, mIL-1β, mIL-4, mIL-5, mIL-10, mIFN-γ, and mGM-CSF ELISA sets and antibody pairs to mouse IgE, 
IgG1, and IgG2a to measure Igs in serum were obtained from BD. Aqua, CFSE, PE–Texas red–labeled antibody against 
CD11c and OVA Alexa Fluor 488 were purchased from Molecular Probes/Invitrogen. PerCp-Cy
5.5
–labeled antibody 
against MHCII and LEAF-purified anti–IL-1α, anti–IL-1β, anti–GM-CSF, and isotype control antibodies for 
neutralization experiments were obtained from BioLegend. 
 
Generation of bone marrow chimeras. 8–10-wk-old Il1r1
-/-
 and WT mice were sublethally irradiated (8 Gy) and 
received 2 × 10
6
 bone marrow cells i.v. from either Il1r1
-/-
 or WT C57BL/6 donors 4 h after irradiation. Mice were 
used in experiments at least 10 wk after bone marrow reconstitution.  
 
Model of HDM-induced asthma. Mice were anesthetized with isoflurane and received 1 μg HDM intranasally 7 d 
later, mice were challenged with 10 μg HDM on five consecutive days under anesthesia. 3 d after the last challenge, 
mice were sacrificed and organs were dissected for analysis. BAL was performed using 3× of 1 ml EDTA-containing 
PBS and analyzed, and lungs were inflated with PBS/OCT (1:1) solution and snap frozen in liquid nitrogen and kept 
at -80°C until further processing. Blood was taken to collect serum and analyzed for HDM-specific Igs. MLNs were 
dissected, and single cell suspensions were prepared by pressing through a 100-μm cell sieve and restimulated in 
vitro with 15 μg/ml HDM for 3 d. Supernatant was collected from these cultures, and cytokine profiles were assayed 
by ELISA. Lung function was performed using Flexivent invasive measurement of dynamic resistance as described 
previously (Hammad et al., 2007). In neutralization experiments, IL-1α and IL-1β were blocked at the time of 
sensitization to HDM by use of 70 μg blocking antibody injected i.t. In other experiments, 150 μg anti–GM-CSF 
antibody or 200 μg recombinant soluble ST2 was injected i.p. at the time of sensitization. 
 
Early innate immune response to HDM. Mice were i.t. instilled with PBS or 100 μg HDM. Apyrase- and uricase-
treated mice were injected i.t. with 4 U/ml apyrase or 100 μg uricase 30 min before exposure to PBS or HDM. Mice 
were injected i.p. with 200 μg recombinant soluble ST2 (rST2). Mice were sacrificed 2 or 24 h after the injection. BAL 
was collected, and the left lung was snap frozen in liquid nitrogen and stored at -80°C for preparation of lung 
homogenates. It was then homogenized with a tissue homogenizer in 500 μl of cold lysis buffer (20 mM Tris-HCl, pH 
8.0, 0.14 M NaCl, 10% glycerol [vol/vol], 1 mM PMSF, 1 mM sodium orthovanadate [Na3VO4], 1 μM NaF, 40 mg/ml 
aprotinin, and 20 mg/ml leupeptin) using a tissue homogenizer (IKA) with the addition of 1% Igepal after 
homogenization. Samples where then kept on ice for 30 min with agitation each 10 min, followed by a 
centrifugation to pellet debris. Cleared lysate was quantified for protein concentration with NanoOrange reagent 
(Invitrogen) according to the manufacturer’s protocol. Cell suspensions were made of the right lung and used for 
FACS analysis. Innate cytokines were measured by ELISA on lung homogenates, and concentrations were corrected 
for the protein content.  
 
OVA experiments. DC migration was investigated by injecting 100 μg OVA Alexa Fluor 488 i.t. and dissecting MLNs 
after 24 h. Cells were stained for flow cytometry, and DCs positive for Alexa Fluor 488 and expressing high levels of 
MHCII and CD11c were considered to be migratory DCs. For i.t. administration of PBS, 100 μg OVA-w ± 80 ng IL-1α, 
80 ng IL-1β, 80 ng LPS, and 8 or 80 ng IL-33 mice were anesthetized with isoflurane at day 0 and 1. At day 10, mice 
were challenged with OVA aerosols (1% OVA grade III solution) for 30 min on three consecutive days. Mice were 
sacrificed 24 h after the last aerosol. BAL was performed and cells were analyzed as described previously (van Rijt et 
al., 2004). MLNs were dissected and restimulated for 4 d with 10 μg/ml OVA-w. Supernatant was harvested at day 4 
and analyzed for cytokines by ELISA. For T cell division experiments, lymphocytes from LNs and spleen from OTII 
TCR Tg mice were isolated and stained with CFSE and injected i.v. in recipient mice. 1 d later, mice received an i.t. 
injection of PBS, 100 μg OVA-Endograde ± 80 ng IL-1α or 80 ng IL-1β. After 4 d, the MLNs were analyzed for T cell 
divisions and cultured for 3 d for cytokine response, without restimulation. Flow cytometry was performed on LSRII 
(BD). 
 
ALI cultures of mouse and human tracheal ECs. The isolation and culture of tracheal ECs were performed with small 
adaptations as previously described (Mayer et al., 2008). 8-wk-old mice were sacrificed with CO2, and trachea were 
dissected free and digested with pronase E and DNase I overnight at 4°C. Cell suspensions were allowed to adhere 
for 2 h in a Petri dish at 37°C. Non-adherent cells were grown for 4–7 d until confluence was reached (>5 kOhm, 
measured by transepithelial resistance) in a transwell system on collagen (Sigma-Aldrich)-coated membranes 
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(Corning). These cells were cultured for 3 wk as ALI cultures and subsequently exposed for 24 h to 100 μg HDM, 10 
ng IL-1α, or 10 ng IL-1β or PBS as a control. Cytokines secreted in medium were measured by ELISA. Human NBECs 
were purchased from Lonza. Cells were cultured in T80 culture flask (Thermo Fisher Scientific) to expand the cell 
numbers in BEGM growth medium as proposed by the manufacturer, until 
+
/- 85–90% confluence of cells. Cells were 
harvested and plated on collagen (Sigma-Aldrich)-pre-coated transwells (Corning) until cells reached confluence. 
Medium on the apical side was removed, and medium at the basolateral side was replaced by B-ALI growth medium 
(Lonza). Cells were cultured for 4 wk in B-ALI growth medium and pulsed overnight with PBS, 100 μg HDM ± IL-1ra, 
or 10 ng recombinant hIL-1α. Cytokine levels were measured in supernatant by ELISA. 
 
Statistical analyses. For all experiments, we calculated the difference between groups with the Mann-Whitney U 
test for unpaired data (SPSS version 15.0). Differences were considered significant when the p-value was <0.05. 
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Recent findings 
In an OVA-tolerance model of allergic asthma HDM was able to break tolerance if administered 
prior to sensitization (Soroosh et al., 2013). In this study, alveolar macrophages were isolated 
and were shown to secrete high amounts of IL-1α if tolerance was blocked. In our model of 
HDM-induced allergic asthma, blocking IL-1α during the secondary immune response did not 
modify the features of asthma (figure 1I). It would be interesting to investigate if alveolar 
macrophages in this model secrete IL-1α during the challenge phase. Since alveolar 
macrophages were demonstrated to induce airway tolerance. This raises the hypothesis that 
IL-1α is only relevant during the sensitization phase, since blocking IL-1α during the secondary 
immune responses did not reduce allergic airway inflammation. 
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In this thesis, we have shown that the activation of the pulmonary immune response is tightly 
controlled by interaction between airway epithelial cells and dendritic cells, occurring via 
release of paracrine cytokines and danger signals. Broadly speaking, DCs can be divided into 
different subsets which are found in different tissue compartments. Most is known about the 
DC subsets that line the conducting airways, and are involved in the recognition of inhaled 
microbes, pollutants and allergens [151]. Recently, our group has found that the main subsets 
involved allergic asthma are mo-DC and CD11b
+
 cDC [19, 152, 153]. Mo-DCs are able to present 
antigen to CD4
+
 T cells, however to a lesser extent than CD11b
+
 cDCs. Both subsets can initiate 
sensitization to HDM after adoptive transfer of mice exposed to HDM. In models where low 
doses of HDM are used to induce sensitization, CD11b
+
 DCs migrate to the MLN and present 
allergens to naive T cells. Recruited mo-DCs are mainly responsible for producing chemokines 
and cytokines that drive Th2 responses during ongoing inflammation, and for local 
restimulation of Th2 effector cells through expression of costimulatory molecules [13]. Not 
surprisingly, depletion of DCs during secondary challenge to allergens abolishes the cardinal 
features of asthma [8]. Interestingly, using higher doses of HDM for sensitization, led to 
recruitment of mo-DCs to the lung which subsequently migrated to the MLNs and had the 
potential to also induce sensitization. In models of viral infection, work to which I contributed, 
found that CD103
+
 cDCs have distinct functions and are very important for cross-presentation 
to CD8 T cells [10], while the CD11b
+
 DCs are mainly important for inducing tertiary lymphoid 
tissues that maintain local Ig synthesis [154].  The origin and general function of airway lining 
dendritic cells is summarized in chapter 1. 
In chapter 3, we have studied one of the most unknown DC subsets of the lungs, that lines the 
lung blood vessels in the lung interstitium. Although there is very little primary research on this 
topic, it has always been assumed that lung interstitial DCs are poorly migratory and only 
contribute to secondary immune responses. We here show that the lung interstitium has a 
warning system made up of cDCs lining the blood vessels and alerting of foreign embolic 
material, leading to recruitment of monocytes. We found that vessel lining interstitial DCs 
recruit inflammatory monocytes by releasing MCP-1 as soon as foreign embolic antigen was 
trapped in the lung-vascular bed. Interstitial DCs are not likely to migrate to the MLN [12]. The 
monocytes develop into DCs that migrate to the MLN and prime for the induction of a T cell 
response directed to antigens found in the embolic material. These T cells return to the site 
where the embolus was trapped and cause a short-lived inflammation.  We can only speculate 
why this form of inflammation develops in response to a sterile stimulus (Sepharose beads 
coated with OVA antigen), even when addition of LPS increased inflammation. Upstream of the 
activation of interstitial DCs, activation of endothelial cells may occur since large foreign 
material leads to disruption of the blood flow in vessels, potentially causing endothelial 
damage. Vascular endothelial cells are exposed to fluid shear stress of a magnitude and 
pattern that varies throughout the vascular tree. These stress conditions alter the 
inflammatory responses of endothelial cells, particularly their ability to recruit leukocytes 
[155]. Therefore it is very likely, that these stressed endothelial cells secrete cytokines 
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providing an inflammatory micro-milieu, in which surrounding tissue cDCs get activated. In 
their turn activated cDCs secrete MCP-1 recruiting CCR2
+
 monocytes or mo-DCs. We did not 
use the markers FcγRI (CD64) and FcεRI (MAR-1) to distinguish mo-DCs and CD11b+ cDCs, since 
those markers were not described at the time we performed these studies. Our observations 
were based on CX3CR1, CD11b and Ly6C expression, however the Ly6C
hi
 mo-DCs could be the 
same population as CD64
+
 monocytes. CD64
+
 monocytes gain MHCII expression and lose their 
Ly6C
+
 expression while becoming a functional DC [28, 156]. CD11b and Ly6C were also used to 
sort monocytes from the bone marrow and transfer them into DC-depleted mice. Adoptive 
transfer of these monocytes restored the embolic antigen presentation in the MLN.  We 
observed that only proper stimulation of DCs occurred if the antigen (coated on the beads) 
was co-administered with endotoxin and anti-CD40L. Mo-DCs were then capable of initiating 
proper CTL responses. These results show embolic antigens are presented in the lung draining 
lymph nodes. The main DC subset involved in antigen presentation, CD11b
+
 cDCs or mo-DCs, 
still remains to be investigated using markers CD64 and MAR1. We also need to further 
research why the inflammation around the Sepharose beads is so short lived, despite the long 
persistence of antigen on the beads and despite provision of LPS and CD40L signals.  
Unraveling the reasons behind this rapid downregulation of the pulmonary immune response 
in the lung interstitium might reveal critical insights in the future as to the pathogenesis of 
interstitial lung diseases like sarcoidosis, also accompanied by temporary lung infiltrates and 
swollen mediastinal lymph nodes. 
In the past, our group has studied extensively how we can modulate the function of DCs using 
pharmacological compounds, and many of these interfere with natural metabolites that also 
influence the basic physiology of DCs. As an example, interfering with the function of 
sphingosine-1-P by use of FTY720 was able to suppress the salient features of asthma [157]. In 
chapter 4, we show that the activation of DCs in the lung can be suppressed by the bile acid 
compound UDCA. In humans, the main primary bile acids are cholic acid and chenodeoxycholic 
acid (CDCA) and the principle secondary bile acids are deoxycholic acid and lithocholic acid. 
The natural occurring ursodeoxycholic acid (UDCA), is an endogenous mediator mainly present 
in low amounts in serum as its taurine conjugate tauroursodeoxycholic acid (TUDCA) [158]. 
UDCA is used in the clinic to treat patients with chronic cholestatic diseases [159]. We found 
that UDCA has the potential to suppress airway inflammation. UDCA has immunosuppressive 
properties by acting on the DCs directly via the farnesoid X receptor (FXR), but the 
downstream signaling pathways effected by UDCA administration still need to be investigated. 
The FX receptor is mainly expressed on hematopoietic cells [160]. CDCA can bind the same 
receptor but did not lead to a decrease in inflammation. Deoxycholic acid and CDCA were 
found to be cytotoxic to T cells and DCs. Binding of bile acids to FXR can lead to induction of 
small heterodimer partner (SHP) within the cytoplasm, although only in combination with 
retinoids [161]. SHP has been recognized as a negative regulator in intracellular signaling which 
is shown in allergic airway inflammation and is expressed predominantly in hematopoietic cells 
[162, 163]. It has been shown to be negatively regulating CD64 and MAR-1 which are both 
expressed on inflammatory DCs [28, 164, 165]. The inhibition of these receptors occurs by 
preventing tyrosine phosphorylation of the receptor and Syk, as well as the increase of 
intracellular calcium release [166]. TUDCA is also a known inhibitor of endoplasmatic reticulum 
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(ER) stress, through its capacity to act as a protein folding chaperone molecule. Perhaps 
inhibiting ER stress signaling leads to reduced inflammation in the model of allergic asthma. 
Polymorphisms in a genetic locus containing ORMDL3 is the only genetic risk factor recently 
associated to asthma in a genome wide association study (GWAS). ORMDL3 is expressed in 
hematopoietic and stromal cells, and alters ER-mediated Ca
2+
 homeostasis and facilitates the 
unfolded-protein response (UPR) [167-169]. The ER protein anterior gradient homolog 2 
(AGR2) is localized to the ER of MUC5AC- and MUC5B-producing airway epithelial cells and 
forms complexes with immature MUC5AC. Expression of AGR2 and MUC5AC in airway 
epithelium from  asthmatics is simultaneously increased. Allergen challenged Agr2 deficient 
mice have impaired mucin production accompanied by increased proportion of mucins 
contained within the ER leading to ER stress in airway epithelium [170]. Reducing ER stress 
could lead to less inflammation, however direct experiments with TUDCA have never been 
performed. One other possibility could be, as shown in a liver transplantation study, that 
protective effects of TUDCA are mediated through a mechanism involving proliferator-
activated receptor-γ (PPARγ) signaling [171]. The FXR is identified as a modulator of lipid and 
glucose metabolism and PPARs are activated by arrays of polyunsaturated fatty acid 
derivatives, oxidized fatty acids and phospholipids. Our group showed in allergic asthma that 
PPARγ activation on DCs prevents induction of Th2-dependent eosinophilic airway 
inflammation and contributes to immune homeostasis in the lung [172]. In allergic asthma 
PPARγ activation by TUDCA on DCs is possible, but needs further investigation. Inhibition of 
CD64 and MAR-1 signaling pathways are very likely to happen since we also found a role for 
Syk signaling on dendritic cells dependent on UA activation (chapter 5). However we have not 
investigated if UA levels are reduced by UDCA treatment. Chapter 4 shows that DC activation 
in the lung is a very tight control point that is implicated in driving Th2 responses to allergens.   
Uric acid crystals were shown to directly engage cholesterol-rich cellular membranes of DCs in 
a receptor-independent manner [173]. In chapter 5, we have further elaborated on the idea 
that endogenous danger signals, released by bronchial epithelial cells are crucial in controlling 
the activation state of DCs in response to allergens. Injection of inert allergens such as OVA 
combined with UA lead to in vivo development of Th2 cell immunity. The early activation and 
recruitment of inflammatory DCs upon UA exposure was mediated by Syk activation and PI3Kδ 
signaling in DCs (chapter 5). DAMPs such as monosodium urate crystals and ATP are described 
to activate the NALP3 inflammasome. Recently also reactive oxygen species (ROS) were 
proposed to cause potassium efflux and thereby inflammasome activation (and vice versa) 
[174]. Although current studies implicated ROS exposure leading to NF-κB upregulated 
expression of NLRP3 and pro-IL-1β transcripts instead of inflammasome activation (reviewed in 
[215]). Surprisingly, mice deficient of any of the IL-1β mediated pathways (NALP3, ASC or IL-
1RI) still initiated Th2 responses to OVA mixed with UA crystals. We also found increased UA 
upon inhalation exposure to HDM in lung lavage fluid of mice, which was diminished in TLR4 
deficient mice. Furthermore real life allergens, like HDM, lead to increased levels of UA in 
bronchoalveolar lavage fluid of allergic asthmatics. To investigate the role of UA in 
sensitization to HDM we used uricase, an enzyme degrading UA. Uricase-treatment at 
sensitization to HDM led to reduced eosinophilic influx and Th2 responses. We have shown 
that allergic asthma to HDM is dependent on TLR4 signaling on lung stromal cells [55]. As 
109 
 
depicted in chapter 1, lung epithelial cells release several cytokines upon HDM exposure. The 
most pronounced AEC cytokines released were also abrogated by the addition of uricase, like 
GM-CSF, TSLP and IL-25. Confocal images of lungs taken after HDM exposure revealed that 
AECs are the source of UA. Complex allergens such as HDM can activate multiple pathways 
simultaneously. Since uric acid and these cytokines can be found at the same time after 
allergen exposure, it is very likely that these multiple pathways exist in parallel [88]. Close 
interaction between epithelial cells and tissue DCs leads to activation of DCs by UA and 
exposure to Th2 inducing cytokines like GM-CSF and IL-25. UA release is reduced in mice 
deficient of TLR4, but not in IL-1RI deficient mice. Suggesting that UA release is downstream of 
TLR4, but upstream of IL-1RI. However, IL-1RI deficient mice were responding to OVA+UA 
crystal sensitization like control mice, suggesting that UA crystals can also boost Th2 immunity 
via other pathways. This correlates well with experimental asthma models where OVA was 
mixed with alum, and in which also the IL-1RI deficient mice developed asthma [149]. 
In addition, injection of pro-inflammatory IL-1β lead to a small increase in UA in the lavage of 
mice, in contrast to IL-1α exposure, however the levels were as high as HDM. It raises again 
the possibility that multiple pathways exist in the sensitization to HDM.  However we could not 
find a role for IL-1β in allergic asthma, nor in caspase1 of Nlrp3 deficient mice which are 
elements upstream of IL-1β to cleave IL-1β into its bioactive form (chapter 1 and 5). 
We found that TLR4 and interleukin 1-receptor 1 (IL-1RI) signaling (chapter 6) on stromal cells 
are both important in the sensitization to HDM [55]. Both pathways could therefore be a 
target in therapeutics against asthma. However TLR4 is used to recognize bacterial infections 
in the lung, since its well-known ligand is lipopolysaccharide (LPS). Blocking the signaling of this 
pathway may induce problems in clearing lung infections. The IL-1/IL-1RI pathway has been 
shown to be involved in other lung diseases like lung fibrosis and chronic obstructive 
pulmonary disease (COPD). However in these diseases especially IL-1β was found to be 
important. Nonetheless, we found in chapter 6, that IL-1α is the most important agonist on 
this pathway in allergic sensitization to HDM. We did not find a role for IL-1α in secondary 
responses to HDM, and also other groups have suggested a dual role for IL-1α [175]. IL-1α is 
suggested to be a danger signal released by necrotic cells, therefore inducing sterile 
inflammation [176]. We propose an autocrine loop of IL-1α leading to activation of lung 
epithelial cells and subsequent release of GM-CSF.  Recruited dendritic cells or monocytes will 
gain their inflammatory state and induce Th2 responses to HDM upon GM-CSF exposure. IL-1RI 
signaling on γδ T cells and Th17 cells leads to release of IL-17 providing a tissue specific 
inflammation [177]. Blocking IL-1RI has already been proposed, in optimizing the blockade of 
this receptor [178, 179]. Since this pathway is necessary in viral clearance, therapeutic 
applications for treatment of asthma might rather lie downstream [180]. IL-1α-IL-1RI signaling 
leads to the release of GM-CSF and CCL20 as well as danger molecules such as IL-33. These 
cytokines influence the onset of asthma creating a pro-inflammatory environment. Chapter 6 
shows that the sensitization to HDM in a model of allergic asthma is tightly controlled by 
airway epithelial cells, influencing the migration and activation of dendritic cells. 
Allergic asthma is a disease of westernized countries. The ‘hygiene hypothesis’ states that viral 
or microbial infections in childhood decrease the incidence of allergic asthma [181]. Asthma, 
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atopy, eczema and hay-fever have a lower prevalence in overcrowding, unhygienic conditions 
and larger family size [182]. Specific immune activation pathways are not clear, however our 
data would suggest that instead of the inflammatory cells rather the AECs become irresponsive 
to allergens if encountered more infections in the past. 
How are these data transferable to human lung disease ? 
In our model of embolic antigen injection, we found that the size of inflammatory infiltrates 
decreases over time and is resolved after about 16 days (chapter 3). This model could 
therefore be a tool to study sarcoidosis since in patients the granulomas resolve over time in 
80% of the cases, but in 10-30% results in fibrosis [183]. In cases when the immune response 
was initiated to the granuloma itself by antigen presenting cells (like macrophages or DCs) 
[184]. This would mean that recruited DCs are necessary for inducing an immune response 
that is predetermined to resolve, however if DCs were depleted no granulomas were formed in 
the first place. This suggests that many T cells inside a granuloma have an inherent anti-
inflammatory character, something that has also been observed in patients with sarcoidosis 
and has been called the immune paradox of sarcoidosis [185]. Experimental and pre-clinical 
work has addressed the role of DCs in COPD and asthma [186]. However less is known about 
interstitial lung diseases like sarcoidosis and lung fibrosis. Sarcoidosis is generally accepted as a 
T cell mediated disorder [187]. In patients with active sarcoidosis increased numbers of 
regulatory T cells (Treg) are found suppressing early stages of granuloma formation [188, 189]. 
Tregs found within the granulomas showed less suppressing capacities beside their high IL-10 
and TGF-β levels, compared to Tregs in the blood of the same patients [190]. In addition 
another study showed that TNFα levels are not completely impaired in sarcoidosis patients by 
their Tregs, while anti-TNFα has been shown to be very effective in this disease [185]. 
Preliminary murine experiments on the role of Tregs in granuloma formation, revealed 
depletion of Tregs at antigen exposure the infiltrate size was reduced. Treg depletion in model 
of RSV infection showed increased viral clearance [191]. In this RSV-model Tregs were found to 
express granzyme B. Granzyme B is found to be expressed by multinucleated giant cells, CD4
+
 
and CD8
+
 T cells in sarcoidosis [192, 193]. Therefore granulomas could be rather maintained 
than suppressed by Tregs (expressing granzyme B).  Subsequent analysis of levels of granzyme 
B on Tregs surrounding the beads in mice and experiments using granzyme B deficient Tregs 
could solve this question. Perhaps by targeting a specific DC subset in sarcoidosis would 
prevent Treg influx into the inflammatory area, leading to reduced risk in fibrosis 
development. It would be necessary to further study which DC subset is involved in antigen 
presentation and granuloma formation in sarcoidosis and fibrosis formation.  
 
UDCA is used in clinics to treat patients with chronic cholestatic diseases like primary biliary 
cirrhosis (PBC). Patients with PBC show a considerable influx of eosinophils in the liver, while 
this is not seen in patients with viral chronic active hepatitis [194]. Screening of liver biopsies 
of PBC patients on cytokines showed an increase in IL-5, IL-6 and IFN-γ compared to controls or 
biopsies of patients with chronic hepatitis C [195]. Eosinophilia and increased Th2 cytokines are 
also hallmarks of asthma (chapter 1). Especially Th2 cytokine IL-13 and eosinophilia were 
reduced in our model after treatment with UDCA. An increase of exhaled nitric oxide (NO) has 
been shown to accompany eosinophilic inflammation. Exhaled NO increases during 
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exacerbation and decreases with recovery in patients with asthma. NO is also implicated in the 
Th1/Th2 balance, less NO leads to increased Th1 expansion. UDCA could reduce NO production 
in vitro in human cell lines most likely at the level of nitric oxide synthase [196, 197].  We 
found that UDCA treatment lead more IFN-γ release by T cells, therefore a shift to Th1. The 
exact mechanism of UDCA is not yet found in human or mouse studies, as well as DC function 
in liver diseases is not well established. Although many activated DCs (CD11c
+
, CD83
+
) are 
found in inflammatory regions in livers of PBC patients [198]. One could speculate that since 
DCs are found to be important for the structure of inflammatory regions [199], UDCA could act 
on the DCs in liver diseases as well, thereby treating the disease. If UDCA would be used as 
treatment in asthma, the next finding should be considered. Since 6 hours after stimulation of 
cells in vitro, UDCA lost its immune regulatory effects [197]. Therefore timing of UDCA 
treatment could be important. Only cells pretreated with UDCA or early in challenge an Th2 
reducing effect was found. 
 
The epithelial network controlling asthma in humans has been proposed for a long time [200]. 
Air pollutants (ozone, NO, tobacco smoke) have been shown to worsen asthma. However 
reaction to air pollutants do not necessarily increase with the severity of asthma [201].  We 
have shown that TLR4 signaling on AECs is important in HDM-driven asthma [55]. CD14 is an 
adaptor molecule necessary for endotoxin/TLR4 signaling. TLR4 has been found to be 
associated with asthma [202]. Remarkably, CD14 polymorphism were found to be protective 
and also gene-environment correlations were found [203, 204]. Another study indicated that 
CD14 and TLR4 undergo endocytosis and is mainly involved in phagocytosis of microbes. 
Endocytosis is increased under exposure to inflammatory mediators and dependents on Syk 
signalling on DCs and macrophages [205]. Our results on UA support these findings. In a model 
using OVA alum, we showed that alum induced responses are dependent on UA. Alum 
injection in vivo increased endocytosis of OVA on peritoneal DCs [72]. It raises the question if a 
genetic defect in CD14 signaling (induced by polymorphisms) would prevent atopy or asthma? 
Therefore it could be very interesting to investigate CD14 expression on DCs after exposure to 
UA or HDM. On human lavage samples we found uric acid to be increased upon exposure to 
real life allergens. In addition blood samples of children with asthma and rhinitis show 
increased UA levels compared to controls [206]. Future research should be done on the role of 
UA in allergic asthmatics or rhinitis patients. 
Downstream of TLR4 signaling we found besides the DC triggering by uric acid, activation of 
the IL-1RI pathway on AECs by IL-1α. Microarray data on human epithelial cell-line after 
exposure to grass pollen extract shows that IL-1α is one of the most up regulated genes after 
stimulation, together with pro-inflammatory IL-6, IL-8 and the natural occurring IL-1receptor 
antagonist (IL-1Ra) [207]. Polymorphisms within the IL-1Ra and IL-1α gene are associated with 
asthma and development of nasal polyps in asthmatics [208], which suggest that the role of 
these cytokines is transferable to patients. Downstream of IL-1RI signaling we found increased 
secretion of epithelial derived cytokines like IL-33 and GM-CSF. Recent genetic studies on 
asthma have identified single nucleotide polymorphisms (SNPs) in the gene coding for IL-33 
receptor IL-1RL1 (ST2 receptor) as well as in the IL-33 locus itself [209].  Polymorphism in the 
CSF2 gene, which is the gene encoding for GM-CSF were found to be correlating with asthma 
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in Swiss and atopic dermatitis in Canadian children [210, 211]. Regulatory gene region of MCP-
1 polymorphism were found as well [212] however not much is known so far on CCL20. Our 
data show a timeline of the cytokine cascade which follows upon HDM exposure. 
Future perspectives 
DCs are very important in antigen presentation, which is known for inhaled allergens. Here we 
show for the first time, DCs presenting bloodborn antigens in the MLN. Targeting DCs or 
depleting them, leads to reduced inflammatory lesions and in asthma to reduced eosinophilia 
and Th2 responses. We have unraveled an important role of airway epithelial cells in 
controlling DC activation by release of pro-inflammatory cytokines and chemokines 
downstream of TLR4/IL-1RI axis. In the future we will analyze how environmental triggers like 
infections, air pollutants (diesel, ozone etc.) affect the balance of these cytokines and thereby 
the function of DCs. This raises the possibility that the epithelium is genetically modified by 
these environmental triggers. A high dose of TLR4 ligand LPS leads to tolerance of the 
epithelium for weeks [213]. It would therefore be very interesting which intracellular inhibitors 
are induced by LPS and how long tolerance sustains. Preliminary data showed that inhibitory 
TNFα induced protein 3 (TNFAIP3 or A20) is increased in the lung after exposure to CPG (TLR9 
agonist) and LPS. 
A20 is a negatively regulator of TLR/IL-1RI and TNF-receptor signaling. Recently multiple SNPs 
in the TNFAIP3 interacting protein 1 (TNIP1) gene, which interact with A20 were associated 
with asthma [214]. A20 therefore is a possible candidate for therapeutic implications on 
structural cells. To investigate A20 regulation in patients, analysis should be done on 
peripheral tissue, like biopsies instead of blood or lavage to be able to analyze gene expression 
and modifications upon allergen exposure and after treatment.  
Concluding remark 
DCs and AECs interact with each other to induce an immune response to foreign particles. 
Research nowadays focusses on the origin and function of DC subsets and the PRR signaling 
pathways involved. Basal research will help finding a new therapeutic strategy which involves 
either instructing AECs or directly targeting DCs. For allergic asthma there is no direct cure yet, 
however understanding the mechanism of sensitization will lead to better medication in the 
future. Since the often prescribed corticosteroids are after all only fighting the symptoms and 
not the onset of the disease. 
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Abbreviations 
 
AEC  airway epithelial cell 
AGR2  anterior gradient homolog 2 
AHR  airway hyperresponsiveness 
AIM2  absent in melanoma 2 
APC  antigen presenting cell 
ASC  apoptosis-associated speck-like protein containing a caspase recruitment  
ATP  adenosine triphosphate 
BAL  bronchoalveolar lavage 
BHR  broncho-hyperresponsiveness 
BMDCs  bone marrow-derived dendritic cells 
CCL  chemokine (C-C motif) ligand 
cDC  classical dendritic cell 
CDCA   chenodeoxycholic acid  
CDP  common DC precursor 
COPD  chronic obstructive pulmonary disease 
CPG-ODN CpG oligodeoxynucleotides 
d  day(s) 
DAMP  danger associated molecular patterns 
DBEC  diseased bronchial epithelial cell 
DC  dendritic cell 
domain 
DT  diphtheria toxin 
DTR  diphtheria toxin receptor 
EC  epithelial cell 
ELISA  enzyme-linked immunosorbant assay 
ER  endoplasmatic reticulum 
FACS  fluorescent activated cell sorting 
GCM  goblet cell metaplasia 
GI  gastrointestinal 
GM-CSF granulocyte macrophage-colony stimulating factor 
GMP  granulocyte-myeloid precursor 
GR  glucocorticoid receptor 
GWAS  genome wide association study 
HDM  house dust mite 
HMGB1 high mobility group box 1 protein 
HSC  hematopoietic stem cell 
HSP   heat shock proteins  
i.n.  intranasally 
i.p.  intraperitoneally 
i.t.  intratracheally 
i.v.  intravenously 
ICS  inhaled corticosteroids 
IgE  immunoglobulin E 
IL  interleukin 
IL-1Ra  IL-1 receptor antagonist 
IL-1RI  IL-1 receptor 1 
IRF3  interferon regulatory transcription factor 3 
ITIM   immune receptor tyrosine-based inhibitory motif 
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LP  lymphoid precursor 
LPS  lipopolysaccharide 
LRR  leucine-rich repeat 
LSPs   leaderless secretory proteins 
MCH  methacholine 
MCP-1  monocyte chemotactic protein-1 
MD2  myeloid differentiation protein 2 
MHC  major histocompatibility complex 
MLN  mediastinal lymph node 
mo-DC  monocyte-derived dendritic cell 
MUC5A  mucin-5A 
MYD88  myeloid differentiation primary response 88 
NALP3  NACHT, LRR and PYD domains-containing protein 3 
NBEC  normal bronchial epithelial cell 
NF-κB  nuclear factor- kappa B 
NLR  NOD like receptors 
NO  nitric oxide 
OB  OVA coated Sepharose bead 
OVA  ovalbumin 
PAMP  pathogen associated molecular patterns 
PAR  protease-activated receptor 
PAS  periodic acid Schiff 
PBC  primary biliary cirrhosis  
PBMCs  peripheral blood mononuclear cells 
PD-1  programmed death -1 
pDC  plasmacytoid dendritic cell 
PMA  phorbol 12-myristate 13-acetate 
Poly(I:C) Polyinosinic-polycytidylic acid 
PPARs   Peroxisome proliferator-activated receptors  
PPARγ   proliferator-activated receptor-γ 
pre-cDC preclassical dendritic cell 
PRR  pattern recognition receptor 
PYHIN   pyrin and HIN domain-containing protein 
RLR  RIG like receptors 
ROS  reactive oxygen species 
SHP   small heterodimer partner 
SNP  single nucleotide polymorphisms 
Tg  transgenic 
Th  T helper cell 
TLR  toll like receptor 
TNFα  tumor necrosis factor- alpha 
Treg  regulatory T cell 
TSLP  thymic stromal lymphopoietin 
TSLPR  TSLP receptor 
TUDCA   tauroursodeoxycholic acid  
UA  uric acid 
UB  uncoated Sepharose bead 
UDCA  ursodeoxycholic acid 
UPR   unfolded-protein response  
XOR  xanthine oxido reductase 
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